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More than two thirds of all cancers are diagnosed in older adults and the diagnosis 
often co-occurs with normal and pathological changes of aging, which include chronic 
diseases and related symptoms. The purpose of this measurement study was to conduct 
initial psychometric testing of a newly developed self-report tool to assess comorbidity 
burden and symptoms, the Comorbidity and Symptom Measurement in Oncology Scale 
(COSMOS), and to examine the feasibility of utilizing it with older cancer survivors. 
Phase 1 of the two-phase design focused on determining content validity using a panel of 
six expert clinicians and researchers. Each subscale item was evaluated for interrater 
agreement of relevancy using the content validity index (CVI). The scale-CVI was .80 for 
the comorbidity burden subscale (CoB) and .98 for the symptom perception subscale 
(SxP). The intraclass correlation coefficient (ICC) for each subscale was .97 (CoB) and 
.84 (SxP), respectively. Subscale items with a CVI of >.83 and ICC >.60 were retained. 
Phase 2 included pilot testing the revised CoB and SxP subscales and symptom 
attribution descriptor scale in a convenience sample of 62 older adult cancer survivors 
(32 on active treatment and 30 off treatment for 1 or more years). Although CoB scores 
were equivalent between groups, off-treatment group participants had significantly more 
thyroid and other miscellaneous conditions. SxP scores were also similar between groups; 
however, the active-treatment group reported significantly more nausea (2 = 4.03, p = 
.045), taste changes (2 = 7.65, p = .006), and body image disturbances (2 = 6.44, p = 
iv 
 
.011) than the off-treatment group. Three clinically relevant symptom-attribution 
descriptors discriminated between treatment status groups, indicating a shift from aging 
and cancer-related attributions in those on active treatment to aging and other causes in 
the off-treatment population. Test-retest reliability indicated strong stability for 
comorbidity burden (ICC = .917) and symptom attribution (ICC = .696). COSMOS was 
judged to be a feasible measure based on subsample interviews, completion time, and 
response patterns. The results of this study support initial validity, reliability, and 
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Older adults comprise one of the most vulnerable and rapidly growing 
populations with cancer. Approximately 77% of all cancers are diagnosed in individuals 
55 years and older, and the diagnosis often co-occurs with the normal and pathological 
changes of aging, which include chronic diseases and conditions (Howlader et al., 2015). 
The average number of comorbidities in the geriatric oncology population increases with 
age and ranges from two to four comorbidities (Cohen, Lan, Archer, & Kornblith, 2012; 
Deimling, Sterns, Bowman, & Kahana, 2005). The most prevalent chronic diseases and 
conditions in geriatric cancer patients include hypertension, cardiovascular conditions, 
arthritis, diabetes, and chronic lung disease, including asthma and chronic obstructive 
pulmonary disease (Bellury et al., 2012; Bender et al., 2008; Cohen et al., 2012; Grov, 
Fossa, & Dahl, 2011). Comorbidities and their symptoms may be associated with many 
adverse health outcomes, including the development of additional health problems, 
functional impairment and decreased mobility, increased hospitalizations, and the 
development of psychological symptoms such as anxiety and depression (Bellury et al., 
2013; Deckx et al., 2012). The presence of comorbidities may have a profound effect on 




with cancer, yet little is known about the impact of comorbidities in this population. 
The “normal” symptom experience for the older adult population has a vague 
definition and may be related to the presence of comorbid conditions. It has been 
suggested that the traditional retirement age may be a developmental marker for changes 
in perception of discomfort, from abnormal to a normal expectation that comes with age 
(Williamson & Schulz, 1995). In addition, the perception of cancer-related symptoms 
may be impacted by beliefs of the expectations of normal aging or by the symptoms of 
other health problems (Mao et al., 2007. These phenomena may begin to explain the 
difference in symptom perception between younger adults and geriatric populations.  
Historically, studies have suggested that older adults experience less severe 
cancer-related symptoms than younger adults, and that these symptoms generally cause 
more distress in younger populations when compared to older adults (Degner & Sloan, 
1995; Williamson & Schulz, 1995). Cheung, Le, Gagliese, and Zimmerman (2011) 
studied 1,358 advanced-cancer survivors in the outpatient care setting to determine age 
and gender differences in reported symptom intensity. The results of the study suggest 
that cancer survivors aged 61 years and older did not experience a clinically significant 
difference in symptom severity and distress when compared to cancer survivors who 
were age 60 years and younger. The literature also suggests that physical symptoms and 
functioning are not directly related to age but rather to the comorbidities that may be 
present (Kolk, Hanewald, Schagen, & Gijsbers van Wijk, 2003; Kroenke, 2001). In 
addition, several studies have begun to associate comorbidity with increased symptoms 
and decreased functioning (Bellury et al., 2013; Bennett, Stewart, Kayser-Jones, & 




available to measure an individual’s symptom attribution related to comorbidities or other 
health-related problems.  
Older adults with cancer may have an altered symptom perception due to their 
experience with co-occurring comorbidities. Altered symptom perception may affect 
“normal signals” to seek treatment if symptoms are perceived to be part of the aging 
process or due to comorbidities. Although studies have shown that an increased number 
of comorbidities is associated with increased symptoms, the phenomenon of symptom 
perception for the older adult with cancer and multiple comorbidities has been minimally 
explored (Bellury et al., 2012; Loerzel, 2015; Spoelstra et al., 2015). A critical evaluation 
of the literature on cancer and comorbidity, measurement of comorbidity, cancer-related 
symptom measurement, and symptom appraisal revealed minimal valid and reliable self-
report tools to measure comorbidity burden, symptom burden, and symptom attribution.  
This literature review provided a basis for the development and preliminary 
content validity of the Comorbidity and Symptom Measurement in Oncology Scale 
(COSMOS). The development and validation of a self-report, user-friendly measurement 
tool for comorbidity and symptom burden will contribute valuable information to the 
comprehensive geriatric assessment of older adults with cancer. This tool may provide 
insight into the impact of comorbidity on perceived symptom burden and lay a 
foundation for focused geriatric symptom assessment and subsequent studies of tailored 
interventions for symptom management and outcome measurement in this population. 
 
Purpose and Aims 
 
The broad goal of this study was to assess the psychometric properties of a self-




in the clinical setting as an integral component of the comprehensive geriatric assessment 
of older adults with cancer. The purpose of this methodological study was to conduct 
initial psychometric testing of COSMOS and examine the feasibility of utilizing it with 
older adults with cancer and comorbidities. The specific aims of the study included the 
following: 
Aim 1.0: Determine the content validity of the Comorbidity and Symptom 
Measurement in Oncology Scale (COSMOS) by utilizing a survey method 
that includes both quantitative and qualitative data collection from a panel of 
expert clinicians/researchers in oncology, gerontology, geriatric oncology, and 
symptom assessment and management. 
Aim 2.0: Determine the construct validity of the COSMOS by utilizing a mixed-
method approach with a group of older adults with cancer. 
Aim 3.0: Determine initial test-retest reliability of the COSMOS in a group of 
older adult cancer survivors who have finished active cancer treatment. 
Aim 4.0: Determine the feasibility of a self-administered measurement tool of 
comorbidities and symptoms in a population of older adults with cancer, 
including tool completion time, response patterns, tool comprehension, 
missing items, and patterns in missing data. 
Aim 5.0: Explore the sensitivity of the COSMOS between known groups of older 
adults on active cancer treatment and off treatment.  





The role of comorbidity may be a significant factor in symptom perception and 
the impact of symptoms on the physical, psychological, and spiritual functioning of older 
adult cancer survivors in all phases of the cancer disease trajectory. In addition, it is 
essential to understand the impact of the normal aging process on the perception of 
cancer-related symptoms and optimal symptom control. Older adults with cancer may 




with comorbidities, yet little is known about this important aspect of symptom 
perception. The attribution of symptoms to expected and accepted physiological 
consequences of aging may lead to a delay in recognizing or failure to recognize cancer-
related symptoms, which may have a negative impact on treatment outcomes and cancer 
survivorship.  
Currently, there are minimal tools available to assess the phenomenon of 
symptom attribution in the older adult cancer population with comorbidities. Attribution 
is important, as it may guide the selection of an optimal intervention. The COSMOS may 
contribute essential information to the overall understanding of the impact of comorbidity 
and aging on the perception of symptoms in older adults with cancer. It is anticipated that 
this instrument will be a valuable assessment tool for oncology clinicians to use in the 
assessment and treatment of complex symptom constellations in the geriatric oncology 
patient. In addition, the COSMOS may provide clinical researchers with a unique tool for 
gathering further information about comorbidity burden and symptom attribution in older 
adult cancer survivors to assist in understanding this phenomenon and answer such 
questions as: Are specific comorbidities linked to specific symptoms as perceived by 
older adults with cancer? How does experience with comorbidity frame the symptom 
experience? How do comorbidity burden and symptom perception impact the diagnosis 
and treatment of cancer in older adults? This information can also be used to formulate 
and test tailored interventions for this vulnerable clinical population. In addition, the 
information gained from the COSMOS may be utilized to enhance targeted cancer 
education for the older adult population. 




comprehensive geriatric assessment that includes physical, psychological, and functional 
status; comorbidity; socioeconomic status; nutrition; polypharmacy; and geriatric 
syndromes (Mohile & Magnuson, 2013). Establishing a valid, reliable, self-administered 
tool such as the COSMOS will make a valuable contribution to comprehensive geriatric 
assessment in the cancer population and guide the development of complex, 




This chapter addresses an overview of the clinical phenomenon to be studied and 
its significance to patient-centered care and optimal care management by an 
interprofessional team. In addition, the purpose and aims of the study are outlined in this 
chapter. Chapter 2 reviews the current relevant literature on chronic illness and cancer, 
cancer-related symptoms, measurement of comorbidity and cancer-related symptoms, 
symptom interpretation, and a conceptual framework that illustrates the potential 
relationships between symptoms, chronic illness, and relevant variables within the cancer 
survivor population. Chapter 3 outlines study methodologies used for instrument 
development, administration, and evaluation. Chapters 4 through 6 are prepared as 
articles intended for publication. Chapter 4 is a literature synthesis that reviews the 
current evidence on the relationship between comorbidity and symptoms in older adults 
with cancer. Chapter 5 reviews the development of a new measure for comorbidity 
burden and symptom perception. Chapter 6 reviews initial psychometric data and the 
findings of the instrument pilot study. Finally, Chapter 7 summarizes the study results, 
outlines limitations, and reviews the implications of this study for clinical practice, 
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REVIEW OF THE LITERATURE 
 
 
This chapter includes a review of background information that is foundational for 
the development of the Comorbidity and Symptom Measurement in Oncology Scale 
(COSMOS) and the interpretation of study results. Relevant literature in the content areas 
of comorbidity and cancer, cancer-related symptoms, measurement of both comorbidity 
and cancer-related symptoms, and the relationship between comorbidity and symptoms is 
reviewed. In addition, a discussion of a conceptual model that blends the Theory of 
Unpleasant Symptoms and the Common Sense model is included as the theoretical 




Comorbidity and Cancer 
 
There is a growing body of literature addressing the effects of comorbidity on 
cancer diagnosis and treatment, cancer-related treatment outcomes such as quality of life, 
and symptom assessment and management in older adults. The effects of comorbidity on 
cancer was one of several areas of research focus, as identified by the report from the 
workshop Exploring the Role of Cancer Centers for Integrating Aging and Cancer 
Research, which was jointly sponsored by the National Institute on Aging and the 




and cancer were identified as (a) the development of a valid comorbidity assessment tool 
that is easy to administer, has minimal patient burden, is culturally sensitive, and is 
economical to administer; (b) exploration of the impact of comorbidity on patient care 
and outcomes of care; and (c) development of predictive models for individualized 
decision making regarding treatment (NCI, 2002). The overall goal of these priorities was 
to develop valid and reliable clinical assessment methods for comorbidity in older adults 
with cancer. The report offered suggestions for implementation of the research priorities, 
including developing a tool based on conceptual and clinically relevant information and 
pilot testing newly developed instruments to establish psychometric data. The 
development of a comprehensive self-report tool that measures comorbidity, symptom 
burden, and symptom attributions will facilitate understanding of the complexities of 
older adults with cancer, comorbidities, and symptoms, and planning and evaluating 
treatment outcomes for this population. 
In 2012, the Institute of Medicine (IOM) published a report entitled Living Well 
with Chronic Illness: A Call for Public Health Action, which defined a chronic illness as 
“a condition that is slow in progression, long in duration, and void of spontaneous 
resolution, and it often limits the function, productivity, and quality of life of someone 
who lives with it” (IOM, 2012, p. 20.). In addition, the report discussed the concept of 
multiple chronic conditions as two or more chronic illnesses that affect one in four 
Americans. Cancer is identified in the report as one of the chronic illnesses that has a 
major impact on health and wellness beyond the initial treatment phase due to age, 
chronic symptoms, multiple chronic conditions, and functional limitations and decline. 




related. Physical functioning in older adults with cancer has been found to be inversely 
correlated with comorbidity, and symptom severity was positively correlated with 
comorbidity (Kurtz, Kurtz, Stommel, Given, & Given, 2001). In addition, comorbidity 
has been found to be related to age and perceived activity restriction in cancer patients 
(Willliamson & Shultz, 1995), and to be an independent predictor of functional 
limitations in the older adult with cancer (Garman, Pieper, Seo, & Cohen, 2003; Vaeth, 
Satariano, & Ragland, 2000). Health care providers must be aware of the normal aging 
process and typical comorbid conditions in older adults and integrate this knowledge into 
geriatric oncology care. 
 
Comorbidity Measurement in the Geriatric Oncology Population 
 
There are several valid and reliable tools for measuring comorbidity that are 
constructed for use with a comprehensive review of the medical chart. Tools commonly 
used to assess comorbidity include the Charlson Index, Cumulative Illness Rating Scale–
Geriatric, Kaplan–Feinstein Index, and Index of Coexisting Disease (De Groot, 
Beckerman, Lankhorst, & Bouter, 2003; Extermann, 2000). The Charlson Comorbidity 
Index is the most widely used measure of comorbidity; it rates 19 diseases with a 
weighted scoring system (1–6 points) that can be adjusted for age and was developed as a 
predictive tool for 1-year mortality among medical patients (Charlson, Pompei, Ales, & 
MacKenzie, 1987; Charlson, Szatrowski, Peterson, & Gold, 1994). The Charlson 
Comorbidity Index is used as the “gold standard” of comorbidity measurement; its 
content validity has been determined over 15 years of use with a wide variety of 
populations. In addition, it is a reliable measure with a test-retest reliability of r = .91 (p = 




trained data collector to extract appropriate information from the medical record and code 
the data. In addition to issues with inaccurate data in the medical record, the use of this 
tool is not practical for the clinician and can be costly for researchers to use.  
A self-report questionnaire version of the Charlson Index was developed by Katz, 
Chang, Sandha, Fossel, and Bates (1996). This tool is comprised of 10 main disease-
oriented questions and several subquestions that assess the presence and severity of 
common comorbidities in older adults. This questionnaire was tested on 170 medical–
surgical inpatients who were 55% female with an average age of 65.3 years; about 13% 
had a cancer diagnosis. Criterion-related validity results were at a moderate level 
(Spearman correlation = .63; p = .0001) with the Charlson Index, and test-retest 
reliability was high (r = .91; p = .0001). The authors identified a potential concern about 
accuracy of the self-report in the lower literacy population (Katz et al., 1996). Currently, 
there are minimal comprehensive self-report measurement tools for comorbidity burden. 
This type of tool has the potential to help clinicians as they formulate a treatment plan 
based on comprehensive patient data. Table 2.1 contains a summary of select comorbidity 
assessment tools. 
 
Cancer-Related Symptoms in the Geriatric Oncology Population 
 
Cancer-related symptoms, including the symptoms of pain, fatigue, nausea and 
vomiting, dyspnea, and depression, have been studied for more than 20 years in a wide 
variety of patients and diagnoses, but very few studies have been specifically focused on 
the older adult population. A small body of research-based evidence is beginning to 
identify inpatients and outpatients aged 27 to 89 years (mean age = 65.7 + 11.9 years) 






Select Comorbidity Assessment Tools 
 
 
Symptom Measure Description Validity & Reliability References 
Charlson Index 
 
Predicts mortality risk 
over a period of a 
few weeks to 10 
years from a broad 
range of diagnoses 
Adaptation also 
predicts mortality, 
length of stay, 
resource utilization, 
and length of stay 
 
Rates 19 diseases with a 
weighted scoring 
system (1–6 points) 
* Adaptation for use with 
large data bases 
Type: Medical record 
data collection 
Uses: Multiple diagnoses 
Content validity: Established 
over 15 years of use 
* Used as the “gold 
standard” of comorbidity 
measurement 
Test-retest reliability: r = .92 











Rating Scale (CIRS) 
– Geriatric 
 
Measures total disease 
burden and severity 
Rates 14 body systems 
with weighted scoring 
system (0 = no 
impairment to 4 = life 
threatening) on a 7-
point Likert-type scale 
Type: Medical record 
data collection 
Uses: Multiple diagnoses; 
specifically tailored for 
the geriatric population 
 
Content validity: Based on 
existing CIRS–General, 
which has established 
validity and reliability 
Concurrent validity: Older 
Americans Activities of 
Daily Living Scale and 
Charlson Index (r = .39) 





Lyman, Parr, & 
Balducci, 1998 
Guralnik, 1996 
Miller et al., 1992 
Disease Count 
 
Measures the number 
of diseases present 
 
Comorbidities are 
counted and totaled 
Type: Medical record 
data collection 
Uses: Multiple diagnoses 
and age groups  
Content validity: Dependent 
on list of comorbidities 
used 
Reliability: Not reported 
Melfi, Holleman, 






Index of Coexistent 
Disease  
 
Measures the burden of 
current and chronic 




Rates 13 categories of 
comorbid diseases with 
two different 
dimensions  
* Index of Disease 
Severity (Grade 0 = no 
coexistent disease to 
Grade 3 = uncontrolled 
disease that causes 
moderate to severe 
disease symptoms) 
* Functional Severity 
(Level 0 = normal 
function to Level 2 = 
serious impairment) 
* Scores based on an  
Content validity: Literature, 
clinical experience 
Concurrent validity: 
Disability scale of Older 
Americans Activities of 
Daily Living Scale  
Interrater reliability: Kappa 
= .5–.6 
-Disease Severity subindex:  
Kappa = .4–.5 
-Functional Severity 
subindex: Kappa = .6–.10 









Table 2.1 (Continued) 
 
 
Symptom Measure Description Validity & Reliability References 
Index of Coexistent 
Disease (continued) 
explicit list of 
symptoms, signs, and 
laboratory tests 







Life Threat Risk Scale 
 
Measures potential 
impact of comorbid 
conditions on short-






dities as absent, active, 
or past history 
Conditions are rated on a 
0–3 scale (0 = 
negligible to 3 = high) 
Type: Medical record 
data collection 
Uses: Cancer patients 
 
Content validity: List of 
comorbid conditions from 
National Institute on 




Reliability: Not reported 






Measures the number 





Evaluates an individual’s 
health based on long-
term drug therapy 
Type: Medical record 
data collection, self-
report 
Uses: A wide variety of 
patient populations 
 
Content validity: Dependent 
on list of drugs used and 
classifications 














Measures the presence 
of comorbid disease 
 
Evaluates the presence of 
disease and in some 
diseases the severity of 
current comorbidities  
Uses a simple 10-item 
questionnaire with a 








Content validity: Charlson 
Index 
Criterion-related validity:  
Charlson Index r = .63 (p = 
.0001) 
Internal consistency: 
Cronbach’s α = not 
reported 
Test-retest reliability: 
Intraclass correlation r = 
.91 (p = .0001) 
Katz, Chang, 
Sandha, Fossel, 




these symptoms, and their relationship with other variables unique to this population. 
Chang, Hwang, Feuerman, Kasimis, and Thaler (2000) studied symptom prevalence, 
intensity, and distress in 240 primarily genitourinary, lung, and hematologic cancers, as 
well as a variety of other cancers. The five most prevalent symptoms reported included 
lack of energy, pain, dry mouth, shortness of breath, and difficulty sleeping. On average, 
study participants reported 11–13 symptoms. Study results indicate that this population 
experienced a high prevalence of intense symptoms and suggested that pain and fatigue 
be considered a marker for the presence of other symptoms. This concept was later 
supported by Given, Given, Azzouz, Kozachik and Stommel (2001), who studied 841 
patients aged 65 years and older with prostate, breast, lung, and colon cancers and found 
that the patients most likely to report pain and fatigue were those who had three or more 
comorbid conditions, lung cancer, and a later stage of disease.  
Dodd, Miaskowski, and Paul (2001) explored the effect of a symptom cluster 
(pain, fatigue, and sleep insufficiency) on the functional status of 93 outpatients (mean 
age =  55.4 years) on chemotherapy at baseline and the end of the third cycle of 
chemotherapy. The symptoms of pain and fatigue contributed most as predictors of 
change in the patient’s functional status. Similar results were obtained by Given, Given, 
Azzouz, and Stommel (2001), who studied 826 patients aged 72–75 years with breast, 
prostate, lung, or colon cancer at the beginning stages of treatment. They found that the 
symptom cluster of pain, fatigue, and insomnia was an independent predictor of a change 
in physical functioning unrelated to treatment or comorbid disease.  
Overall, little is known about symptom experience of the geriatric oncology 




symptoms, and the impact of these symptoms on function and quality of life. In addition, 
there is an emerging body of knowledge addressing the overall symptom experience in 
older adults as it relates to specific diagnoses, stage of disease, cancer-related treatments, 
disease progression, and comorbidities (Lacasse, 2016). 
 
Measurement of Cancer-Related Symptoms 
 
There are several valid and reliable measurement tools commonly reported in 
oncology symptom research, including the Symptom Distress Scale (Degner & Sloan, 
1995; McCorkle & Young, 1978), the Edmonton Symptom Assessment Scale (Bruera, 
Kuehn, Miller, Selmser, & Macmillan, 1991), the Memorial Symptom Assessment Scale 
(Portenoy et al., 1994), the Rotterdam Symptom Checklist (de Haes, van Knippenberg & 
Neijt, 1990), and the M. D. Anderson Symptom Inventory (Cleeland et al., 2000). Table 
2.2 provides a detailed description of these tools and their psychometric properties; a 
summary of the symptoms included in each tool is listed in Table 2.3. 
Both the Memorial Symptom Assessment Scale–Short Form (MSAS-SF; Chang, 
Hwang, Feuerman, Kasimis, & Thaler, 2000) and the Rotterdam Symptom Checklist (de 
Haes et al., 1990) appear to have the most comprehensive list of symptoms that are 
congruent with the most common symptoms found in older adults with cancer (American 
Cancer Society, 2016). Both scales have good internal consistency and validity. The 
MSAS-SF appears to be commonly used in the United States to assess the presence and 
severity of cancer-related symptoms (Chang, Hwang, Feuerman, Kasimis, & Thaler,  
2000). This tool measures the presence of 32 symptoms and their level of distress, if 
present. 






Select Cancer-Related Symptom Assessment Tools 
 
Symptom Measure Description Validity & Reliability References 
Edmonton Symptom 
Assessment Scale  
 




time: ~8 min. 
Nine-item VAS (0–
100mm) to measure 
current symptom levels 
* Numeric rating scale 
can be substituted 
Type: Self-report 
Population: Palliative 
care; medical oncology 
inpatients/outpatients—
elder males with 
advanced disease 
 
* Concurrent validity: 
RSCL, Brief Pain 
Inventory, MSAS, FACT-
G 
* Convergent validity: KPS, 
inpatient status 
* Internal consistency: 
Cronbach’s α = .79 
* Test-retest reliability: 2 
days = .86 (p<.0001); 1 






Chang, Hwang, & 





Craft, & Lickiss, 
1998 
 
M. D. Anderson 




symptoms and their 
interference with 
various aspects of a 
patient’s life in a 24-
hour time period 
Estimated completion 
time: ~8 min. 
 
Thirteen core items 
measured on presence 
and severity (0–10 
scale) 





with multiple cancer 
types 
* Content validity: 
Literature, clinical 
expertise 
* Concurrent validity: 
MSAS 
* Convergent validity: KPS, 
disease severity, number of 
symptoms 
* Internal consistency: 
Cronbach’s α = .85 
(general); Cronbach’s α = 
.82 (gastrointestinal 
symptoms); Cronbach’s α 
= .91 (interference) 
 












severity, and distress 




and distress on three 
subscales 
Estimated completion 
time: ~10 min. 
 
Thirty-two items 
measured on 5-point 
Likert-type scale for 
symptom distress 











* Content validity: MSAS 
* Concurrent validity: 
FACT- G 
* Convergent validity: KPS, 
extent of disease, inpatient 
status 
* Internal consistency: 
Cronbach’s α = .80 global 
distress index; Cronbach’s 
α = .82 physical distress 
index; Cronbach’s α = .76 
psychological distress 
index; Cronbach’s α = .87 
total MSAS 
* Test-retest reliability: 1 







Chang et al., 1998 





A 31-item checklist that 
assesses symptom 
presence and bother  
Content validity: Literature, 
clinical expertise, patient 
validation 






Table 2.2 (Continued) 
 
 









time: ~8 min. 
using a 4-point Likert- 
type scale (0 = not 
bothered at all to 4 = 










Symptom Distress Scale 
Internal consistency: 
Cronbach’s α = .88 
(psychological scale) 










time: ~3 min. 
 
Original tool had 10 
items 
Thirteen items measured 
on a 5-point Likert-
type scale for 
symptom distress 
Some revised versions 




types of cancer 
patients 
 
* Content validity: 
Literature; established with 
patients actively 
undergoing chemotherapy 
and radiation treatments for 
cancer 
* Convergent validity: 
Inventory of current 
concerns, Profile of Mood 
States subscales 
* Internal consistency: 
Cronbach’s α = .78–.89 
* Test-retest reliability: r = 
.78 











Note. RSCL = Rotterdam Symptom Checklist; MSAS = Memorial Symptom Assessment Scale; FACT-G = 






















Rotterdam Symptom Checklist 
31 Items 
Symptom  









Sensation of well-being 
Shortness of breath 
 
(Chang, Hwang, 
Feuerman, & Kasimis, 
2000; Jenkins, Schulz, 
Hanson, & Bruera, 2000; 












Lack of appetite 
Nausea 




Shortness of breath 
 
Additional Items 
* BMT:  
Bleeding 
Diarrhea 
Difficulty paying attention 
Feeling physically sick 
Mouth sores 
Weakness 
* Gastrointestinal Cancer:  
Soreness at radiation site 
Changes in skin 

















Lack of appetite 
Lack of energy 
Mouth sores 
Nausea 
Numbness and tingling 
Pain 
Changes in sexual interest 
Shortness of breath 
Abdominal aches 
Anxiety 
Burning or sore eyes 
Constipation 
Decreased sexual interest 
Depressed mood 










Lack of appetite 
Lack of energy 
Hair loss 




Shortness of breath 
















(McCorkle & Benoliel, 






























(Cleeland et al., 2000) 
Sweats 







Feuerman, Kasimis, & 


















subscales, including a physical and psychological symptom scale and a global distress 
scale, and has been tested in oncology inpatient and outpatient populations. This tool has 
acceptable internal consistency reliability (Cronbach’s α = .76–.87), variable 1-week test-
retest reliability (Pearson r = .40–.84), and convergent validity with the Functional 
Assessment of Cancer Therapy–General (FACT-G) tool. Few studies have explored the 
use of these tools in the geriatric oncology population, and there is little published 
research on measurement tools that assess older adults’ appraisal of the origin of a 
particular symptom or group of symptoms. 
Recently, the Patient-Reported Outcomes Measurement Information System 
(PROMIS) initiative developed standardized tools for measuring common patient-
reported outcomes in health care (Cella et al., 2010). There are multiple PROMIS 
measures available for many outcomes related to symptoms commonly found in cancer-
survivor populations, such as pain, fatigue, sexual function, sleep disturbance, anxiety, 
distress, sleep disturbance, gastrointestinal symptoms, dyspnea, and cognitive 
functioning. In addition, the Global Health Scale is a 10-item scale and assesses general 
health; quality of life; physical, mental, and social health; physical function; and three 
symptoms (pain, fatigue, and emotional symptoms; Hays, Bjorner, Revicki, Spritzer, & 
Cella, 2009). However, there is no global symptom assessment. Wagner et al. (2015) 
recently demonstrated the successful integration and use of select PROMIS symptom and 
physical-function measures into the electronic medical record to provide automated 










An individual’s interpretation of his or her symptoms can be comprehensively 
understood by using an information-processing model such as the Common Sense Model 
(CSM). This model proposes that people have specific ideas about their illnesses and that 
these ideas guide coping behaviors for health and illness (Ward, 1993). The CSM 
describes three stages of information processing, including cognitive and emotional 
representation of illness, coping with illness, and appraisal of the effectiveness of the 
coping strategy. The representation of symptoms includes the following characteristics of 
a symptom: identity, perceived cause, temporal nature, outcomes of disease related to the 
symptom, and ideas about potential treatments. The coping stage includes an individual’s 
behavioral action based on the representation of the illness or symptom. The appraisal 
stage involves the individual’s evaluation of the outcomes of the coping phase, which 
may change the person’s representation or coping behaviors for the symptom. This 
general framework integrates the physical, psychological, and social dimensions of 
symptom perception and subsequent choices of symptom-management actions. It assists 
the clinician in understanding the complex nature of symptom interpretation and its 
potential impact on patient-care treatments and outcomes.  
Understanding the subjective differences between the origins of symptoms in the 
older adult may be significant in the development and implementation of tailored 
interventions for symptom management in this population. The distinction between the 
disease process, treatment side effects, and the normal physiological changes of aging 
may guide individual health-behavior choices. Results of a study of HIV-positive 




can make specific distinctions between identifiable causes of physiological symptoms of 
disease and treatment (Johnson, Stallworth, & Neilands, 2003). In addition, older adults 
may have a multidimensional representation of aging. Using the CSM framework, older 
adults with cancer and comorbidities use body sensations, past experiences of illnesses 
and symptoms, and related interactions with family, friends, and health care providers to 
make decisions about their symptoms. A study by Prohaska, Keller, Leventhal, and 
Leventhal (1987) revealed that mild symptoms of short or long duration are more likely 
to be attributed to aging than severe, short-term symptoms. In addition, the attribution of 
mild symptoms with gradual onset to aging resulted in a greater acceptance of symptoms 
with a subsequent delay in seeking health care for the symptoms (Prohaska et al., 1987). 
Little is known about older adults with cancer and comorbidities and their perception of 
symptoms and their related causes. Understanding symptom perception in older adults 
with cancer may lead to more timely diagnosis and treatment of disease and 
comprehensive symptom management. 
Gender may also play an important part in the interpretation of symptoms of 
chronic and acute illnesses. The literature on cardiac patients suggests that men and 
women have different perceptions of cardiac-related symptoms. Granot, Ferber, and 
Azzam (2004) conducted a study of 61 adults (29 women, 32 men) with complaints of 
chest pain and a diagnosis of unstable angina to evaluate the multidimensional perception 
of the experience of chest pain symptoms between men and women. The mean age of the 
study population was 68.5 years. Structured interviews were conducted with study 
participants and results suggest that there are gender differences in the perception of the 




tended not to attribute their chest pain to heart disease, and demonstrated more perceptual 
responses to pain by reporting more symptoms than men. In contrast, Jackson, 
Chamberlin, and Kroenke (2003) studied 528 people at a general-medicine walk-in clinic 
with a chief complaint of physical symptoms and found that there were no significant 
gender differences in symptom distribution, duration, and severity; however, women 
were more likely to report symptoms as currently bothersome.  
Van Wijk, Huisman, and Kolk (1999) conducted a longitudinal study to explore 
the gender differences in daily symptom reporting by 153 participants (>50% women). 
They found significantly higher symptom reporting by women, and that illness behavior 
was strongly associated with the experience of physical symptoms. Finally, Hofman and 
colleagues (2004) studied the perception of expected side effects associated with cancer 
therapy in 938 cancer patients. Results indicate that the median number of side effects 
expected was nine and that women expected more side effects than men. An additional 
finding was that participants aged 60 and older expected fewer side effects than younger 
participants. In summary, it appears that there is a gender difference in symptom 
perception but it is unclear how this difference may be moderated by age and 
comorbidities. 
 
Cancer-Related Symptom Appraisal in Older Adults 
 
Some older adult patients may learn to cope with chronic symptoms (such as pain 
and fatigue) as a normal part of the aging process, have different expectations regarding 
functional ability compared to younger adults, perceive symptoms as age-related, and 
experience less symptom distress due to their frame of reference. McMillan (1989) 




outpatients being treated for lung or breast cancer. Subjects were stratified into two age 
groups for comparison: those <55 years and those >56 years. Age and symptom severity 
were correlated and comparative results showed that younger patients reported a higher 
symptom severity than older patients. This study suggests that older patients experience 
physical symptoms with less intensity than younger patients; however, it is unknown 
whether this is due to a decreased overall symptom experience or an altered symptom 
perception by older patients (McMillan, 1989). The meaning of aging is very individual 
and has many dimensions that create an individual context for defining symptoms. 
Dimensions for ascribing meaning to symptoms experienced by older individuals include 
the unique individual, their life experiences, chronic conditions, and individual beliefs 
about quality of life. 
Symptom perception is also multidimensional and incorporates gender and 
cultural perspectives, life experience and beliefs, and the overall meaning of a particular 
sensation (Teel, Meek, McNamara, & Watson, 1997). The life experience of an older 
adult with cancer is likely to include comorbidities that have an impact on the meaning of 
symptoms for the individual and his or her family. Literature suggests that comorbidities 
and symptoms within the oncology population may be predictors of overall prognoses 
and may have a major impact on treatment decisions and disease outcomes (Hall et al., 
2002; Piccirillo & Feinstein, 1996; Repetto et al., 1998; Satariano & Ragland, 1994). 
Currently, there are few measures that examine comorbidity and symptom perception in 
cancer patients. The development of a tool that can be used by clinicians to identify the 
burden of comorbidity and coexisting symptom perception in older adults with cancer 




among this population. 
 
Comorbidity and Symptoms 
 
Age has been linked to physical symptoms and comorbidities. Older age may be 
related to increased physical symptoms mediated by an increased number of chronic 
illnesses (Kolk, Hanewald, Schagen, & Gijsbers van Wijk, 2003). In addition, a study of 
advanced lung cancer survivors aged 65–89 with increased comorbidities found that the 
participants with increased comorbidities tended to report increased numbers of 
symptoms (Gift, Jablonski, Stommel, & Given, 2004). An interviewer-administered tool 
to measure comorbidities and their associated symptoms was developed by Crabtree, 
Gray, Hildreth, O’Connell, and Brown (2000). The Comorbidity Symptom Scale (CSS) 
was developed based on interview data that identified the most prevalent comorbidities 
found in older adults. The scale incorporates the presence of 23 comorbidities and the 
severity of their associated symptoms. Test-retest reliability in a group of cataract surgery 
patients aged 65–92 years was reported as r = .87 (p<.001). This scale allows the 
interviewer to obtain symptom data directly from the patient, but comorbidities might not 
be identified using this measure if there are no associated symptoms. In addition, the CSS 
has moderate concurrent validity with assessments of perceived health, anxiety and 
depression, and activities of daily living. This tool provides a general overview of 
comorbidity and specific symptoms, but does not allow for broad assessment of 
symptoms with multiple attributes such as disease, treatment, and aging. A further review 
of the literature that addresses the intersection between cancer, comorbidities, and 







The Theory of Unpleasant Symptoms (TOUS) was used as the conceptual basis 
for the initial development of the COSMOS (Lenz, Pugh, Milligan, Gift, & Suppe, 1997; 
Lenz, Suppe, Gift, Pugh, & Milligan, 1995). This middle-range theory describes both the 
antecedents and sequelae of unpleasant symptoms such as cancer-related fatigue or pain. 
The model incorporates three factors that influence symptoms, including physiological, 
psychological, and situational factors. Physiological factors that may precede unpleasant 
symptoms include normal and altered body function or comorbidity, an individual’s level 
of energy, and an individual’s cellular response to healing. Psychological factors include 
the state of mental health, such as depression or anxiety, and the individual’s reaction to 
illness. The situational factors include social support, living arrangements, and so forth. 
These three factors interact with each other and have a direct impact on the development 
and exacerbation of symptoms and an individual’s symptom perception. Symptoms in 
this model are depicted as having four components: distress, duration, quality, and 
intensity. Symptoms are also thought to occur in groups or clusters, interact with each 
other, and ultimately affect an individual’s functional status, cognitive functioning, and 
physical performance. The effect of symptoms on overall performance, in turn, has an 
adverse impact on the symptoms and factors that were antecedent to symptom 
development.  
A blended conceptual model using the CSM of symptom perception and appraisal 
and the TOUS was used as a basis for the current study. The Perception of Unpleasant 
Symptoms model describes physiological, psychological, and situational factors as 




Perception of these factors influences overall symptom burden that affects the outcomes 
of the symptom experience and comorbidity management. In this study, this outcome was 
defined as interference with functioning. The impact of the perception of symptoms and 
comorbidities may affect both symptom burden and general functioning. Interference 
with functioning, in turn, has an effect on perception of symptoms and comorbidities. A 
depiction of this model is presented in Figure 2.1. 
This model suggests that symptom-management interventions may be effective at 
the antecedent level to prevent or decrease the perception of symptoms and comorbidities 
and the subsequent development of symptoms that have an impact on functional 
performance (Lenz et al., 1997). The COSMOS may provide valuable insight into some 
of the antecedents to symptom development in the older adult and guide symptom-
management interventions to increase performance that may be affected by symptoms. 
The presence of comorbidity in the older adult with cancer may lead to the development 
of complex symptoms, which may affect overall functioning and quality of life (Dodd et 




This chapter summarizes a theoretical- and practice-based foundation for the 
development of a comprehensive clinical assessment tool for cancer survivors with 
multiple chronic illnesses and symptoms. In addition, classic measures for comorbidity 
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Figure 2.1 Blended model of Theory of Unpleasant Symptoms and Common Sense 
Model. 
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The Comorbidity and Symptom Measurement in Oncology Scale (COSMOS) is a 
newly developed scale that measures comorbidity burden and symptom perception. 
COSMOS uniquely combines a self-report assessment of a broad range of comorbidities 
commonly found in older adults, such as arthritis and cardiovascular, renal, 
gastrointestinal, hepatic, endocrine, and neurological disease processes, with a 
comprehensive symptom perception assessment (Tabloski, 2014). The juxtaposition of 
reported comorbidities and symptom perception provides the older adult with an 
opportunity to consider symptoms within the context of her or his current health, 
inclusive of comorbidities, cancer diagnosis, treatment, and perceptions of the aging 
process. The scale may provide a unique view of the symptom experience of the older 
adult with cancer and lead to symptom-management guidelines tailored to the specific 
needs of older adults with cancer and comorbidities. 
The COSMOS was developed for a target population of older adults (>65 years 
old) with cancer who have more than one comorbidity and more than one symptom. 
During construction of this new measure, specific physiological changes of aging were 




clarity of thought with complex concepts, and impaired vision (Burnside, Preski, & 
Hertz, 1998; Ingram et al., 2002; Rasin, 2004). The COSMOS has a simple construction, 
easy readability, and simple instructions. It is anticipated that the scale can be read easily 
with 12-point font and a high-contrast print of black lettering on a white background. The 
estimated time for completion of the scale is about 15 minutes, and it can be completed 
by a proxy respondent if the patient is unable to physically complete the scale. The 
COSMOS is a self-report scale and should be a valid and reliable measure of the patient’s 
comorbidity burden and symptom perception (Ingram et al., 2002; Silliman & Lash, 
1999; Tishelman, Taube, & Sachs, 1991). Subscales were developed based on simplicity 
and ease of use and include dichotomous, Likert-type, and categorical scales. 
The major components of the scale are comorbidity burden and symptom 
perception. Comorbidity burden is defined as the presence of illness or chronic condition 
manifested over a lifetime or past year or month and its effect on daily life. Chronic 
conditions that may have acute exacerbations may be more sensitive to temporal changes 
and are assessed within a shorter timeframe to capture this phenomenon. Symptoms are 
defined as “subjective experiences reflecting changes in a person’s biopsychosocial 
function, sensation, or cognition” (University of California, San Francisco School of 
Nursing Symptom Management Faculty Group, 1994, p. 273). Symptom perception has 
been defined as an individual’s cognitive appraisal of a sensation or function within a 
multicontextual perspective (Teel, Meek, McNamara, & Watson, 1997). This study 
defines symptom perception to include symptom bother (how much a symptom bothers 
an individual). In addition, symptom attribution is defined as the individual’s view of 




Research Design and Methods 
 
Overview of Design 
 
A crucial factor in instrument development is the assessment of content validity. 
The determination of content validity includes a two-stage process, as described by Lynn 
(1986). The first stage is described as the developmental stage, which incorporates 
identification of the content domain(s), comprehensive item generation, and construction 
of a useable format for generated items. Preliminary content validity for COSMOS was 
derived from a critical evaluation of the literature on the measurement of comorbidity, 
cancer and comorbidity, cancer-related symptom measurement, and symptom appraisal. 
The content of the comorbidity subscale was derived from a review of the literature on 
measurement of comorbidities and oncology-related studies that included symptom 
assessment and comorbidities. The symptom perception subscale is an adaptation of the 
Memorial Symptom Assessment Scale–Short Form (MSAS-SF), which is reported to 
have moderate-to-good validity and reliability in the older adult cancer population 
(Chang, Hwang, Feuerman, Kasimis, & Thaler, 2000). In addition, initial content validity 
of the symptom subscale was supported by reviewing a list of symptoms that accompany 
the most prevalent cancers within the older adult population (aged 60+ years), including 
lung, breast, prostate, colorectal, pancreatic, bladder, and ovarian cancers, and leukemia 
and non-Hodgkin’s lymphoma (American Cancer Society, 2016). 
This study was a continuation of the instrument development process and 
implemented Stage 2, which is the judgment-quantification stage. This stage included 
utilizing a panel of experts to determine the relevancy of each item in the instrument and 




to assess and shape a new instrument for pilot testing. The next step in the study was to 
complete the determination of content validity and perform initial testing of COSMOS in 
a population of older adults with cancer. 
A mixed-method study design was used to conduct initial psychometric testing of 
COSMOS and examine its feasibility in measuring comorbidity and symptom perception 
in older adults with cancer. Initial content validity was determined by using a panel of six 
expert clinicians who had a working knowledge of oncology care, gerontology, or 
geriatric oncology care and symptom assessment and management. The original tool was 
revised based on the results of the expert panel critique and pilot tested with a population 
of older adults with cancer. A mixed-methods approach to data collection was used in 
both the initial determination of content validity and the pilot test of the instrument. 
Quantitative data were collected from the panel of experts regarding the relevance of 
comorbidity assessment questions and symptom perception scales. Qualitative data in the 
form of written comments were collected with regard to specific suggestions for revision 
of the original tool, including omission of critical comorbidity and symptom questions. 
During the pilot testing phase of the study, participants were asked to complete the 
revised tool and then were invited to comment on specific aspects of the tool. Purposeful 
revision of the tool was based on the pilot data. The study schema is shown in Figure 3.1. 
 
Description of Instrument 
 
The COSMOS (version 1) is a self-administered scale that measures comorbidity 
burden and multidimensional symptom perception in adults with cancer. The COSMOS 
includes the comorbidity burden subscale, the symptom perception subscale, and a 





Figure 3.1 Study schema. 
Phase 1: Determining Content Validity 
 
Stage 1: Developmental (completed preliminary work) 
*Identification of content domain through (a) review of literature: measurement of 
comorbidity, comorbidity and cancer, cancer-related symptom measurement, and 
symptom appraisal; and (b) clinical experience 
*Comprehensive item generation 
*Construction of tool format 
 
Stage 2: Judgement-Quantification 
Expert Panel (6) 
▪ Clinical practice or research expertise in oncology, gerontology, or geriatric 
oncology care and symptom management 
▪ Publications within specialty area in refereed journals (>3) 
▪ National presentations in area of expertise (>2) 
▪ Varied geographic locations 
 




Receiving second or subsequent 
chemotherapy, radiation therapy,  or 
biotherapy, OR 2 weeks post 
surgical intervention 









n = 30 
[15 Test-retest] 
   
Phase 2: Pilot Test Revised Tool 
 
Participant Eligibility: 
▪ Age of >65 years 
▪ Cancer diagnosis for >2 months 
▪ >2 documented comorbidities 
▪ >1 documented symptoms 
▪ Can read, write, comprehend, and speak English 
▪ Alert and oriented to person, place, and time  
Exclusion Criteria: Cognitive impairment or disorientation as 
determined by the Mini Mental Status Exam 




The comorbidity burden subscale combines a 38-item checklist comprised of 
yes/no questions that assess the presence of a comorbid disease and a four-point scale for 
rating the effect of the comorbidity on daily life. The scale has 32 items focused on 
physical conditions, four items focused on psychological conditions, and two chronic 
symptoms that can be defined as a chronic comorbidity (pain and fatigue). Overall 
readability of this subscale is a 7.1 grade level, as measured by the Flesch-Kincaid 
Readability Scale (Paz, Liu, Fongwa, Morales, & Hays, 2009).  
The symptom perception subscale has three component scales, including the 
presence of physical and psychological symptom scale, the symptom bother scale, and 
the symptom attribution scale. The symptom presence subscale has 32 items (26 physical 
symptoms and six psychological symptoms). This scale is an adapted version of the 
MSAS-SF, which measures the presence of symptoms and their level of distress if 
present (Chang et al., 2000). The original MSAS-SF has been tested in oncology inpatient 
and outpatient populations and has established internal consistency reliability 
(Cronbach’s α = .76–.87), variable 1-week test-retest reliability (Pearson r = .40–.84), 
and convergent validity with the Functional Assessment of Cancer Therapy–General tool 
(Chang et al., 2000). The symptom bother subscale of the COSMOS is a three-point 
Likert-type scale designed to measure symptom distress; it was collapsed from the 
original five-point scale in the MSAS-SF. This scale was collapsed to facilitate the 
completion of the tool with minimal response burden for the older adult population. The 
symptom attribution subscale includes five descriptors designed to collect data on 
participants’ perceptions about the cause of their symptom, including cancer, cancer 




explanation. In addition, there is a space for participants to add and evaluate other 
symptoms they are experiencing that are not on the list. Overall readability of this 
subscale is a 3.8 grade level as measured by the Flesch-Kincaid Readability Scale (Paz et 
al., 2009). Table 3.1 describes the scoring system for the COSMOS. 
 




A panel of 12 experts was invited to participate in the evaluation of the content of 
the scale. Seven expert clinicians/researchers agreed to participate; however, only 6 
completed the survey within the study timeframe. Each participant met the following 
inclusion criteria: 
▪ Clinical practice or research expertise in oncology, gerontology, or geriatric 
oncology care and symptom management 
▪ Publications within specialty area in refereed journals (>3 publications) 
▪ National presentations in area of expertise (>2 presentations) 
Experts were identified through specialty-organization contacts and literature searches for 
publications listed in traditional health care literature databases. Every effort was made to 




Expert Panel Tool-Critique Form 
 
Each participant in the panel of experts received a copy of COSMOS version 1 
(v1; Appendix A) and used a critique form to record item relevancy and overall 
instrument relevancy for COSMOS. A Likert scale was used for determining relevancy of 






Scoring Guidelines for COSMOS 
 
 








Assesses the presence 
of comorbidity over 




Yes = 1 
No = 0 
 





perceived effect of 
comorbidities on 




Each comorbidity:  
0 = “not at all” 
+1 = “a little” 
+2 = “some” 





Assesses total burden 
of comorbidity on 
daily life 
 
Continuous Total comorbidities present plus 
comorbidity impact score 





Assesses the presence 
of symptoms over 
the previous month 
Dichotomous 
Nominal 
Yes = 1 
No = 0 
Physical: 0–26 
Psychological: 0–6 







Measures the amount 
of symptom distress 
or bother 





Each symptom:  
+0 = “none or a little” 
+1 = “some” 








Continuous Total symptoms present and 
symptom bother scores 








perceived origin of 
each symptom 
present 
Nominal Each symptom scored on each 
“attribute”: aging, cancer, cancer 
treatment, medication for 
noncancer conditions, or other 
Attributes are used as descriptors for 








Rating New Item Relevancy 
 
 
4-Point Rating Scale for Describing Relevancy of Items and Scales 
Rating Description 
1 Not relevant 
 
2 Unable to assess relevance without item revision, OR  
Item is in need of such revision that it would no longer be relevant 
 
3 Relevant but needs minor alteration 
 
4 Very relevant and succinct 
 
    Adapted from Lynn, 1986, p. 384. 
 
addition, each expert panelist was asked to comment on specific aspects of the overall 
tool, such as clarity of instructions, time frames of patient experiences, critical omissions 
from each scale, suggestions for specific item revision, tool format, and general overall 




I obtained initial approval for the study from the University of Utah Institutional 
Review Board and the Clinical Cancer Investigations Committee. Study approval was 
also obtained from University of Arizona Medical Center (UAMC), which provided 
access to all UAMC entities. Following approval, I identified potential expert panel 
participants according to the eligibility criteria stated above. Each potential expert 
panelist (N = 12) was contacted via email and invited to participate in the study by using 
a standardized letter explaining the purpose of the study, their role within the study, and 
the expected time frame of the study. The panel recruitment letter is shown in Appendix 




packet was sent to them and they were given 4 weeks to return their responses about the 
scale; the packet included the following: 
▪ An introduction letter to the study;  
▪ A brief description of the scale, its content domains, the objectives for scale 
construction, and a definition of terms; 
▪ Specific instructions and guidelines for study participation and data collection; 
▪ A copy of COSMOS v1; 
▪ A copy of the scale, with relevancy rating scale and comments fields for each 
item; and 
▪ A self-addressed, stamped envelope for returning item ratings and comments. 
The full expert panel packet is provided in Appendix C. 
Participants were asked to rate each item to assess the relevancy of each item of 
the comorbidity burden subscale, symptom perception subscale, symptom attribution 
descriptors, and the entire tool. In addition, each panelist was asked to identify omissions 
from this subscale and comment on items that were identified as having minimal 
relevancy (those rated with a 1 or 2). In addition, each expert panelist was asked to 
comment on specific aspects of the overall tool, including clarity of instructions, overall 
format in relation to the target population, and any omissions from either subscale. 
Reminder emails were sent to the experts at 2  and 4 weeks after the initial packet 
mailing. 
Item revisions were incorporated into the second version of the scale. Revision 
suggestions from the expert panel had strong agreement, and the process did not need to 









A detailed plan was developed for coding and building a database for quantitative 
data in SPSS 23.0® for Windows. All quantitative data were entered into one database by 
the PI and then compared with raw data for accuracy. Mismatched data were re-entered. 
Open-ended responses from the participants were carefully analyzed for specific 
suggestions for improvement by me. 
Professional characteristics of the expert panel, such as number of years in 
nursing, number of years in specialty practice (oncology, gerontology, symptom 
management), and current professional position and responsibilities, were described 
using descriptive statistics, including frequencies for nominal data and measures of 




Aim 1 was to determine the content validity of the COSMOS using a survey 
method with a panel of expert clinicians/researchers in oncology, gerontology, and 
geriatric oncology and symptom management. 
The content validity index (CVI) is defined as the proportion of experts who rate 
an item as 3 or 4 on the relevancy rating scale previously defined (Lynn, 1986; Waltz, 
Strickland, & Lenz, 1991). For example, if 5 out of 6 experts rate an item as 3 or 4, the 
CVI for that item is .83, which is the minimal level required to establish content validity 
at the .05 significance level (Lynn, 1986). However, Polit, Beck, and Owen (2007) 
suggested that a CVI for an individual item within a scale of greater than .78 can be 
considered as excellent agreement, regardless of the number of expert raters. The CVI for 




as content valid (Lynn, 1986; Waltz et al., 1991). The minimal criteria for retaining each 
item was a CVI of >.83 (an agreement of 5 out of 6 expert panelists), with p<.05. A 
limitation of using the CVI alone is that it simply reflects the proportion of agreement 
without accounting for panel experts’ agreement by chance. An attempt to control for this 
limitation is to use a conservative number of expert panelists and analyze all rating 
categories separately. An additional measure of agreement was also used. 
The total intraclass correlation coefficient (ICC) of agreement was calculated for 
the comorbidity burden and symptom perception subscales and an individual ICC was 
calculated for each item within each subscale. The ICC has been defined as a special case 
of the weighted multirater kappa when rating categories are equally spaced along a single 
dimension (Fleiss & Cohen, 1973). The ICC (2,1) was chosen for this study, which 
reflects a two-way, random effects, absolute statistic. The interpretation of the multirater 
kappa coefficient and ICC are similar, and similar definitions and interpretations of 
values can be used (Fleiss & Cohen, 1973). The level of strength of agreement of ICC 
can be described as follows: a value of <.40 is considered poor strength of agreement, 
.40–.59 is fair strength, .60–.74 is good strength, and ≥.75 is excellent strength (Cicchetti, 
1984; Fleiss 1971; Wynd, Schmidt, & Schaefer, 2003). The evaluation of the content 
validity results was based on the absolute responses of 6 expert panelists using both the 
CVI and ICC. The minimal criteria for retaining each item is a CVI of >.83 (an 
agreement of 5 out of 6 expert panelists), with p<.05 and an ICC of >.60. Of note, a CVI 
of .80 was used for two items that were answered by only 4 experts. Subscale revisions 
were based on the interrater agreement of the expert panel and their qualitative 




▪ Items with CVI>.80 and ICC>.60 were retained for pilot testing. 
▪ Items with CVI of .5–.79 (identified as having potential relevancy) were 
revised and incorporated into the tool. 
▪ Items identified as omissions by >2 panelists were developed and added to the 
tool. 
▪ Recommendations identified in the comments of >2 expert panelists were 
considered for incorporation into the revised tool prior to pilot testing.  
Descriptive interview data such as comments on specific aspects of the overall 
scale, including clarity of instructions, time frames of patient experiences, critical 
omissions from each scale, suggestions for specific item revision, tool format, and 
general overall comments about the tool, were analyzed to identify key critique elements 
based on the categories listed above. Following the comprehensive generation of items 
and review by experts in the field, final decisions were made regarding item inclusion 
and the final format of the instrument was prepared for administration to a representative 
target sample. 
 
Pilot Test of COSMOS 
 
Sample and Setting 
 
A convenience sample of 62 participants was recruited from outpatient care 
settings in southwest Arizona. Initial participant contacts were made via primary cancer 
care providers at a comprehensive cancer center affiliated with a university teaching 
hospital after appropriate eligibility screening. In addition, participants were recruited 
from a variety of community groups, including faith communities and cancer support 
groups. Participant eligibility criteria for pilot testing of COSMOS included:  
▪ Age>65 years; 




▪ >2 comorbidities, as documented in the medical record; 
▪ >1 symptoms, as documented in the medical record; 
▪ The ability to read, write, comprehend, and speak English; and 
▪ A Mini Mental Status Exam (MMSE) score of >23. The first 40 participants 
were screened using the MMSE. It was found that this screening criterion was 
very consistent, and resulted in no potential participants being ruled out. Due 
to the consistent screening results, this criterion was dropped so as to facilitate 
recruitment and study enrollment. 
Participants were stratified into two groups according to treatment status. Both 
men and women undergoing active cancer therapy (chemotherapy, radiation therapy, 
biotherapy, hormonal therapy, and up to 2 weeks after cancer-related surgery) or those 
who were >1 year off of cancer-related treatment were recruited. Convenience quota 




This phase required the careful consideration of sample size, which facilitated 
initial scale development. The determination of an appropriate sample size was crucial to 
the accurate development of the instrument. If a sample size is too small, it will lead to 
inaccurate internal consistency calculations, yielding an erroneous inclusion or exclusion 
of items and diminished applicability across populations (DeVellis, 2003). 
Several discussions about sample size in pilot studies have been published. 
Julious (2005) suggested that a minimum of 12 participants per group should be 
considered for studies in the medical field. This suggestion is congruent with van Belle’s 
(2002) assertion that at least 12 observations should be used in constructing a confidence 
interval. More recently, Johanson and Brooks (2010) recommended that 30 representative 




focused on preliminary scale development. 
Hertzog (2008) published an extensive discussion of the determination of sample 
size for pilot studies based on the construction of confidence intervals (CIs) and attrition 
rates. It is suggested that a sufficient sample size of 10 participants for simple 
instrumentation issues such as clarity of instructions, item wording, and instrument 
administration issues is appropriate. Hertzog suggested that a CI of at least 90% be 
observed when measuring internal consistency and test-retest reliability. Based on 
Hertzog’s calculations, a minimal sample size of 35–40 per group for test-retest 
reliability (r = .70–.80) and 25–40 per group for internal consistency (Cronbach’s 
alpha>.70) is suggested. The minimal recommendation for sample sizes related to 
instrumentation is 25 participants per group, although 35–40 participants per group are 
preferred (Hertzog, 2008). 
The calculation of sample size using optimal statistical power is a widely accepted 
method of determining a statistically supported sample size for a pilot. A priori statistical 
power calculation based on the preliminary exploration of the performance of a newly 
developed measure for comorbidity burden and symptom perception was performed. 
Sample size was based upon an anticipated effect size, desired power of .8, and 
significance of p<.05 (two-tailed).  
Effect size was calculated based on studies that reported similar variables based 
on similar study populations. Bender et al. (2008) reported on a study that examined 
symptom clusters in adults with chronic health problems, including both cancer survivors 
and participants with no cancer history (n = 154 and n = 846, respectively), who had an 




comorbidities in cancer survivors and a mean of 5.1 (SD = 2.9) comorbidities in 
participants with no cancer history. A moderate effect size of .59 was calculated, 
indicating that it was anticipated that a moderate difference might be detected between 
the number of comorbidities in the cancer and noncancer survivor populations. It was 
likely that this difference would include the measure of comorbidity burden that accounts 
for presence of the comorbidity and its effect on the individual’s everyday life.  
The effect size for symptom burden was calculated using information from 
Heidrich, Egan, Hengudomsub, and Randolph (2006), who conducted a comparative 
study of women aged 65 and older, including 18 breast cancer survivors and 24 women 
without a breast cancer history. They found no significant group differences with regard 
to symptom presence, bother, and chronic health problems. Based on this study 
population, the calculated effect size for symptom presence (.079), symptom bother 
(.125), and chronic health problems (.31) can be considered small. The populations 
described in the study conducted by Bender et al. (2008) were also examined for 
symptom presence. Bender and colleagues found no difference between the symptom 
presence of cancer survivors (M = 7.8, SD = 4.3) and those with no cancer history (M = 
7.8, SD = 4.4). Both studies supported the conclusion that there is a very small difference 
between the symptoms reported by cancer populations and noncancer populations. It is 
important to note that the treatment statuses of these two study populations were not 
clearly described. The examination of the sensitivity of an instrument to detect a 
moderate difference between cancer survivors on active treatment and those off treatment 
for 1 of more years may yield valuable information about cancer-related symptom 




presented in Table 3.3. 
The sample size for comorbidity presence was calculated for a moderate 
anticipated effect size (Cohen’s d = .5) with power of .8 and resulted in 128 participants 
(64 participants/group) (Lenth, 2009; Soper, 2012). In addition, the sample size for 
symptom burden was calculated for a small anticipated effect size (Cohen’s d = .3) with 
power of .8 and resulted in 788 participants (394 participants/group) (Lenth, 2009; Soper, 
2012). The results of the sample size calculation for anticipated small and moderate effect 
sizes extend beyond the minimal recommendation of 25–40 participants per group for 
instrumentation pilot studies (Hertzog, 2008; Johanson & Brooks, 2010), and were not 








Number of  
Comorbidities Reported 
Number of  
Symptoms Reported 
Symptom Burden Score 
(Presence & Bother) 
Bender et al., 2008 
 
With cancer (all types): 
n = 154 





With cancer: M = 6.8 
(SD = 2.9) 
No cancer history: M = 
5.1 (SD = 2.9) 





With cancer: M = 7.8 
(SD = 4.2) 
No cancer history: M = 
7.8 (SD = 4.4) 





With cancer: Not 
applicable 








With breast cancer: n = 
18 
No breast cancer 






With cancer: M = 5.44 
(SD = 4) 
No cancer history: M = 
4.5 (SD = 2) 







With cancer: M = 12.17 
(SD = 5.88) 
No cancer history: M =  
11.75 (SD = 4.79) 






With cancer: M = .84 
(SD = .54) 
No cancer history: M =  
.75 (SD = .4) 






Based on current literature, power analysis, and considerations of feasibility of 
recruitment of a vulnerable population, a recruitment goal of 30 participants in each 
treatment group, with an anticipated yield of 25 complete data sets per group, was 




The MMSE was initially used to screen potential participants for their cognitive 
capacity to participate in the study. The MMSE is designed to assess global cognitive 
status and requires 5–10 minutes to administer, although it is not a timed test (Folstein, 
Folstein, & McHugh, 1975). The MMSE has been used in a wide variety of populations 
and is a valid and reliable measure of global cognitive status. This measure consists of 
two parts; the first requires verbal responses only and assesses orientation, memory, and 
attention, while the second assesses the ability to name objects, follow verbal and written 
commands, write a sentence, and copy a pentagon. The maximum score is 30, and lower 
scores indicate lower cognitive functioning. In a study by Crum, Anthony, Bassett, and 
Fulstein (1993), 18,056 adults were assessed with the MMSE and their results were 
correlated with age and education. The results of this study indicate that MMSE scores 
decrease with age and that lower educational background is associated with lower MMSE 
scores. This study suggests that the usual cutoff score of 23 yields a sensitivity of 87% 
and a specificity of 82% for determining cognitive functioning (Crum et al., 1993).  
COSMOS v2 was used to measure comorbidity burden and symptom perception 
(symptom presence, distress, and attribution) in older adults with cancer. The intent of 
this scale is to measure several physiological and psychological factors, as described in 




as comorbidity burden and the presence of common symptoms. COSMOS v2 is shown in 
Appendix D. 
A general information questionnaire (GIQ) was used to collect descriptive data on 
each participant, including their cancer history, medical diagnoses, current medications, 
marital status, living arrangements, ethnicity, income, education, perceived overall 
health, and quality of life. These variables are considered as antecedent factors (physical, 
psychological, and situational) of unpleasant symptoms, as defined by the Perception of 
Unpleasant Symptoms model; individual factors or groupings of these factors may have a 
significant impact on symptom perception. The GIQ is provided in Appendix E. 
A subscale of the Functional Performance Index was used as a general measure of 
physical and social functioning (Leidy, 1999). The functional interference subscale (FIS) 
is a five-item scale that measures the general interference of health in the performance of 
daily activities on a six-point scale, ranging from 1 = not at all to 6 = a great deal. The 
scale evaluates the overall effect of general health, inclusive of comorbidity and 
symptoms on functional performance. The general performance level in daily activities is 
a consequence of situational factors such as comorbidity, anxiety, and depression, and 
may have an indirect impact on symptom perception.  
Semistructured, audiotaped interviews were conducted with 7 study participants. 
Interviews included questions regarding the participants’ response to the tool and their 
perspectives on symptoms in the context of chronic illness. Interviews were conducted 
with select participants until response saturation was achieved. This information was 
analyzed for themes to inform and further refine the tool and its content. Questions for 




Overall, measures were carefully chosen to reflect the integration of COSMOS 
into the Perception of Unpleasant Symptoms model as a useful tool for measuring 




After the revisions of the original COSMOS were completed, participants were 
recruited from the comprehensive cancer center affiliated with a university teaching 
hospital and a variety of community-based cancer survivor groups. I collaborated with 
health care providers to identify a convenience sample of potential participants who fit 
the eligibility criteria. All identified potential participants were screened for eligibility 
and given a participant recruitment letter that included study information; the letter is 
shown in Appendix G.  
I explained the study to eligible participants, confirmed eligibility, and invited 
those eligible to engage in the study. I obtained informed consent from all participants 
and gave verbal and written instructions to each. A total of 32 older adults with cancer 
who were undergoing active treatment (chemotherapy and/or radiation therapy) and 30 
who were at least 1 year posttherapy were enrolled. All participants were assessed for the 
ability to complete the instruments on their own; assistance was provided to those who 
were unable to write and/or unable to see due to physical limitations. All questionnaires 
were printed in 12-point font to increase readability. In addition, significant researcher–
participant interactions and observations about the administration of the tool in the older 
adult population were noted.  
Fifteen of those in the off-therapy group were invited to participate a second time 




addressed, stamped envelopes were mailed out to the participants. Follow-up phone call 
and email reminders were utilized. The participant letter for the test-retest survey packet 
is in Appendix H. 
A convenience sample of participants was invited to participate in a 
semistructured interview after completing the questionnaire. Each interview was 
conducted via telephone and was audio recorded by me. Each participant interviewed had 
an opportunity to review the questionnaire prior to and during the interview. Interviews 
were transcribed by a research assistant and carefully checked against the tapes by me. I 
corrected transcripts and added specific nuances of the discussions, such as pauses, sighs, 




Descriptive statistics were used to analyze the sample characteristics, including 
age, gender, ethnicity, cancer history, medical diagnoses, current medications, current 
cancer treatment, marital/partner status, socioeconomic status, educational level, work 




Aim 2.0 was to determine the content validity of the COSMOS by utilizing a 
mixed-method approach with a group of older adults with cancer. Pretest data gathered 
by using COSMOS were compared to the themes identified through qualitative analysis 
of individual participants’ discussions of the tool. Data were analyzed for congruency and 





Descriptive statistics were used to analyze initial COSMOS data, including 
frequencies and proportions of comorbidities and symptoms. Measures of central 
tendency were used to describe continuous scored variables such as comorbidity burden 
and symptom perception. Each group of symptom attributes was analyzed using 
frequencies and proportions as related to each specific symptom. 
Each semistructured interview conducted after completion of COSMOS was 
audiotaped by me and transcribed by a research assistant. Data were cleaned by me prior 
to analysis through listening to each interview and matching it to the transcript for 
accuracy of discussion and additions, including voice inflection, pauses, and other parts 
of the discussion that may not have been transcribed. In addition, anecdotal notes taken 
by me were added to the qualitative data. I reviewed all transcripts and developed an 
initial coding schema for “chunks” of data to identify general recurrent themes. Chunks 
of data were organized initially using the main topics for the interview questions (specific 
queries about the comorbidity and symptom subscales and the overall perception of 
symptoms within the context of comorbidities).  
Recurrent patterns of data about various aspects of the tool were incorporated into 
the subsequent revision of the tool. Themes identified in the qualitative data about 




Aim 3.0 was to determine the initial test-retest reliability of the COSMOS. The 
COSMOS was initially delivered to the group of older adults who finished active cancer 
treatment, then again 2 to 4 weeks from the initial administration date. A modified GIQ 




the measure. Data were analyzed using the ICC to determine the repeatability and 




Aim 4.0 was to determine the feasibility of a self-administered measurement tool 
of comorbidities and symptoms in a population of older adults with cancer, including tool 
completion time, response patterns, tool comprehension, missing items, and patterns in 
missing data. Descriptive statistics were used to determine tool completion time, response 
patterns, and patterns of missing data. Frequencies and proportions were used for nominal 
data, and measures of central tendency for continuous data. Qualitative data were 
analyzed for themes associated with comprehension of all aspects of the instrument and 
for ease of administration and completion. Both quantitative and qualitative data were 




Aim 5.0 was to explore the sensitivity of the COSMOS between groups of older 
adults on active cancer treatment and those off treatment. Hypotheses tested included the 
following: 
1. The average number of comorbidities in participant groups with cancer on active 
treatment and cancer survivors is the same. 
2. Cancer survivors off treatment will attribute their symptoms to aging more than 
those who are on active treatment. 
3. Participants on active treatment will report more symptoms than participants off 










The secondary aim was to explore the relationship of comorbidities and 
symptoms and general functioning. Hypotheses tested included the following: 
1. Increased comorbidity burden is associated with increased symptom perception. 
2. Increased comorbidity burden and symptom perception are associated with 
increased interference in the performance of daily activities. 
Descriptive statistics were used to analyze demographic data, including 
proportions and frequencies for nominal data and measures of central tendency for 
continuous data. Select demographic data such as age, gender, ethnicity, cancer history, 
medical diagnoses, current medications, current cancer treatment, marital status, 
socioeconomic status, social support, living arrangements, and perceived overall life 
satisfaction were correlated with comorbidity burden, symptom burden, symptom 
distress, symptom attribution, and general functioning. Differences between groups with 
regard to demographic data, comorbidities, symptoms, comorbidity burden, symptom 
perception, and general functioning were explored using an independent samples t test for 
continuous variables and Chi Square test for dichotomous variables. Variance between 
the two groups of participants assisted in determining initial measurement sensitivity. In 
addition, functional interference scores were correlated with comorbidity burden, 
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SYMPTOM EXPERIENCE AND CHRONIC ILLNESS IN  
 
OLDER ADULT CANCER SURVIVORS: 
 





The purpose of this study was to review the current evidence that explores the 
relationship between chronic illness and the symptom experience in older cancer 
survivors. Data sources included Medline, CINAHL, PsychInfo, Embase, Academic 
Search Complete, and Dissertation Abstracts. Current evidence suggests that there is a 
relationship between the number of symptoms, the presence of symptoms, symptom 
bother, and the presence of comorbidities in older adults with cancer; however, evidence 
on the nature of these relationships is unclear and may be linked to other factors, such as 
the functional status of cancer survivors. Adults aged 65 and older represent more than 
60% of the cancer survivor population. It is important that oncology nurses understand 
the complex nature of symptoms in older adults that can be attributed to a multitude of 
causes. This knowledge may help nurses plan and deliver comprehensive symptom 










Older adults are one of the most vulnerable and rapidly growing populations with 
cancer. By 2030, approximately 20% of the population will be 65 years or older (Federal 
Interagency Forum on Aging-Related Statistics, 2012). About 60% of all cancer survivors 
are aged 60 years and older, with nearly half (45%) of all older cancer survivors being 70 
years and older (American Cancer Society, 2014). In addition, cancer often occurs along 
with normal and pathological changes of aging, including chronic conditions (Miller et 
al., 2016). The most prevalent chronic diseases and conditions in geriatric oncology 
patients include diabetes, venous thrombosis, osteoporosis, chronic obstructive 
pulmonary disease, dyslipidemia, hypertension, thyroid dysfunction, obesity, and 
dementia (Deckx et al., 2012). These conditions are similar to the chronic health 
conditions in adults 65 years and older as described by the Federal Interagency Forum on 
Age-Related Statistics (2012), including hypertension, arthritis, heart disease, cancer, 
diabetes, chronic respiratory disease, and stroke. Comorbidity is associated with many 
adverse health outcomes, including the development of additional health problems, 
functional impairment/decreased mobility, increased hospitalizations, and the 
development of psychological symptoms such as anxiety and depression (Crabtree, Gray, 
Hildreth, O’Connell, & Brown, 2000; Gijsen et al., 2001; Guralnik, 1996).  
In addition, many chronic conditions have symptoms that overlap with cancer-
related symptoms. Acute and chronic symptoms can have a profound impact on an 
individual’s survivorship trajectory and quality of life. Symptoms associated with cancer 
have been studied for more than three decades, and there are many tools available to 




tools available for assessing cancer-related symptoms include the Symptom Distress 
Scale (Degner & Sloan, 1995; McCorkle & Young, 1978), Edmonton Symptom 
Assessment Scale (Bruera, Kuehn, Miller, Selmser, & Macmillan 1991), Memorial 
Symptom Assessment Scale (Portenoy et al., 1994), Rotterdam Symptom Checklist (de 
Haes, van Knippenberg, & Neijt, 1990), and M. D. Anderson Symptom Inventory 
(Cleeland et al., 2000). Clinically, general symptom assessment is somewhat 
standardized, but cancer symptom assessment often involves symptom clusters and other 
variables, which increases the complexity of comprehensive symptom assessment. There 
are many methods currently used to assess symptoms and symptom clusters (Lacasse & 
Beck, 2007). 
The “normal” symptom experience for the older adult population is vaguely 
understood and may be correlated with the presence of chronic conditions. It has been 
suggested that the traditional retirement age may be a developmental marker for changes 
in perception of discomfort from abnormal to a normal expectation that comes with age 
(Williamson & Schulz, 1995). Thus, in older adults, cancer-related symptoms may be 
perceived as a normal part of aging or as being caused by other health problems (Repetto 
et al., 1998). This perception of “normal symptoms” may begin to explain the difference 
in symptom perception between younger adults and geriatric populations. 
Some older adults may learn to cope with chronic symptoms (such as pain and 
fatigue) as a normal part of the aging process, and may experience less symptom distress 
due to their frame of reference. In addition, they may have different expectations 
regarding changes in functional ability when compared to younger adults. The aging 




normalize symptoms as part of the aging process. Symptoms are viewed in the context of 
the uniqueness of the individual, their life experiences, and perceptions of individual 
quality of life. 
Reiner and Lacasse (2006) reviewed symptom correlates in the gero-oncology 
population based on an analysis of 27 articles focused on the relationships of specific 
cancer-related symptoms, symptom management, and physical functioning in older adult 
cancer survivors. The review explicated the interrelationship between high-incident 
symptoms in the population of older adult cancer survivors, such as pain, fatigue, sleep 
disturbance, depression, and functional loss. The integrated data from this review suggest 
that increased symptom severity has a negative impact on mental and physical 
functioning that is intensified by the presence of multiple comorbidities. 
Older adults with cancer may have altered symptom perception due to their 
experience with co-occurring comorbidities. Altered symptom perception may affect 
“normal signals” to seek treatment if symptoms are perceived to be part of the aging 
process or due to comorbidities. Although there have been many publications in the gero-
oncology literature on the topic of comorbidity and cancer, little is known about the 
interrelationship between comorbidity and symptoms in older cancer survivors. The 
purpose of this chapter is to review the current evidence exploring the relationship 




The following clinical questions were used to guide this evidence-based review of 
relevant literature addressing chronic illness and symptoms in cancer survivors: 




illness on the symptom experience of older cancer survivors? 
2. How are symptoms and comorbidity measured in symptom-related research 
on older adults with cancer? 
3. What are the current conceptual frameworks being used for understanding the 




Chronic illnesses may co-occur, such as arthritis and hypertension, or occur 
sequentially, such as diabetes and renal failure. Each illness may have acute 
exacerbations influenced by progression of another condition, treatment regimes, or 
changes in psychological or social circumstances. Comorbidity is defined in this review 
as the presence of one or more chronic conditions in addition to cancer. 
Symptoms are defined as an unpleasant sensation, which may have a rapid or 
gradual onset and last for moments or months or years. Symptoms are “subjective 
experiences reflecting changes in a person’s biopsychosocial function, sensation, or 
cognition” (University of California, San Francisco School of Nursing Symptom 
Management Faculty Group, 1994, p. 273). Symptom burden is defined as a subjective 
but quantifiable symptom presence, its frequency, and its severity, that places a 
physiological burden on patients and results in negative physical and emotional human 




A literature search was conducted using the following inclusion criteria: 
publications in peer-reviewed journals from July 1993 to March 2016. Literature included 
in the review had the following characteristics: study population of cancer survivors 




related symptoms, greater than two symptoms, and comorbidity measured and analyzed 
in the study. The databases used in this search included MEDLINE, CINAHL, PsychInfo, 
EMBASE, Academic Search Complete, and Dissertation Abstracts. Exclusion criteria 
included articles written in a language other than English, review articles, case studies, 
articles with a primary focus on cancer diagnoses and specific treatments, symptoms 
leading to cancer diagnosis, supportive care and symptom interventions, and symptoms 
related to end-of-life care. Search terms included aged, elderly, geriatric cancer survivor, 
gero-oncology, cancer symptoms, symptom distress, symptom clusters, comorbidity, and 
chronic illness. The search string that yielded the most relevant studies was aged/elderly, 
cancer survivor, symptoms, and comorbidity. The words comorbidity and chronic illness 
were interchanged within the search and the term comorbidity had a higher yield of 
relevant articles. The initial search yielded 163 unique publications. Titles and abstracts 
were screened by the author for relevance and inclusion criteria. A focused search 
expansion of oncology nursing and interprofessional journals published from 2010 to 
2016 yielded eight additional relevant publications. A critical review of the identified 
publications yielded 20 relevant publications that met the inclusion criteria. 
 
Results and Discussion 
 
Based on the inclusion criteria, 20 studies were selected to include in this review. 
A flow chart summarizing the results of the search is included in Figure 4.1. One group 
of studies (N =  8) included participants from one large database developed by a team of 
researchers at the University of Michigan (Gift, Jablonski, Stommel, & Given, 2004; 
Given, Given, Azzouz, Kozachik, & Stommel, 2001; Given, Given, Azzouz, & Stommel, 























Database Search of MEDLINE, 
CINAHL, PsychInfo, EMBASE, 
Academic Search Complete, and 
Dissertation Abstracts 
n = 206 publications 
 
Duplicates excluded 
n = 51 
Total articles screened by title and abstract  
N = 214 
 
 
Articles included in the review  
n = 20 
Total articles screened for eligibility = 163 
 
Articles excluded based on inclusion criteria = 123 
>Specific symptom = 40 
>Specific cancer treatment = 8 
>Supportive care/quality of life = 57 
>Specific cancer-related symptoms = 8 
>Specific symptom management interventions = 8 
>Noncancer population = 2 
Articles excluded 
after full text review  
n = 40 
 
Articles retained for full text review for 
eligibility criteria 
n = 40 
Additional articles from search 
expansion of oncology nursing 
and interprofessional journals 
 




Stommel, Given, & Given, 1999,  2000, 2001). The original database used by this group 
of studies was developed from 1993 to 1997, was focused on community-based home 
care in an older adult cancer survivor population, and included participants from 28 
hospitals and cancer centers in Michigan and one cancer center in Indiana. There were 
more than 800 participants in this study group, who were 65 years and older and were 
newly diagnosed with breast, colon, prostate, or lung cancer; almost half (48%) had three 
or more comorbidities. In addition, each of the eight studies measured symptoms, 
comorbidities, and physical functioning. Two out of the eight studies reported on the lung 
cancer subpopulation (Gift et al., 2004; Kurtz et al., 2000); four out of eight explored 
symptom clusters within the study population, including pain, fatigue, and insomnia (Gift 
et al., 2004; Given et al., 2001; Given, Given, Azzouz, & Stommel, 2001; Kozachik & 
Bandeen-Roche, 2008). This group of studies was clustered for this chapter in order to 
minimize sampling bias, and is referred to as the Given-Kurtz studies. These studies are 
described in Table 4.1. 
Twelve other studies met selection criteria (Beck, Towsley, Caserta, Lindau, & 
Dudley, 2009; Bellury, Pett, Ellington, Beck, Clark, & Stein, 2012; Bender et al., 2008; 
Cohen, Lan, Archer, & Kornblith, 2012; Deimling, Sterns, Bowman, & Kahana, 2005; 
Grov, Fossa, & Dahl, 2011; Heidrich, Egan, Hengudomsub, & Randolph, 2006; Loerzel, 
2015; Mao et al., 2007; Royer, Phelan, & Heidrich, 2009; Spoelstra et al., 2015; Van 
Cleave, Egleston, Ercolano, & McCorkle, 2013). The details of these studies are 
presented in Table 4.2. Four out of the 12 studies were focused on female breast cancer in 
the older adult population (Bellury et al., 2012; Cohen et al., 2012; Heidrich et al., 2006; 





Table of Evidence: Symptom Experience and Comorbidity in Older  
Adults with Cancer—Given-Kurtz Studies 
 
 
Authors, Type of Study, 
and Purpose 
Variables of Interest Sample Description Focused Findings 
Gift, Jablonski, Stommel, & 
Given, 2004 
Type of study: Secondary 
analysis, descriptive, 
correlational 
Purpose: Explore co-occurrence 
of symptoms, variance of 
symptom in relation to 
antecedents, and the effect of 
co-occurring symptoms on 






Stage of disease 
Symptom occurrence 
Symptom severity 
N = 220 
Age: M = 72 years; SD = 7.5 
Gender: 61% female 
Cancer diagnosis: Newly diagnosed lung 
cancer with 62% in Stage 3 or 4 
Treatment status:  69% on active treatment 
Number of comorbidities: M = 3.5 (range: 1–
9) 
Number of comorbidities was one of the 
significant predictors for an identified 
symptom cluster (fatigue, nausea, weakness, 
appetite loss, altered taste, and vomiting) for 
lung cancer patients 
Patients with more comorbidities tended to 
report more symptoms (F = 2.84, df = 9, 
p<.004) 
Patients receiving chemotherapy reported 
more symptoms than those not on 
chemotherapy. 
 
Given, Given, Azzouz, 
Kozachik & Stommel, 2001 
Type of study: Exploratory, 
correlational, longitudinal 
Purpose: Examine co-
occurrence and patterns of 
change in pain, fatigue, and 
other symptoms in newly 
diagnosed older adult patients  
 
Age 






N = 841 
Age: >65yrs 
Gender: 45% female 
Cancer diagnosis: Newly diagnosed breast, 
colon, lung, and prostate cancer 
Treatment status: >40 or <40 days after 
surgery or radiation therapy and >40 or <40 
days into chemotherapy or no therapy 
Number of comorbidities: 74% of study 
population with 2 or more  
 
Patients with >3 comorbid conditions tended 
to report both increased pain and increased 
fatigue and had significantly more symptoms 
overall. 
Patients within 40 days of surgery and 
radiation therapy were more likely to report 
pain and fatigue. 
Patients within 40 days of chemotherapy were 
more likely to report fatigue. 
Given, Given, Azzouz, & 
Stommel, 2001 
Type of study:  Exploratory, 
correlational, longitudinal 
Age 
Cancer site and stage 
Comorbidity 
Physical function 
N = 826 
Age: >65 years 
Gender: 41%–50% female (varied by 
diagnosis) 
The symptom cluster of pain, fatigue, and 
insomnia was a significant predictor of 
functional decline. 






Table 4.1 (Continued) 
 
 
Authors, Type of Study,  
and Purpose 
Variables of Interest Sample Description Focused Findings 
Given, Given, Azzouz, & 
Stommel, 2001 (continued) 
Purpose: Determine the effect of 
initial cancer treatments on 
patients’ levels of physical 
functioning prior to and at 6 
weeks following diagnosis 
 
Symptom cluster: Pain, 
fatigue, and insomnia 
Cancer diagnosis: Newly diagnosed breast, 
colon, lung, and prostate cancer 
Treatment status: Varied with each disease; 
time frame of treatment to data collection 
undisclosed 
Number of comorbidities: 25% = 0, 30% = 1, 
45% = 2 or more 
greater odds of decreased physical 
functioning. 
Patients on multimodal treatment regimens 
combined with the patient-reported symptom 
cluster of pain, fatigue, and insomnia had 
increased likelihood of functional status 
deterioration. 
Hodgson & Given, 2004 
Type of study: Secondary 
analysis, exploratory, 
descriptive, correlational 
Purpose: Examine the factors 
associated with recovery of 
functional ability of older 










N = 172 
Age: >65 years 
Gender: 43% female 
Cancer diagnosis: Newly diagnosed breast, 
colon, lung, and prostate cancer 
Treatment status: Postop for 4 to 16 weeks 
Number of comorbidities: M = 2.59; SD = 
1.72 (range: 0–13) 
 
A higher number of comorbidities were 
associated with decreased functional 
recovery after surgery. 
A higher number of reported symptoms and 
increased symptom severity were associated 
with a decreased likelihood of functional 
recovery after surgery. 
Kozachik & Bandeen-Roche, 
2008 
Type of study: Secondary 
analysis, exploratory, 
descriptive, correlational 
Purpose: Explore patient, 
disease, and treatment 
characteristics that predict 
patterns of the symptom 
cluster of pain, fatigue, and 
insomnia during the first year 
of a cancer diagnosis 
 
Age 
Cancer site and stage 
Comorbidity 
Gender 
Stage of disease 





N = 867 
Age: >65 years (M = 72.6 years) 
Gender: 46% female 
Cancer diagnosis: Newly diagnosed breast, 
colon, lung, and prostate cancer 
Treatment status: Initial diagnosis, treatment, 
and posttreatment 
Number of comorbidities: M = 2.7 (27% with 
>4) 
Number of symptoms: M = 7.9 
 
The prevalence of pain, fatigue, and insomnia 
(PFI) changed throughout the cancer 
diagnosis and treatment period. 
The relative risk of reported PFI peaked at the 
midpoint of cancer therapy and diminished 
by 1 year after diagnosis. 
Comorbidity was a significant predictor of PFI 






Table 4.1 (Continued) 
 
 
Authors, Type of Study,  
and Purpose 
Variables of Interest Sample Description Focused Findings 
Kurtz, Kurtz, Stommel, Given, 
& Given (1999) 
Type of study: Exploratory, 
descriptive, correlational 
Purpose: Determine the 
influence of comorbidity, type 
of cancer, and age on 
symptom reporting and mental 
health in older adult women 
 
Age 




N = 299 
Age: >65 years (M = 73 years) 
Gender: 100% female 
Cancer diagnosis: Breast, colon, and lung 
cancer 
Treatment status: 6 months after surgery and 
on adjuvant therapy 
Number of comorbidities: M = 2.68 (Range: 
0–13) 
Age, type of cancer, and number of 
comorbidities are predictors of symptom 
severity. 
There is a minimal relationship between 
number of comorbidities and symptom 
severity (r = .15, p<.009), physical 
functioning (r = .174, p< .003), and age (r =   
-.269, p<.001). 
Increased symptom severity, advanced age, 
and increased comorbid conditions 
correspond to increased loss of physical 
functioning. 
 
Kurtz, Kurtz, Stommel, Given, 
& Given, 2000 
Type of study: Cross-sectional, 
exploratory, descriptive, 
correlational 
Purpose: Examine the 
determinants of functional loss 
in older adults with lung 
cancer 
Age 




N = 129 
Age: Age: >65 years (M = 71.7 years) 
Gender: 42% female 
Cancer diagnosis: Lung cancer (late stage) 
Treatment status: 45.8% with surgery, 
radiation therapy, or chemotherapy only; 
54.2% on multimodality therapy 
Number of comorbidities: M = 3.1 (SD = 1.81) 
 
Patients who reported higher symptom 
severities tended to be older and reported 
more comorbidities. 
Symptom severity, prediagnosis physical 
function, and age were significant in 
predicting loss of physical function during 
treatment. 
Kurtz, Kurtz, Stommel, Given, 
& Given, 2001 
Type of study: Exploratory, 
descriptive, correlational 
Purpose: Explore the 
determinants of physical 
functioning deficit and their 
influence on depressive 
symptoms in older adults with 
Age 







N = 420 
Age: 65–98 years 
Gender: 57.6% female 
Cancer diagnosis: Breast, colon, lung, and 
prostate cancer (75% with Stage I or II 
disease) 
Treatment status: 47.9% with surgery only; 
52.1% with surgery and adjuvant radiation or 
chemotherapy 
Symptom severity was moderately related to 
comorbidity (r = .329, p = .05). 
Symptoms of depression were moderately 
related to symptom severity (r = .51, p = 
.05). 
Comorbidity was inversely related to physical 
functioning at prediagnosis (r = .32, p = 
.05). 






with decreased physical function both  
Table 4.1 (Continued) 
 
 
Authors, Type of Study, 
and Purpose 
Variables of Interest Sample Description Focused Findings 
Kurtz, Kurtz, Stommel, Given, 
& Given, 2001 (continued) 
cancer 
 








Table of Evidence: Symptom Experience and Comorbidity 
in Older Adults With Cancer 
 
Authors, Type of Study, 
and Purpose 
Variables of Interest Sample Description Focused Findings 
Beck, Towsley, Caserta, 
Lindau, & Dudley, 2009 




characteristics of and 
relationships between the 
symptom experience, health-
related quality of life, and 
functional  performance of 
older adult cancer patients at 
1 and 3 months posttreatment 
Comorbidity 
Physical functioning 
Quality of life 
Specific symptoms: Pain, 




N = 52 
Age: M = 71.54years (SD = 4.92) 
Gender: 44.2% female 
Cancer diagnosis: Prostate, breast, other 
cancer 
Treatment history: 
Radiation therapy = 73.1% 
Chemotherapy = 19.2% 
Both radiation and chemotherapy = 
7.7% 
Number of symptoms: M = 4.58 (1 
month after treatment completion); (M 
= 3.9 (3 months after treatment) 
Number of comorbidities: M = 3.5 
(range: 1–9) (88% of participants 
reported comorbidities, with 25% 
reporting >3 comorbidities) 
 (>3 comorbidities = ~25% 
 
Cancer survivors reported 1–13 symptoms. The 
most commonly reported symptoms included 
urinary frequency, pain, cough, and shortness of 
breath. The most commonly reported symptoms 
had a moderate symptom severity (range: 2.6–
3.16). 
The most frequently reported comorbidities were 
arthritis (38.5%), diabetes (25%), hypertension 
(23.1%), and heart disease (21.2%). 
The number of comorbidities was significantly 
correlated with three symptoms: fatigue (r = .31), 
depression (r = .43), and global sleep quality (r = 
.38). 
 
Bellury, Pett, Ellington, Beck, 
Clark, & Stein, 2012 
Type of study: Secondary 
analysis, exploratory, 
descriptive 
Purpose: Evaluate a conceptual 
model of gero-oncology 
survivorship, including 






N = 759 
Age: M = 77.6 years (SD = 5.3) 
Gender: 100% female 
Cancer diagnosis: Breast cancer 
Treatment history: M = 2.7 modalities 
(SD = 1.5) 
* Surgery = 90.9% 
* Hormone therapy = 8.8% 
* Radiation therapy = 5.9% 
Symptom bother was strongly correlated with 
comorbidity (r= .45) and physical activity (r= -
.49). 
Symptom bother and comorbidity were stable 
across survivorship cohorts. 
Increased comorbidity was associated with more 
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Authors, Type of Study, and 
Purpose 
Variables of Interest Sample Description Focused Findings 
Bellury, Pett, Ellington, Beck, 
Clark, & Stein, 2012 
(continued) 
and symptoms, on 
functioning 
 * Chemotherapy = 37.7% 
Length of survivorship: 29.4% at 2 years, 
33.6% at 5 years, 37% at 10 years 
Symptom assessment: M = 44.8 (SD = 
9.7; range = 30–112.5) 
Comorbidities: M = 2.3 (SD = 1.8) 
 
 
Bender et al., 2008 
Type of study: Secondary 
analysis (two separate studies 
used), exploratory, 
descriptive 
Purpose: Identify and compare 
symptom clusters in cancer 
survivors with chronic illness 








N = 154 with cancer history and 485 
without cancer history 
Age: M = 66.5 (SD = 13.6 years) 
Gender: Women>men 
Cancer diagnosis: All types; primarily 
breast, prostate, melanoma, colon, and 
gynecological cancers 
Treatment status of cancer survivors: 
30% on active treatment 
Number of comorbidities:  
Participants with cancer: M = 6.8 (SD = 
2.9) 
Participants without cancer: M = 5.1 
(SD = 2.9) 
Number of symptoms: 
Subjects with cancer: M = 7.8 (SD = 
4.2) 
Subjects without cancer: M = 7.8 (SD = 
4.4) 
 
A similar symptom cluster (pain, fatigue, and sleep 
disturbance) was found in those with cancer and 
comorbidities and those with cancer only. 
Most study participants (97%)  reported that their 
cancer was controlled, which suggests that 
symptoms reported may have been due to chronic 
conditions. 
Participants with a cancer history reported 
significantly more comorbidities than those with 
no cancer history (p< .001). 
The most prevalent comorbidities or chronic 
conditions reported included cardiovascular 
disease (44%), hypertension (41%), osteoarthritis 
(44%), and urinary incontinence (49%). 
Symptom clusters tended to be clusters associated 
with the participants’ primary chronic illness. 
Symptoms that had a significant effect on quality 
of life were mostly related to the primary chronic 
illness. 
 
Cohen, Lan, Archer, & 
Kornblith, 2012 






N = 153 
Age: <65 years = 79; >65 years = 74 
Gender: 100% female 
Cancer diagnosis: Breast cancer 
Older participants had significantly more 
multimorbidities than those <65 years. 
The most prevalent comorbidities in those >65 
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Authors, Type of Study,  
and Purpose 
Variables of Interest Sample Description Focused Findings 
Cohen, Lan, Archer, & 
Kornblith, 2012 (continued) 
Purpose: Assess the impact of 
age, comorbidities, and 
symptoms on the functional 





Treatment status: Off treatment (data 
collected from cancer survivors 17–25 
years after diagnosis) 
Number of comorbidities:  
<65 years = 57% with >1 comorbidity 
>65 years = 75.7% with >1 
comorbidity 
 
hypertension (47%), heart trouble (24.3%), 
circulation problems (24.3%), and osteoporosis 
(21.6%). Only hypertension was significantly (p< 
.001) higher in participants >65 years.  
The most common reported symptoms included 
fatigue, pain, insomnia, and dyspnea. There was 
no difference in reported symptoms between age 
groups. 
Symptoms had significantly stronger association 
(F= 53.6, p<.001) than comorbidities (F = 27.5, 
p< .001) with decreased physical function. 
 
Deimling, Sterns, Bowman, & 
Kahana, 2005 




and select characteristics of 
long-term older cancer 
survivors and their 









N = 321 
Age: M = 72.3 years (SD = 7.5) (85% 
participants>65 years) 
Gender: 59.2% female 
Cancer diagnosis: Breast (41.4%), 
colorectal (29.9%), and prostate cancer 
(28.7%) 
Treatment status: Long-term cancer 
survivors >5 years after treatment and 
diagnosis 
Number of comorbidities: M = 3.7 (SD = 
2.4) 
 
Slightly more than a third (37.7%) of survivors had 
>1 symptoms attributed to cancer and treatment. 
One third of cancer survivors reported five or more 
chronic health conditions such as hypertension, 
allergies, back problems, heart trouble, or urinary 
tract disorders. 
Grov, Fossa, & Dahl, 2011 
Type of study: Cross-sectional, 
correlational, comparative 
Purpose: Examine comorbidity, 
symptoms, lifestyle, and 
psychosocial determinants of 
Activities of daily living 
Cancer survivor time 
Comorbidity 
Instrumental activities of 
daily living 
Physical function 
N = 479 
Short-term survivors (1–5 years) = 265; 
long-term survivors (>5 years) = 214 
Age: M = 77.3 years (SD = 5.4) (all 
participants >70 years) 
Gender: 46.5% female 
No significant difference was found between older 
cancer survivors and age and gender-matched 
controls regarding number of self-reported 
comorbidities and symptoms. However, older 
cancer survivors reported significantly higher use 
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Authors, Type of Study, 
and Purpose 
Variables of Interest Sample Description Focused Findings 
Grov, Fossa, & Dahl, 2011 
(continued) 
older cancer survivors as 
compared to age and gender-







Cancer diagnosis: Gastrointestinal 
(23%), prostate (22%), breast (16%), 
and other cancers (39%) 
Number of comorbidities: >2 
comorbidities in 43% of short-term 
survivors and 34% of long-term 
survivors 
 
(65%) (p = .0005). 
Common symptoms reported by both short- and 
long-term survivors included muscular pain and 
stiffness (26%–75%, depending on anatomical 
site), headache (19%), gastrointestinal complaints 
(13%), and somatic complaints (12%). 
Common comorbidities reported in both short- and 
long-term survivors included hypertension 
(35%), arthritis (28%), diabetes (12%), asthma, 
and thyroid disease, osteoporosis, and 
musculoskeletal disease (8% each). 
 
Heidrich, Egan, Hengudomsub, 
& Randolph, 2006 
Type of study: Descriptive, 
correlational 
Purpose: To compare 
symptoms, symptom beliefs, 
and quality of life of older 
female breast cancer 
survivors with older women 
without breast cancer 
Comorbidity 




N = 42 
Age: ≥64 years (M = 76 years) 
Gender: 100% female 
Cancer diagnosis: Breast cancer (42.9%) 
compared with women without cancer 
(57.1%) 
Treatment status: 50% breast cancer 
participants on Tamoxifen 
Number of comorbidities: M = 5.44 (SD 
= 4.0) for breast cancer participants 
Symptoms reported as high frequency: 
Pain (76.2%), memory problems 
(76.2%), joint pain (59.5%), stiffness 
(59.5%), dry skin (52.4%), fatigue 
(52.4%) 
 
Women in both groups most often attributed 
symptoms to aging, chronic illness, or an 
unknown cause.  
Aging was the most frequently reported cause of 
symptoms, followed by chronic illness. 
Symptom distress was significantly associated with 
the belief that symptoms were caused by chronic 
illness (r = .42), breast cancer (r = .39), and “I 
don’t know” (r = .52) (p< .05). 
Symptom distress was not found to be related to 
the belief that symptoms were caused by aging. 
 
Loerzel, 2015 





N = 100 
Age: ≥65 years (M = 71.9 years) 
Gender: 48% female 
High-incidence comorbidities reported by 
participants included high blood pressure (66%), 





Table 4.2 (Continued) 
 
 
Authors, Type of Study, 
and Purpose 
Variables of Interest Sample Description Focused Findings 
Loerzel, 2015 (continued) 
Purpose: To explore the 
symptom experience of older 
adults receiving 




Cancer diagnosis: Lung (21%), breast 
(18%), gastrointestinal (18%), 
hematologic (16%), head and neck 
(16%), and other cancers (11%) 
Treatment status: On chemotherapy 
Number of comorbidities: 39% of 
participants with 1–2; 59% of 
participants with >3 
Number of symptoms: M = 7.15 (range = 
2–16) 
 
disorders (19%), and diabetes (18%). 
Adults aged ≥71 years reported more symptoms as 
compared to those aged 65–70 years.  
Older adults experienced a significant number of 
moderate to severe symptoms while receiving 
chemotherapy.  
Participants with a higher number of comorbidities 
reported significantly more symptoms (t = -
2.335, df = 98, p = .022).  
Mental health functioning had a positive 
relationship with the number of symptoms. 
Instrumental and physical activities of daily living 
were decreased in participants reporting a higher 
number of symptoms and comorbidities. 
 
Mao, Armstrong, Bowman, 
Xie, Kadakia, & Farrar, 2007 
Type of study: Descriptive, 
comparative 
Purpose: To understand the 






N = 1,904 cancer survivors  
Age: 50.2% >65 years 
47.8% <5 years since diagnosis; 52.2% 5 
years since diagnosis 
Gender: 58.8% female 
Cancer diagnosis: Breast (17.1%), 
gynecological (14.9%), prostate 
(10.2%), and colorectal cancer (9.3%) 
Treatment status: Unknown 
Number of comorbidities: 21.7% had 
two or more 
Symptoms reported as high frequency: 
Pain (34%), insomnia (30%), 
psychological—anxiety and depression 
(26%) 
 
Cancer survivorship and comorbidity were 
associated with higher symptom burden. 
Cancer survivors with two comorbidities had 
higher risk of pain (OR = 17.39), psychological 
distress (OR = 7.38), and insomnia (OR = 7.71). 
Cancer survivors with three or more comorbidities 
had a significantly higher risk of experiencing 
pain (OR = 35.56), psychological distress (OR = 
15.12), and insomnia (OR = 10.25). 
Cancer survivors >65 years reported lower 
symptom burden than those <65 years. 
Cancer survivors reported a higher rate of pain, 
psychological distress, and insomnia than 
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Authors, Type of Study, 
and Purpose 
Variables of Interest Sample Description Focused Findings 
Royer, Phelan, & Heidrich, 
2009 
Type of study: Secondary 
analysis, qualitative content 
analysis 
Purpose: To describe symptom 
representations, symptom 
management strategies, and 
perceived barriers to 
symptom management based 






N = 61 
Age: M = 69.5 years (SD = 5.2; range = 
65–86 years)  
Gender: 100% female 
Cancer diagnosis: Breast (M = 4.7 years; 
range = 1–35 years after diagnosis) 
Treatment history: Mastectomy (65%), 
radiation therapy (51%), lumpectomy 
(48%), hormone therapy (35%), 
chemotherapy (23%)  
Number of comorbidities: M = 4.8 (range 
= 1–11) 
Number of symptoms: M = 17 (range = 
5–30) 
The highest comorbidities reported by survivors 
included arthritis (67%), hypertension (54%), 
depression (25%), and bronchitis/emphysema 
(21%). 
The highest reported symptoms included stiffness 
(84%), joint pain (80%), aching (79%), fatigue 
(77%), and pain (75%). 
Most women described the cause of their 
symptoms as having multiple factors (97%). 
Additional reported causes of symptoms included 
chronic or comorbid conditions (67%), cancer or 
its treatment (34%), and aging (8%). 
Sixty-two percent of participants reported that their 
symptoms caused some physical limitation. 
 
Spoelstra et al., 2015 
Type of study: Descriptive, 
exploratory, longitudinal 
Purpose: To evaluate symptom 
prevalence, severity, and 
attribution and interference 
with comorbidity 
management in patients on 




Symptom occurrence  
Symptom severity 
 
N = 30 
Age: M = 65.1 years (SD = 9.8) 
Female: 50% 
Diagnosis: Colorectal (33%), leukemia 
(13.3%), breast (10%), and other 
cancers (40%) 
Cancer stage: 60% with Stage IV disease 
Treatment status: 100% on oral 
anticancer agents  
Number of comorbidities: M = 2 (SD = 
1.7) (33.3% with 3 or more 
comorbidities) 
Patients with more comorbidities tended to report 
higher symptom severity. 
The most prevalent symptoms reported included 
fatigue, pain, numbness and tingling, and sleep 
disturbance.  
The most commonly reported comorbidities 
included hypertension and cardiac disease. 
All participants reporting comorbidities indicated 
that cancer treatment interfered with self-
management of comorbid conditions.  
Commonly reported symptom attributions included 
cancer treatment as the most common, followed 
by cancer, cancer treatment, and comorbidity.  
 
Van Cleave, Egleston, 
Ercolano, & McCorkle, 2013 
Cancer site 
Cancer treatment 
N = 356 
Age: M = 71.8 years (SD = 5.4) (45.1 %  
Patients with three or more comorbidities reported 
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Variables of Interest Sample Description Focused Findings 
Van Cleave, Egleston, 
Ercolano, & McCorkle, 2013 
(continued) 
Type of study: Descriptive, 
correlational 
Purpose: To determine the 
influence of age on symptom 
distress among older adults 
undergoing surgical 








were 65–69 years, 33.1% were 70–74 
years, 21.8% were >75 years) 
Gender: 50.3% female 
Cancer diagnosis: Genitourinary (27%), 
gynecologic (23%), thoracic (22.4%), 
and digestive cancer (22.4%); 84.7% 
were newly diagnosed 
Treatment status: Surgery alone (46.6%), 
surgery and chemotherapy (31.6 %), 
surgery and radiation (9.2%), surgery, 
radiation, and chemotherapy (12.6%) 
Number of comorbidities: 67.2% with 2 
or more 
Number of symptoms at baseline: 63.8% 
with three or more 
 
with <2 comorbidities. 
Symptoms decreased over the normal postoperative 
recovery time from baseline to 3 and 6 months 
(p< .002). The majority of participants had three 
or more symptoms at baseline. 
The type of treatment was not associated with 
symptom distress. 
Participants aged ≥75 years reported greater 
symptom distress over the 6-month postoperative 
period than those aged 65–69 years (p = .049). 








term older cancer survivors who were more than 5 years beyond their cancer diagnosis 
(Deimling et al., 2005; Grov et al., 2011). Three studies explored the differences between 
older adult cancer survivors and controls with no cancer history (Bender et al., 2008; 
Heidrich et al., 2006; Mao et al., 2007). Eight out of these 12 studies used specific 
measures of symptoms, comorbidities, or chronic illnesses and physical functioning.  
 
Influence of Chronic Illness on Symptom Experience  
in Older Adults With Cancer 
 
The symptom experience of older cancer survivors can be characterized as a blend 
of cancer-related symptoms and those related to chronic illness, illness conditions, and 
aging. The Given–Kurtz studies (1999–2008) collectively suggest that cancer survivors 
who reported three or more comorbidities in addition to their cancer diagnosis had more 
symptoms (M = 4.7) than those who reported zero to two comorbidities. Kozachik and 
Bandeen-Roche (2008) examined data from 867 participants and found that symptoms of 
pain, fatigue, and insomnia were affected by increased comorbidities early in the cancer-
treatment trajectory; however, increased comorbidity was not a significant predictor of 
pain, fatigue, and insomnia after the first 2 months of the cancer experience. In another 
study, younger age and increased number of comorbidities were significantly related to 
higher symptom severity in a population 6 months after cancer surgery and on 
chemotherapy (Kurtz et al., 1999).  
Researchers in several studies concluded that their study populations 
demonstrated that patients with an increased number of chronic illnesses also had 
increased symptoms or symptom burden (Beck et al., 2009; Bellury et al., 2012; Gift et 




Stommel, 2001; Hodgson & Given, 2004; Kozachik & Badeen-Roche, 2008; Kurtz et al., 
1999, 2000, 2001; Loerzel, 2015; Mao et al., 2007; Spoelstra et al., 2015; Van Cleave et 
al., 2013). Mao and colleagues (2007) compared cancer survivors with the general 
population and found that cancer survivors have a higher ongoing symptom burden than 
those with no cancer history. The symptoms of pain, psychological distress, and insomnia 
were reported as ongoing symptom concerns in the study population. Grov et al. (2011) 
assessed symptoms in older cancer survivors and found no significant difference in 
symptoms reported by short-term survivors (1–5 years from diagnosis) as compared to 
long-term survivors (>5 years from diagnosis). Bender and colleagues (2008) examined 
cancer as a chronic illness and compared symptoms and symptom clusters assessed in 
older adults with rheumatoid arthritis and urinary incontinence with or without a cancer 
history. This study found that the number of symptoms reported by individuals with 
cancer, as compared with other chronic conditions (rheumatoid arthritis and urinary 
incontinence), was similar, with a mean of 7.8 (SD = 4) symptoms. No unique symptom 
clusters were found among study participants with and without cancer. The results of this 
study suggest that the symptoms experienced by the participants were more related to the 
participants’ chronic health issues as compared with a cancer history.  
 
Measurement of Symptoms 
 
Symptom presence, symptom severity, and symptom burden (interference and 
severity) were measured using a variety of scales and methods in the studies selected for 
this review. These measures are described in Table 4.3.  The Given–Kurtz studies and 
two others used an interview method of symptom assessment (Deimling et al., 2005; Gift 






Symptom Measures Used in Studies of 
Older Adult Cancer Survivors 
 
 
Study Authors Symptom Measure Description Other Symptom Measures Used 
Beck, Towsley, 
Caserta, Lindau, & 
Dudley, 2009 
 
Side Effect Checklist 
Self-report, 18-item scale 
Symptom time frame: Previous week 
Brief Pain Inventory 
General Fatigue Scale 
Pittsburgh Sleep Quality Scale 
Geriatric Depression Scale 
 
Bellury et al., 2012 Modified Rotterdam Symptom Checklist 
Self-report, 30-item scale 
Symptom time frame: Previous week 
 
None 
Bender et al., 2008 Comorbidity Questionnaire, symptom 
assessment subscale 
Self-report, 32 items 
Symptom time frame: Current 
 
None 
Cohe, Lan, Archer, 
& Kornblith, 2012 
European Organization for Research 
Treatment of Cancer  
Self-report, 8 symptoms 






Author-constructed index based on 
participant interview 
Interview 
Variable based on 22 possible symptoms 
Symptom time frame: Current 
 




Symptom Experience Scale 
Interview, 33–37 items 
Symptom time frame: Previous 2 weeks 
 
Center for Epidemiological Studies 
Depression Scale (CES-D) 
Grov, Fossa, & 
Dahl, 2011 
Checklist of Somatic Disease 
Self-report, six major symptoms 
Symptom time frame: Variable per 
symptom 
 






Symptom Bother Scale–Revised 
Self-report, 37-item scale 
Symptom time frame: Current 
CES-D symptom attribution 
subscale 
State-Trait Anxiety Inventory 
 
Loerzel, 2015 Symptom Representation Questionnaire 
Self-report, 22 items 
Symptom time frame: Previous week 
 
None 
Mao et al., 2007 National Health Interview Survey 
Self-report, multiple nested items 







Table 4.3 (Continued) 
 
 
Study Authors Symptom Measure Description Other Symptom Measures Used 
Royer, Phelan, & 
Heidrich, 2009 
Symptom Bother Scale 
Self-report, 34 items 




Spoelstra et al., 
2015 
Symptom Experience Inventory 
Self-report via interview, 15 items 








Symptom Distress Scale 
Self-report, 13-item scale   
Symptom time frame: Previous 7 days 
 
Mental health measures (SF-12,a 
SF-36,b CES-D) 
a  Medical Outcomes Study: 12-item short form survey instrument. 





Stommel, 2001; Hodgson & Given, 2004; Kozachik & Badeen-Roche, 2008; Kurtz et al., 
1999, 2000, 2001; Spoelstra et al., 2015). The majority of the studies used the self-report 
survey method of symptom assessment based on a specific symptom measure. Three 
studies used additional measures for specific symptoms (Beck et al., 2009; Heidrich et 
al., 2006; Van Cleave et al., 2013). In addition, a total of seven studies plus the Given–
Kurtz studies used symptom measures that included assessment of symptom presence and 
an element of symptom burden severity, bother scales, or impact   on quality of life (Beck 
et al., 2009; Bellury et al., 2012; Bender et al., 2008; Gift et al., 2004; Given, Given, 
Azzouz, Kozachik, et al., 2001; Given et al., 2001; Heidrich et al., 2006; Hodgson & 
Given, 2004; Kozachik & Badeen-Roche, 2008; Kurtz et al., 1999, 2000, 2001; Loerzel, 
2015; Royer et al., 2009; Spoelstra et al., 2015; Van Cleave et al., 2013). The scales used 
to assess symptom severity ranged from three to five points, while the scales measuring 
symptom bother ranged from four to five points. All reviewed studies used a specific but 
different measure of cancer-related symptoms. Two studies using the revised Symptom 
Bother Scale measured symptom distress and symptom beliefs regarding the cause of 
symptoms, including aging, cancer, chronic illnesses, or unknown (Heidrich et al., 2006; 
Royer et al., 2009). Of interest, 97% of the study population reported multiple causes for 
most symptoms. 
The most common symptoms assessed across all reviewed studies included pain, 
fatigue, and sleep-related problems. Items to measure pain included the following 
descriptors: generalized pain, back pain, joint pain, and muscle pain. Fatigue was 
described by the use of terms such as lack of energy and tiredness. Sleep-related 




disturbances, problems falling asleep, early wakening, and waking too often. Other high-
frequency symptoms, reported by >30% participants in more than one study, included 
urinary symptoms (increased frequency and incontinence), bowel symptoms 
(constipation and diarrhea), decreased appetite, respiratory symptoms (dyspnea, cough), 
memory problems, and dry skin. The measurement of cancer symptoms was different in 
each study and included several dimensions of the symptom experience. 
 
Measurement of Comorbidity 
 
Comorbidity in the oncology population has been measured in clinical research 
using a variety of valid and reliable tools, including the Charlson Index, Cumulative 
Illness Rating Scale–Geriatric, Kaplan-Feinstein Index, and Index of Coexisting Disease 
(DeGroot, Beckerman, Lankhorst, & Bouter, 2003; Extermann, 2000). Many of these 
measures require intensive chart review and complex calculations of severity of illness. 
Self-report of chronic illness is another reliable method to obtain these data (Ingram et 
al., 2002; Katz, Chang, Sandha, Fossel, & Bates, 1996). The most common reporting of 
comorbidity data in cancer symptom research is a simple count of comorbidities. These 
data are often used as a demographic variable to assist in explaining symptom burden or 
symptom clusters, or as the relationship of symptoms and physical functioning, or as a 
covariate to equalize groups on the overall severity of illness. 
Four basic measures of comorbidity were used in the studies reviewed. Six out of 
11 studies used a simple checklist of chronic illnesses (Beck et al., 2009; Bellury et al., 
2012; Given et al., 2001; Grov et al., 2011; Royer et al., 2009; Van Cleave et al., 2013). 
The majority of these studies reported a simple count of comorbidities and analyzed their 




studies assessed comorbidities via an interview process using a simple checklist. This 
method has been determined to be a valid measure of comorbidity (Vaeth, Satariano, & 
Ragland, 2000). 
Three studies used measures or questionnaires based on the Older American 
Resource and Service Schedule of Illnesses (OARS) questionnaire and methodology 
(Duke University Center for the Study of Aging and Human Development, 1978). The 
OARS is commonly used to assess the general health status of community-dwelling older 
adults. Loerzel (2015) collected comorbidity and physical functioning data using items 
from the OARS Multidimensional Functional Assessment Questionnaire and mental 
health functioning data from the psychiatric evaluation subscale. Cohen et al. (2012) used 
a self-report, modified version of the OARS questionnaire, which measured presence of 
22 comorbidities and their degree of interference with daily activities. Heidrich and 
colleagues (2006) also used a modified version of the OARS that was tailored for use 
with older women. Deimling et al. (2005) used the Health Conditions Index, which was 
adapted from the OARS, and included a sum of the number of self-reported health 
conditions based on a list of 27 possible conditions.  
Mao and colleagues (2007) used a series of interview questions around functional 
limitations and the health condition that was causing the limitation. Chronic conditions 
were then counted and presented as an absolute number. No validity or reliability data 
were available for this method. Bender et al. (2008) assessed both comorbidities and 
symptoms using the Comorbidity Questionnaire, a self-report tool based on the Charlson 
Comorbidity Index (Charlson, Pompei, Ales, & MacKenzie, 1987). The comorbidity 




subscale assessed the presence of chronic illness and whether or not (a) a health care 
provider diagnosed it, (b) it was present within the previous 5 years, (c) it was currently 
being treated, (d) it required hospitalization, and (e) its impact on quality of life.  
 
Conceptual Frameworks Related to Cancer Symptom Research 
 
The third research question focused on examining the use of conceptual 
frameworks in the reviewed studies. Six out of 20 studies identified a specific conceptual 
model related to symptoms to guide the study. Beck et al. (2009) used Armstrong’s 
Symptoms Experience model to explore symptom experience, health-related quality of 
life, and functional performance in urban and rural older adult cancer survivors. The 
Symptom Experience Model (SEM) provides a general explanation of the symptom 
experience (Armstrong, 2003). Within this model, the symptom experience is described 
as the perception of symptoms with regard to frequency, degree of distress, intensity, and 
the meaning of each symptom. In the SEM, symptom perception includes each symptom 
or group of symptoms as they are experienced by the individual within the context of the 
meaning of symptoms (Armstrong, 2003). 
Two studies used Leventhal’s Common Sense Model (CSM) of symptom 
attribution to explore symptoms, symptom beliefs, and their relationship to quality of life 
(Heidrich et al., 2006), symptom management strategies, and perceived barriers to 
symptom management (Royer et al., 2009). The symptom experience in older adults with 
cancer is highly variable and reflects many antecedents to the diagnosis and treatment of 
cancer, including previous life experiences with chronic illness and its treatments. An 
individual’s interpretation of his or her symptoms can be comprehensively understood by 




people have specific ideas about their illnesses and that these ideas guide coping 
behaviors for health and illness (Haggar & Orbell, 2003; Leventhal, Meyer, & Nerenz, 
1980; Ward, 1993). This general framework integrates the physical, psychological, and 
social dimensions of symptom perception and subsequent choices of symptom-
management actions. In addition, older adults may have a multidimensional 
representation of aging. A study by Prohaska, Keller, Leventhal, and Leventhal (1987) 
revealed that mild symptoms of short or long duration are more likely to be attributed to 
aging than severe, short-term symptoms. In addition, the attribution of mild symptoms 
with gradual onset to aging resulted in a greater acceptance of symptoms with a 
subsequent delay in seeking health care for the symptoms (Prohaska et al., 1987).  
One of the eight Given–Kurtz studies identified the Theory of Unpleasant 
Symptoms (TOUS) as a basis for the study (Gift et al., 2004). The TOUS incorporates 
three factors that influence symptoms, including physiological (including comorbidities), 
psychological, and situational factors (Lenz, Pugh, Milligan, Gift, & Suppe, 1997; Lenz, 
Suppe, Gift, Pugh, & Milligan, 1995). In this model, symptoms are thought to (a) occur 
in groups or clusters, (b) interact with each other, and (c) ultimately affect an individual’s 
symptom perception, functional status, cognitive functioning, and physical performance. 
The TOUS model also illustrates the effect of symptoms on overall performance, such as 
physical and cognitive functioning that has an impact on the symptoms and the factors 
that preceded symptom development, such as comorbidities. 
The integration of the SEM, CSM, and TOUS begins to illuminate the complexity 
of symptom perception by older adults with cancer and comorbidities. This population 




symptoms, and related interactions with family, friends, and health care providers to 
make decisions about their symptoms. In addition, health care providers can use an older 
cancer survivor’s personal perspective regarding her or his symptoms to develop a 
comprehensive, patient-centered symptom-management plan. Both the SEM and TOUS 
may be useful as frameworks for symptom management research in the gero-oncology 
population (Brant, Beck, & Miaskowski, 2009). 
Bellury and colleagues (2011) proposed an integrated conceptual model of elderly 
cancer survivorship that incorporates elements of cancer survivorship, personal factors, 
and gero-oncology (age-related concerns and health-related issues). This model begins to 
illuminate the complex relationship between comorbidity, cancer, and symptoms in older 
adults (Bellury et al., 2011). The model enhances the general understanding of the 
essential elements in gero-oncology populations and may provide a basis for 
comprehensive interprofessional and multidisciplinary care management of older adult 
cancer survivors. Bellury et al. (2012) used the conceptual model of elderly cancer 
survivorship to explain the influence of select variables of aging, cancer, and symptoms 
on physical functioning of older breast cancer survivors. 
A broader nursing model, the Vulnerability/Risk/Human Response model, was 
used by Van Cleave et al. (2013) to select specific independent and dependent variables 
to determine the influence of age on symptom distress in older adults with cancer who 
were undergoing thoracic, abdominal, or pelvic surgery. This model is based on an 
ecological framework of health using a biopsychosocial perspective and describes the 
integration of individual factors (age, cancer-related information, chronic illness, 




by an advanced-practice nurse) that affect human responses such as symptom distress and 
physical functioning (Shaver, 1985). 
In summary, multiple conceptual models are used in cancer research. The 
diversity of symptom-related models enhances understanding of the complex dimensions 
of symptom science. The diversity of conceptual frameworks used in symptom research 
may serve to enhance understanding of the relationships of symptom correlates in the 




This integrated review included several research studies with participants younger 
than 65 years and may not be fully representative of the gero-oncology population. 
Across the studies included in the review, there was wide variation in the gero-oncology 
population regarding cancer diagnoses, treatment history, and treatment status. Eight 
studies included in the review analyzed subsets of the same database, which increases the 
risk for error in drawing conclusions about the relationship between symptoms and 
chronic illness in cancer survivors. These studies were grouped as one study, the Given–
Kurtz studies, and analyzed along with 12 additional studies for this review. The final 
limitation is the complexity of searching for appropriate literature to include in the 
review. The search strategy yielded a moderate number of studies that met the inclusion 




Although the specialty of gero-oncology has grown over the past 10 years, there is 




between cancer, comorbidity, and symptoms in older adults. This may relate to the 
perception of cancer as a chronic illness and the complexity of the relationship between 
chronic illnesses and symptoms within the context of the expected changes of aging. A 
moderate relationship between chronic illness and symptoms was reported across studies 
and ranged from r = .31 (depression only) to r = .45 (symptom bother). In addition, 
physical and mental functional interference is intertwined with the perception of 
interference of both symptoms and chronic illness (Reiner & Lacasse, 2006). 
There is a wide range of measures used in research that address symptoms, 
comorbidity, and cancer in older adults. The nonstandard measures used across studies 
create a challenge for comparing the symptom characteristics and comorbidities and their 
relationship across populations. While there is a list of core of symptoms assessed in the 
cancer population, there is a wide variety of cancer symptom assessment lists. Similarly, 
there is a wide range of comorbidities that are assessed in studies on cancer survivors. 
Several studies reported a list of common comorbidities usually found in older adults, 
while others reported lists that incorporated symptom-related chronic conditions, such as 
anxiety and depression, and geriatric syndromes, such as vision and hearing impairment, 
balance problems, memory problems, and urinary incontinence. In addition, there is wide 
variation in the time frame for reporting symptoms, ranging from “over the past week” to 
“during the past year.” The recent development of Patient-Reported Outcomes 
Measurement Information System tools (www.healthmeasures.net/explore-measurement-
systems/promis) may provide some standardization to measurement of symptoms 
commonly found in older cancer survivors. Most of the studies use comorbidities as a 




variable of interest. 
 
Implications for Interprofessional Care and Research 
 
Clinicians in cancer care are often presented with challenging patient care 
situations that include normal physiological and psychological changes with age, multiple 
comorbidities and chronic conditions and their treatments, and complex social situations. 
Comprehensive, multidimensional care incorporates a patient’s past and current health 
care experiences and plans for future issues in cancer survivorship. Understanding the 
interrelationship between the cancer experience in older adults, acute and chronic 
symptoms, and cancer as a chronic illness is essential in coordinating ongoing care for 
this complex population. In addition, understanding the origins of symptoms in the older 
adult may be significant in the development and implementation of tailored interventions 
for symptom management in this population. The distinction between the disease process, 
treatment side effects, and the normal physiological changes of aging may guide 
individual health-behavior choices.  
During the diagnosis and treatment phase, cancer is often viewed as an acute 
illness; however, this view may change in the posttreatment phase. Coordination of care 
of cancer survivors as they transition to their primary care provider is also challenging, 
depending on the patient’s circumstances and the impact of cancer and its treatment on 
other chronic illnesses (Hewitt, Greenfield, & Stovall, 2006). In addition, the patients’ 
perceptions of cancer as a chronic illness have the potential to reshape the care plan for 
the general health and wellness of older cancer survivors. Long-term cancer-survivorship 
care plans may facilitate the care transition from oncologist to primary care physician, 




survivor’s personal health history of chronic conditions (Hewitt et al., 2006). 
One interesting area for further study is the concept of chronic illness burden and 
symptom perception in cancer survivorship. Older adults translate chronic illness and 
symptoms within a context of prior experiences with health and illness, perceptions of 
illness and symptoms, and general perceptions and expectations of aging (Williamson & 
Schulz, 1995). It is also important to consider the generational cohort effect on healthy 
aging as individuals become more educated about health promotion, disease prevention, 
and healthy aging behaviors. Another issue that needs further exploration is that of 
perception of comorbidity burden prior to cancer diagnosis and during the immediate 
posttreatment and long-term survivorship periods, and its impact on overall quality of life 
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DEVELOPMENT OF A SELF-REPORT TOOL FOR 
 
MEASURING COMORBIDITY BURDEN AND  
 
SYMPTOM PERCEPTION IN OLDER 
 





One third of all cancers are diagnosed in older adults (aged 65+). The diagnosis 
often co-occurs with normal and pathological changes of aging that include chronic 
diseases and related symptoms. Individual perception of the impact of chronic illness and 
symptoms may have a profound effect on the health care choices of an older adult. The 
Comorbidity and Symptom Measurement in Oncology Scale (COSMOS) is a newly 
developed self-report tool for measuring comorbidity burden and symptom perception in 
the oncology population. It is projected that COSMOS could be easily used in the clinical 
setting as an integral component of the comprehensive geriatric assessment of older 
adults with cancer. This chapter describes the initial development of the COSMOS using 
a multistep approach to determine content validity, beginning with a thorough review of 
relevant literature. A panel of six expert clinicians and researchers in geriatric oncology 
and symptom management participated in a survey with both quantitative and qualitative 




item and subscale relevancy was calculated using the content validity index (CVI) and 
Interclass Correlation Coefficient (ICC) statistic. General scale revisions included 
retaining items with an item CVI of >.80 and ICC>.60. In addition, qualitative comments 
from the expert reviewers were used to clarify specific items in each subscale. This 
chapter discusses the process and results for determining content validity for a newly 





Older adults with cancer comprise more than two thirds of the cancer population, 
and it is estimated that older adults with cancer have an average of two to four 
comorbidities (Cohen, Lan, Archer, & Kornblith, 2012; Howlander et al., 2015). The 
most common comorbidities in older adults are arthritis, cardiovascular disease (heart 
disease and hypertension), diabetes, and chronic respiratory diseases (Federal Interagency 
Forum on Age-Related Statistics, 2012; Vaeth, Satariano, & Ragland, 2000). The 
symptom experience in older adults with cancer is often complex and includes symptoms 
related to cancer, its treatment, and chronic conditions. Normal expectations of aging 
include both the development of chronic conditions and symptoms that may affect 
physical and emotional functioning (Repetto et al., 1998; Williamson & Schulz, 1995). 
There are several valid and reliable measures of comorbidities in adult populations, but 
currently, few tools are available to measure comorbidity burden via self-report 
(DeGroot, Beckerman, Lankhorst, & Bouter, 2003; Extermann, 2000; Katz, Chang, 
Sandha, Fossel, & Bates, 1996). In addition, there are multiple tools available to assess 




Existing measures have not provided an easy way to link symptom measurement 
with measurement of comorbidity burden. Another gap has been the inability to measure 
symptom attribution. Thus, if a patient reports pain, it is difficult to know whether the 
pain is related to cancer, another chronic illness, or physical changes associated with 
aging. The use of a self-assessment scale that combines comorbidity burden and 
symptom perception may facilitate communication between cancer survivors and the 
health care team, leading to holistic and comprehensive symptom management that is 




The purpose of this study was to describe the initial development and content 
validity of a self-report scale for measuring comorbidity burden and symptom perception: 
the COSMOS. This tool combines a self-report assessment of a broad range of 
comorbidities commonly found in older adults, such as cardiovascular, renal, 
gastrointestinal, hepatic, endocrine, and neurological disease processes and their impact 
on daily life, with a comprehensive symptom-perception assessment. The juxtaposition of 
reported comorbidities and symptom assessment provides the older adult with an 
opportunity to consider symptoms within the context of his or her current health, 
inclusive of comorbidities, cancer diagnosis, treatment, and perceptions of the aging 
process. The assessment of comorbidity burden and symptom perception has the potential 
to facilitate focused, timely care for cancer survivors. This assessment may also be  
valuable for facilitating communication between cancer survivors and their primary care 
providers as they transition from the acute treatment of cancer to long-term follow up. 








COSMOS was based on a blended conceptual model developed from the Theory 
of Unpleasant Symptoms (TOUS; Lenz, Pugh, Milligan, Gift, & Suppe, 1997) and the 
Common Sense Model (CSM; Prohaska, Keller, Leventhal, & Leventhal, 1987; Ward 
1993). The model, depicted in Figure 5.1, provides a conceptual basis for the constructs 
of comorbidity burden and symptom perception. Comorbidity burden is defined as a 
combination of the presence of chronic illness and the interference of each illness with 
general daily life. The construct of symptom perception is multidimensional and includes 
symptom presence, symptom bother, and the client’s perception of the cause of the 
symptom. Identification of the perceived cause of each symptom links chronic illness, 
cancer, their treatments, and aging as possible considerations for interpretation of the 
meaning of a symptom or group of symptoms. This knowledge can better facilitate 
implementation of a key guiding principle in symptom management: Treat the cause. 
TOUS is a middle-range theory describing both the antecedents and sequelae of 
unpleasant symptoms such as cancer-related fatigue or pain (Lenz et al., 1997; Lenz, 
Suppe, Gift, Pugh, & Milligan, 1995). This theory incorporates three factors that 
influence symptom perception, including physiological, psychological, and situational 
factors. These three factors interact with each other and have a direct impact on the 
development and exacerbation of symptoms. Symptoms are also thought to occur in 
groups or clusters, to interact with each other and ultimately affect an individual’s 
functional status, cognitive functioning, and physical performance. The effect of 
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Figure 5.1 Relationship of COSMOS and conceptual model. Bolded words indicate 
dimensions of measurement. 
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factors that were antecedent to symptom development. 
This model suggests that symptom-management interventions may be effective at 
the antecedent level to prevent or decrease symptom development or at the symptom 
level to prevent or decrease the impact of the symptoms on performance (Lenz et al., 
1997). The presence of multiple comorbidities in the older adult with cancer may lead to 
the development of complex symptoms that can affect overall functioning and quality of 
life (Dodd, Miaskowsi, & Paul, 2001; Gift, Jablonski, Stommel, & Given, 2004). 
An individual’s interpretation of her or his symptoms can be comprehensively 
understood by using an information-processing model such as the CSM. This model 
proposes that people have specific ideas about their illnesses and that these ideas guide 
coping behaviors for health and illness (Haggar & Orbell, 2003; Leventhal, Meyer, & 
Nerenz, 1980; Ward, 1993). The CSM describes three stages of information processing, 
including cognitive and emotional representation of illness, coping with illness, and 
appraisal of the effectiveness of the coping strategy. This general framework integrates 
the physical, psychological, and social dimensions of symptom perception and 
subsequent choices of symptom-management actions. The distinction between the disease 
process, treatment side effects, and the normal physiological changes of aging may guide 
individual health-behavior choices. 
The COSMOS subscales are based on a cancer survivor’s perception of his or her 
chronic illnesses and symptoms within the context of past and present cancer 
experiences. The comorbidity burden subscale measures the presence of chronic illness 
and the impact or burden on daily life. The symptom perception subscale measures the 




perception includes symptom distress, duration, intensity, and attribution. Individuals 
may consider physiologic, psychological, and situational/social factors as they think 





Overview of Scale Development 
 
Development of a measure for a complex phenomenon requires a rigorous and 
organized approach. Lynn (1986) suggested using a two-stage process including the 
developmental stage and the judgment-quantification stage. The developmental stage 
includes three steps: (a) identification of the content domain, (b) item generation to fully 
represent the essential areas within the domain, and (c) assembly of generated items into 
a usable form for piloting with a target population. The judgment-quantification stage 
includes using a panel of experts to evaluate each item and the instrument for relevancy 
and representativeness of the domains being measured. This process is similar to the 
eight-step process outlined by DeVellis (2003), which also includes conducting a pilot of 
the scale in a representative sample population, evaluating items based on pilot data, and 
optimizing scale length.  
The determination of validity is a critical step in the development of relevant and 
accurate measures of complex clinical phenomenon. Content validity can be defined as 
the extent to which a measure reflects a specific content domain (Carmines & Zeller, 
1979; DeVellis, 2003). The determination of content validity includes a comprehensive 
review of literature relevant to the phenomenon of interest, clear definitions of the 








COSMOS was initially developed by the investigator based on an extensive 
review of relevant literature on comorbidity assessment, symptom assessment, and 
symptom attribution. The scale was conceptualized to include two components, the 
comorbidity burden subscale (CoB) and the symptom perception subscale. The CoB is 
based on a comprehensive review of several well-established measures of comorbidity, 
including the Charlson Index (Charlson, Pompei, Ales, & MacKenzie,1987; Charlson, 
Szatrowski, Peterson, & Gold, 1994), Cumulative Illness Rating Scale–Geriatric 
(Extermann, Overcash, Lyman, Parr, & Balducci, 1998; Guralnik, 1996; Miller et al., 
1992), Index of Coexistent Disease (Imamura, McKinnon, Middleton, & Black, 1997), 
Life Threat Risk Scale (Yancik et al. 1996; Yancik & Wesley, 1998), and Charlson Self- 
Report Questionnaire (Katz et al., 1996). A brief description of each comorbidity 
measure can be found in Table 5.1. 
The first version of the CoB subscale was a 37-item checklist comprised of yes/no 
questions to assess the presence of a chronic disease or chronic condition and the impact 
of the chronic illness on the patient’s daily life, with possible responses ranging from 
“not at all” to “a great deal.” The scale had 33 items focused on physical illness or 
chronic conditions and four items focused on cognitive or psychological conditions. The 
initial CoB subscale had a Flesch Reading Ease score of 66 and a Flesch-Kincaid Grade 
Level of 6.4 as measured by the Flesch-Kincaid Readability Scale (Paz, Liu, Fongwa, 
Morales, & Hays, 2009).  






Select Measurement Scales for Comorbidity 




Charlson Index Predicts mortality risk over a period of a few weeks to 10 years in a broad range of 
diagnoses by rating 19 diseases with a weighted scoring system (1–6 points) 
Data collection method: Medical record review 





Evaluates the presence of disease and severity of current comorbidities using a 
simple 10-item questionnaire with a combination of yes/no and multiple-choice 
questions 
Data collection method: Self-report 





Evaluates 14 body systems using a weighted scoring system (0 = no impairment to 
4 = life threatening) on a 7-point Likert scale 
Data collection method: Medical record review 
(Extermann, Overcash, Lyman, Parr, & Balducci, 1998; Guralnik, 1996; Miller et 
al., 1992 
 
Index of Coexistent 
Disease 
Rates 13 categories of comorbid diseases with 2 different dimensions: Index of 
Disease Severity (Grade 0 = no coexistent disease to Grade 3 = uncontrolled 
disease that causes moderate to severe disease symptoms) and Functional 
Severity (Level 0 = normal function to Level 2 = serious impairment); total 
scores based on an explicit list of symptoms, signs, and laboratory tests 
Data collection method: Medical record review 
(Imamura, McKinnon, Middleton, & Black, 1997) 
 
Life Threat Risk 
Scale 
Measures the potential impact of 35 comorbid conditions on short-term survival of 
the individual using a 0–3 scale (0 = negligible to 3 = high) 
Data collection method: Medical record review 





comprehensive review of the most prevalent symptom-assessment tools being used in 
clinical oncology research, including the Edmonton Symptom Assessment Scale (Bruera, 
Kuehn, Miller, Selmser, & Macmillan, 1991; Chang, Hwang, & Feuerman, 2000; 
Jenkins, Schulz, Hanson, & Bruera, 2000; Philip, Smith, Craft, & Lickiss, 1998), M. D. 
Anderson Symptom Inventory (Cleeland et al., 2000), Memorial Symptom Assessment 
Scale–Short Form (Chang, Hwang, Feuerman, Kasimis, & Thaler, 2000; Portenoy et al., 
1994), Rotterdam Symptom Checklist (de Haes, van Knippenberg, & Neijt, 1990), and 
Symptom Distress Scale (Degner & Sloan, 1995; McCorkle & Benoliel, 1983; McCorkle 
& Young, 1978; Munkres, Oberst, & Hughes, 1992).  
A brief description of each symptom measure can be found in Table 5.2. After 
consideration of the format and symptom lists of the most commonly used oncology 
assessment tools, the symptom perception subscale was adapted (with permission) from 
the Memorial Symptom Assessment Scale–Short Form (MSAS-SF; Chang, Hwang, 
Feuerman, Kasimis, et al., 2000). The content of this scale was further validated by 
comparing it to a list of symptoms that accompany the most prevalent cancers within the 
older adult population, including lung, breast, prostate, colorectal, pancreatic, bladder, 
and ovary cancers, and leukemia and non-Hodgkin’s lymphoma (American Cancer 
Society, 2015). 
Version 1 of the SxP included three dimensions for each symptom: presence of 
physical or psychological symptoms, symptom bother, and perceived cause of current 
symptoms. The symptom-presence dimension had 34 items (28 physical symptoms and 6 
psychological symptoms). The symptom-bother dimension was a three-point Likert scale 












Measures current symptom levels of nine symptoms using a visual analogue 
scale (0–100mm) 
Data collection method: Self-report 
(Bruera, Kuehn, Miller, Selmser, & Macmillan, 1991; Chang, Hwang, & 
Feuerman, 2000; Philip, Smith, Craft, & Lickiss, 1998) 
 
M. D. Anderson 
Symptom Inventory 
Measures presence and severity on a 0–10 scale for 13 symptoms; also 
includes a six-item symptom-interference scale 
Data collection method: Self-report 




Measures symptom presence of 32 items and symptom distress of each using 
a five-point Likert scale; the scale includes three short-form subscales: high 
and low prevalence physical and psychological symptoms 
Data collection method: Self-report 
(Chang, Hwang, Feuerman, Kasimis, & Thaler, 2000; Chang et al., 1998; 




Measures symptom presence and bother using a four-point scale (0 = not 
bothered at all to 4= bothered very much) 
Data collection method: Self-report 




Measures 13 items on a five-point Likert scale for symptom distress 
Data collection method: Self-report 
(Degner & Sloan, 1995; McCorkle & Benoliel 1983; McCorkle & Young, 





collapsed from the original five-point scale in the MSAS-SF to simplify the scale for 
clinical use. The symptom attribution subscale is a five-point categorical scale that 
describes the cancer survivor’s perceptions about the cause of each symptom, including 
aging, cancer, cancer treatments, medications for noncancer conditions, and other causes. 
In addition to the symptom list, there was a space for participants to add and evaluate 
other symptoms they were experiencing that were not on the list. The initial SxP had a 
Flesch Reading Ease Score of 84 and a Flesch-Kincaid grade level of 4.2.  
COSMOS was developed for a target population of older adults (>65 years) with 
cancer, other comorbidities, and symptoms. Self-report symptom scales have been 
reported as being useful and reliable in oncology populations (Ingram et al., 2002; 
Silliman & Lash, 1999; Tishelman, Taube, & Sachs, 1991). Throughout the development 
stages of the COSMOS, several population-specific considerations were taken into 
account, such as physiological changes of aging, measurement burden, “test anxiety,” 
decreased clarity of thought with complex concepts, and visual acuity (Burnside, Preski, 
& Hertz, 1998; Ingram et al., 2002; Rasin, 2004). COSMOS (version 1) was formatted in 
a concise grid that included a simple checklist and check-box approach. The COSMOS 
had a simple construction, with mostly dichotomous rating scales, easy readability, and 
simple instructions. It was anticipated that the scale could be read easily with the 12-point 
font and a high contrast print of black lettering on a white background. The estimated 
time for completion of both the CoB and SxP was about 15 to 20 minutes. The scale was 
designed to be completed by cancer survivors themselves, or could be read and recorded 
by an assistant if the patient had physical limitations such as impaired sight or grip 









The process for selecting a panel of content experts was based on 
recommendations outlined by Grant and Davis (1997) and Lynn (1986). Following study 
approval by the University of Utah Institutional Review Board, 12 potential expert 
clinicians and researchers were identified by the author based on the following inclusion 
criteria: (a) clinical practice or research expertise in oncology or gerontology/geriatric 
oncology care and symptom management, (b) publications within their specialty area in 
refereed journals (>3 publications), and (c) national presentations in their area of 
expertise (>2). Experts were identified through gerontology and oncology specialty-
organization contacts and literature searches for publications listed in traditional health 
care literature databases. Every effort was made to recruit expert panelists from a variety 
of geographical areas in the United States. Potential expert panelists received an 
invitation to participate in the evaluation of the content of the COSMOS subscales using 
a standardized letter delivered via email. The invitation explained the purpose of the 
study, the expert’s role within the study, and the expected time frame of the study.  
When a panelist agreed to participate within the specified time frame, an expert 
panel packet including the following items was sent to them via email, and they were 
given 4 weeks to return their responses:  
▪ An introduction letter to the study;  
▪ A brief description of the tool, its content domains, the objectives for tool 
construction, and a definition of terms; 




▪ A copy of the original scale (COSMOS); and 
▪ A copy of the scale for rating relevancy of each item  and a comment field for 
each item. 
Each participant on the panel of experts used a critique form to record item relevancy and 
overall instrument relevancy for COSMOS. A four-level Likert-type rating scale was 
used for ratings of relevancy of the items, as outlined in Table 5.3 (Lynn, 1986). 
In addition, each expert panelist was asked to comment on specific aspects of the 
overall tool, such as clarity of instructions, time frames of patient experiences, and 
critical omissions from each subscale, and to offer suggestions for specific-item revision 
and scale format and general overall comments about the scale. Reminder emails were 
sent to expert panelists at 2 and 4 weeks after the initial email with the content validity 
packet. 
All data were entered into two parallel but separate databases and then compared 
for accuracy; any mismatched data were compared with the original data and reentered. 
Qualitative data were derived from expert panelists’ written comments and analyzed for 








1 Not relevant 
 
2 Unable to assess relevance without item revision OR  
item is in need of such revision that it would no longer be relevant 
 
3 Relevant but needs minor alteration 
 
4 Very relevant and succinct 
 




clarification of directions within the survey format and suggestions for simplifying the 
format. 
Data for each subscale were analyzed using descriptive statistics and by 
calculating the CVI and ICC for each item, each subscale in general, and the instrument 
as a whole. The CVI is defined as the proportion of experts who rate an item as “3” or 
“4” on the relevancy rating scale previously defined (Lynn, 1986; Waltz, Strickland, & 
Lenz, 1991). For example, if five out of six experts rate an item as “3” or “4,” the CVI for 
that item is .83, which is the minimum level required to establish content validity at the 
.05 significance level (Lynn, 1986). However, Polit, Beck, and Owen (2007) suggested 
that a CVI for an individual item within a scale of greater than .78 can be considered as 
excellent agreement, regardless of the number of expert raters. The CVI for the entire 
subscale is the proportion of content experts who judge the overall instrument as content 
valid (Lynn, 1986; Waltz et al., 1991).  
A total ICC of agreement was calculated for the CoB and SxP and an individual 
ICC was calculated for each item within each subscale. The ICC has been defined as a 
special case of the weighted multirater kappa when rating categories are equally spaced 
along a single dimension (Fleiss & Cohen, 1973). The ICC (2,1) was chosen for this 
study, which reflects a two-way, random effects, absolute statistic. The interpretation of 
the multirater kappa coefficient and ICC are similar, and similar definitions and 
interpretations of values can be used (Fleiss & Cohen, 1973). The level of strength of 
agreement of ICC can be described as follows: a value of <.40 is considered poor strength 
of agreement, .40–.59 is fair strength, .60–.74 is good strength, and .75 and above is 




Tool revisions were based on the interrater agreement of the expert panel and 
their qualitative comments. Decision rules regarding items include the following: 
▪ Items with CVI >.80 and ICC >.60 were retained for pilot testing. 
▪ Items identified as having potential relevancy with CVI of .5–.79 were revised 
and incorporated into the tool. 
▪ Items identified as omissions by >2 panelists were developed and added to the 
tool. 
▪ Themes identified in the comments of >2 expert panelists were considered for 
incorporation into the revised tool prior to pilot testing.  
Qualitative data such as comments on specific aspects of the overall tool, including 
clarity of instructions, time frames of patient experiences, critical omissions from each 
scale, suggestions for specific item revision, tool format, and general overall comments 
about the tool, were analyzed for themes to identify key critique elements based on the 




Seven out of the 12 experts contacted agreed to participate in the expert panel. 
The results of the expert panel are based on the 6 who completed the survey within the 1-
month response time via email or facsimile communication. Five expert participants had 
more than 10 years of experience in oncology nursing and 1 had more than 10 years of 
experience in gerontology; 3 were advanced-practice clinicians and 2 were primary 
researchers; and 1 was active in both clinical practice and research. Four out of 6 
panelists had specific expertise in gerontology or gero-oncology and 5 had specific 
expertise in symptom assessment and management. All panelists were affiliated with 
academic institutions as clinicians, faculty, or clinical researchers, and had more than 10 




The evaluation of the content validity results was based on the absolute responses 
of 6expert panelists using both the CVI and ICC. The CVI was calculated using the 
number of experts who rated an item as “relevant but needs minor revision” or “very 
relevant and succinct” divided by the total number of experts who rated the item. The 
minimal criteria for retaining each item was a CVI of >.83 (an agreement of 5 out of 6 
expert panelists) with p<.05 and an ICC>.60. Of note, a CVI of .80 was used for two 
items that were answered by only 4 experts. Table 5.4 is a composite of CVI data for the 
CoB and Table 5.5 is a composite of CVI data for the SxP.  
 
Comorbidity Burden Subscale 
 
Thirty-seven items were evaluated by the expert panel and five items had a CVI 
<.80. These items included trouble moving one side of the body, dialysis or kidney 
transplant, lupus, behavior problems, and gall bladder and pancreas problems. The initial 
average measures ICC for the subscale was .972 (p = .000). The average CVI of the CoB 
was .798. Several items were suggested for inclusion in the CoB, including incontinence, 
chronic obstructive pulmonary disease (COPD), asthma, forgetfulness, and reproductive-
related issues such as menopausal symptoms, prostate problems, and ovary or uterus 
problems. Qualitative comments focused on clarifying language for describing specific 
comorbidities in layman’s terms, clarifying directions within the survey format, and 
suggestions for simplifying the format. 
 
Symptom Perception Subscale 
 
Thirty-four items were evaluated and 33 items were rated with a CVI >.80. One 






Content Validity for Single Items Within 




No. of Raters Who 
Scored Item as 





Stroke 6/6 1.0 
Heart attack 5/6 0.83 
Arrhythmias 5/6 0.83 
Blood clot 5/6 0.83 
Stomach ulcer 5/6 0.83 
Liver problems 5/6 0.83 
Bowel problems 5/6 083 
Diabetes/high blood sugar 5/6 0.83 
Thyroid problems 5/6 0.83 
Kidney trouble 5/6 0.83 
Brittle bones/osteoporosis 5/6 0.83 
Arthritis 5/6 0.83 
Overweight by 50 pounds or more 5/6 0.83 
Depression 5/6 0.83 
Anxiety 5/6 0.83 
Cancer (more than one type) 5/6 0.83 
Poor blood flow in arms and legs 5/6 0.83 
Trouble breathing while sitting 5/6 0.83 
Trouble breathing while moving 5/6 0.83 
General breathing problems 5/6 0.83 
Severe indigestion at bedtime 5/6 0.83 
Long periods of forgetfulness 5/6 0.83 
Shuffling gait/trembling hands 5/6 0.83 
Broken bones 5/6 0.83 
Vision problems 5/6 0.83 
Hearing problems 5/6 0.83 
Balance problems 5/6 0.83 
Multiple infections 5/6 0.83 
Bleeding problems 5/6 0.83 
Anemia 5/6 0.83 
High blood pressure 4/5 0.80 
Heart failure 4/5 0.80 
Problem with gallbladder or pancreas 4/6 0.67 
Trouble moving one side of body 4/6 0.67 
Dialysis/kidney transplant 4/6 0.67 
Lupus 4/6 0.67 
Behavior problems 1/6 0.17 






Content Validity for Single Items Within 




No. of Raters Who 
Scored Item as 





Difficulty concentrating 5/5 1.0 
Trouble remembering 5/5 1.0 
Pain 5/5 1.0 
Lack of energy 5/5 1.0 
Cough 5/5 1.0 
Dry mouth 5/5 1.0 
Nausea 5/5 1.0 
Feeling drowsy 5/5 1.0 
Numbness/tingling in hands and feet 5/5 1.0 
Difficulty sleeping 5/5 1.0 
Feeling bloated 5/5 1.0 
Problems with urine 5/5 1.0 
Vomiting 5/5 1.0 
Shortness of breath 5/5 1.0 
Sweats 5/5 1.0 
Hot flashes 5/5 1.0 
Problems with sexual interest 5/5/ 1.0 
Itching 5/5 1.0 
Lack of appetite 5/5 1/0 
Dizziness 5/5 1.0 
Difficulty swallowing 5/5 1.0 
Mouth sores 5/5 1.0 
Taste changes 5/5 1.0 
Weight loss 5/5 1.0 
Hair loss 5/5 1.0 
Constipation 5/5 1.0 
Diarrhea 5/5 1.0 
“I don’t look like myself” 5/5 1.0 
Worrying 5/5 1.0 
Feeling irritable 5/5 1.0 
Feeling anxious 5/5 1.0 
Feeling nervous 5/5 1.0 
Changes in skin 4/5 .08 
Hot flushes 3/5 0.6 




SxP was .843 (p = .000). The SxP CVI was .98. Only 5 expert panelists provided ratings 
on each item in this subscale, with a high level of agreement for most items. One panelist 
provided only qualitative data that were incorporated into the subscale revisions. Two 
expert panelists including “feeling sad or blue” or “hopelessness and helplessness” 
suggested one item for inclusion in the subscale. Qualitative comments focused on 
clarifying language for several symptoms, including changes in skin, pain, sleep-related 
symptoms, feeling bloated, problems with urination, sweats, and sexuality related 
symptoms. Similar suggestions were made for the CoB regarding clarification of 
directions within the survey format and suggestions for simplifying the format.  
 
General Scale Revisions 
 
Several reviewers (4/6) commented that the original grid format was too complex 
for older adults to navigate without becoming confused or frustrated. One major revision 
of the COSMOS scale was formatting, with minor content adjustments. A second review 
by the expert panel was deferred based on the high level of agreement about vague items 




Data were analyzed using the item–content validity index, the scale average–
content validity index, and the ICC for each item to control for the limitations of using 
either statistic alone. Both the CVI and ICC results were used to inform decisions about 








Comorbidity Burden Subscale 
 
Based on the results from the expert panel, three items were deleted, two items 
were revised to improve language clarity, and three items were added. Based on the 
criteria of a CVI less than .80, indicating low rater agreement on item relevancy, the 
items behavior problems, dialysis, and lupus were deleted. The average measures ICC 
was .974 (p = .000) for the revised subscale with deleted items. This result reflects a 
strong level of agreement regarding item relevancy for the subscale and supports content 
validity. In addition, language was clarified on several comorbidity items based on the 
experts’ feedback, including items related to cardiac disease, bone health, joint 
replacements, ulcers, and liver disease. Additions were made based on comments from 
the expert panel, including the following: Symptom-related breathing questions were 
replaced by specific questions about asthma and COPD, separate questions were 
developed for chronic gallbladder and pancreas issues, and language was clarified for 
specific chronic illness questions. In addition, the language in the instructions for the 
subscale was clarified. All changes in language for original and additional questions were 
generated by suggestions from at least 2 expert panelists. A major change was made from 
a complex, grid-like format of the original scale to a straightforward format, as illustrated 
in Figure 5.2. This change was based on comments made by expert panelists and 
endorsed by select experts in gerontologic research via personal communication. The 
simplified format incorporated many of the general principles for conducting research 









 Figure 5.2 Comorbidity burden subscale, revised format. (Sample item.) 
 
 
Symptom Perception Subscale 
 
The results from the expert panel rating validated the relevancy of 33 of the 
original 34 items, with CVI >.80. These items were retained and one item (hot flushes) 
was combined with hot flashes at the suggestion of 3 out of 6 reviewers. The average 
measures ICC was .884 (p = .0001) for the revised subscale. Overall results from the 
expert panel data support content validity of the SxP. One item, “feeling sad or blue,” 
was added to the list of symptoms based on suggestions from the expert panel. Also 
based on their suggestions, one combination item was formed that included worrying, 
feeling anxious, and feeling nervous. In addition, language was clarified for several 
symptom descriptions and instructions for completing the subscale. The SxP was also 
reformatted, as illustrated in Figure 5.3. As in the case of the CoB, this change was made 
to simplify the format for older adults and was endorsed by select experts in gerontologic 
research. Overall, 31 items were retained unchanged, one item was added, and three 
items were merged with similar items. 
 
Initial Scoring Guidelines 
 
The CoB score consists of the self-reported presence of chronic illness and its 
effect on daily life. One point is assigned for each reported comorbidity and zero to four  
3. Have you ever had an irregular 
heartbeat that needed medications or 
a pacemaker? 
 
 _____Yes ______No 
 
If you answered yes, please answer 
the question on the right.  
How much does this affect your 
current daily life? (Check one.) 
 
□ Not at all 
□ A little 
□ Some 




3. During the past month, 
have you had pain? 
 
 _____Yes _____No 
 
 
If you answered yes,  
please answer the 
questions on the right.  
 
3b. How much does this symptom bother you? 
□ None OR a little 
□ Some 
□ A great deal 
 
3c. Check any of the following statements that 
you think are true about your symptom of pain. 
 ___It is caused by aging. 
 ___It is caused by my cancer.  
 ___It is caused by my cancer treatments. 
 ___It is caused by my medicines for noncancer 
conditions. 
 ___This symptom has some other cause.  




Figure 5.3 Symptom perception subscale, revised format. (Sample item.) 
 
 
points are added based on the reported effect of the comorbidity on the individual’s life. 
The higher the score for this subscale, the higher the comorbidity burden. The SxP score 
includes self-reported symptom presence and symptom bother. One point is assigned for 
symptom presence and zero to two points are added based on symptom bother. The 
higher the score for the symptom scale, the more intensely the symptom is perceived by 
the participant. Symptom attribution is constructed as a simple description of the 
perceived cause of each symptom by the participant. Participants were instructed to 




There were several challenges in the development of the COSMOS subscales and 
their scoring. One issue was the identification of the most relevant and appropriate 
chronic illnesses to assess in older adults using a self-report instrument. The use of 




health conditions may have an impact on the participant’s response and the outcome of 
the CoB. Chronic illnesses may be described with specific diagnostic labels or symptom-
related language, and may blur the lines between comorbidity and symptom assessment. 
The issue of clear, concise formatting for an older adult population was addressed by the 
expert panel’s opinions and suggestions. Theoretical concepts were also considered 
regarding the intersection of chronic illnesses and their symptoms with cancer-related 
symptoms and the best method to assess this intersection. Another issue that was raised 
by the expert panel was the fundamental overlap between a chronic illness and a chronic 
symptom, such as pain or depression. 
Statistical analysis for determining content validity was carefully considered to 
prevent inherent limitations of using one specific method to determine item relevancy for 
each subscale. A limitation of using the CVI alone is that it simply reflects the proportion 
of agreement without accounting for expert panelists’ agreement by chance. An attempt 
to control for this limitation is to use a conservative number of expert panelists and 
analyze all rating categories separately. An additional measure of agreement, such as the 
ICC, can also be used. It is suggested that the ICC has several limitations, such as 
restricted information for evaluating individual items and individual feedback from 
expert panelists (Polit et al., 2007). Another potential limitation of using the ICC alone is 
the possibility of obtaining a high level of agreement in situations in which content 
validity is low (Polit et al., 2007). Using both statistical methods for evaluating content 










COSMOS version 2 (v2) was pilot tested with a target population of older adults 
with cancer, chronic illnesses, and symptoms to assess initial construct validity, 
reliability, and issues involved in scale completion (Lacasse, 2016c). Further revisions 
will be considered based on the results of pilot testing. Once initial validity and reliability 
are examined, it is envisioned that this scale may be used as a component of 
comprehensive geriatric assessment in oncology patients and may assist in targeted 
assessment of the impact of comorbidities and symptoms on overall functioning. In 
addition, the symptom attribution information may help clinicians integrate a targeted 
assessment and intervention approach to cancer survivors with specific comorbidities and 
symptoms. It also may be useful in the research setting as a basis for evaluating and 
predicting health-related outcomes for older adults with cancer and complex cancer 
symptom management. COSMOS results may also assist in the assessment of quality-of-
life dimensions in cancer survivors related to the impact of comorbidity burden and 
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COMORBIDITY AND SYMPTOM MEASUREMENT IN 
 







Older adults aged 65 years or older comprise more than 50% of cancer survivors. 
The diagnosis of cancer often co-occurs with other chronic illnesses and expected 
physiologic changes of aging. Perceptions of symptoms in the context of aging and 
chronic illness may have a profound impact on the diagnosis, treatment, and symptom-
management outcomes of cancer survivors. The purpose of this study was the initial 
evaluation of the psychometric properties of a newly developed self-report tool for 
measuring comorbidity burden and symptom perception, the Comorbidity and Symptom 
Measurement in Oncology Scale (COSMOS). Following a study to establish content 
validity, the revised COSMOS (COSMOS v2) was pilot tested using a mixed-methods 
approach with a convenience sample of 62 cancer survivors aged 65 years or older with 
two or more comorbidities, one or more symptoms, and the ability to read and speak 
English. Participants were stratified into those on active cancer treatment (n = 32) and 
those off treatment for 1 year or more (n = 30). Each participant completed a paper-and-




interviewed to explore their experience with the COSMOS v2 and their perceptions about 
symptoms. Initial psychometric results indicate that the COSMOS v2 discriminates 
between cancer survivor treatment groups. Significant differences were found between 
treatment groups, with the off-treatment group having more comorbidities, such as 
osteoporosis and thyroid disease. There was also a difference between groups on the 
presence of specific comorbidities, as well as the presence and attribution of specific 
symptoms. Both subscales demonstrated strong test-retest reliability with the comorbidity 
burden subscale intraclass correlation coefficient (ICC) = .917 and the symptom 
perception subscale ICC = .696. There is evidence to support the validity and reliability 
of COSMOS v2 in a sample of older adult cancer survivors with multiple comorbidities 
and symptoms. COSMOS has potential for use in clinical practice, education, and 
research as a basis for patient-centered care management and optimizing quality of life in 




Older adults are one of the most vulnerable and rapidly growing populations with 
cancer. Approximately two thirds of all cancers are diagnosed in individuals 65 years and 
older, and the diagnosis often co-occurs with the normal and pathological changes of 
aging, which include chronic diseases and conditions (Institute of Medicine[IOM], 2013). 
In an epidemiological study of more than 3,500 survivors of breast, prostate, lung, 
colorectal, and bladder cancers aged 60 years or older, it was found that 54.3% had two 
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or more preexisting chronic conditions (Deckx et al., 2012). This study also compared 
chronic illnesses in cancer survivors and noncancer survivors and found that the most 
common illnesses in both groups were ischemic heart disease, hypertension, diabetes, 
lipid disorders, arthritis, low back pain, benign prostatic hypertrophy, dementia, and 
chronic obstructive pulmonary disease (COPD). The study also revealed that the presence 
of chronic illness in both groups was comparable, with the exception of venous 
thrombosis, which was significantly more prevalent in cancer survivors. In addition, 
previous reports of prevalent chronic diseases and conditions in geriatric cancer patients 
included gastrointestinal problems, thyroid dysfunction, and anemia (Vaeth, Satariano, & 
Ragland, 2000). 
Comorbidity is associated with many sequelae that affect physical, mental, and 
social health outcomes, including functional impairment, symptoms, decreased mobility, 
anxiety, depression, and diminished social interaction (IOM, 2012; Valderas, Starfield, 
Sibbald, Salisbury, & Roland, 2009). Multiple site-specific physiologic effects have been 
identified in cancer survivors and can be considered as either immediate or late effects of 
specific therapies (Hewitt, Greenfield, & Stovall, 2006). Some of these late effects 
overlap with physiologic changes of aging and common comorbidities associated with an 
older age. Older adults may perceive symptoms as age-related and may learn to cope with 
chronic symptoms (such as pain and fatigue) as a normal part of the aging process. Some 
older adults with chronic illnesses may have different expectations regarding functional 
ability, and experience less overall symptom distress due to their frame of reference. The 
meaning of aging is very individual; normal symptoms are defined in the context of the 




quality of life. 
The role of multiple chronic conditions may be a significant factor in symptom 
perception and the impact of symptoms on the physical, psychological, and spiritual 
functioning of geriatric patients in all phases of the cancer disease trajectory. Although 
studies have shown that an increased number of comorbidities is associated with 
increased symptoms (Cella et al., 2010), the phenomenon of symptom perception in the 
older adult with cancer and multiple comorbidities has been minimally explored. 
 
Measurement of Comorbidities and Symptoms in Cancer Survivors 
 
There are several valid and reliable tools for measuring the burden of comorbidity 
that require a trained observer and chart review to extract data for comorbidity burden 
estimations. Tools commonly used to assess comorbidity include the Charlson 
Comorbidity Index, Cumulative Illness Rating Scale–Geriatric, Kaplan-Feinstein Index, 
and Index of Coexisting Disease (De Groot, Beckerman, Lankhorst, & Bowler, 2003; 
Extermann, 2000). The Charlson Comorbidity Index is the most widely used measure of 
comorbidity; it requires the use of a trained data collector to extract appropriate 
information from the medical record and code the data (Charlson, Pompei, Ales, & 
MacKenzie, 1987; Charlson, Szatrowski, Peterson, & Gold, 1994). A self-report 
questionnaire version of the Charlson Comorbidity Index also exists and is comprised of 
10 main disease-oriented questions that assess the presence and severity of common 
comorbidities in older adults (Katz, Chang, Sandha, Fossel, & Bates, 1996). The 
Charlson Comorbidity Index assigns weights to diseases based on morbidity risk and 
excludes conditions that affect quality of life but have limited impact on morbidity. 




physiologic burden and survival estimates that often inform treatment decisions for older 
adults with cancer; however, these measures lack the patient-centered perspective of 
burden of chronic illness on an individual’s daily life. 
Cancer-related symptoms have been studied for more than 20 years, but few 
studies have specifically focused on the older adult population of cancer survivors with 
multiple chronic illnesses. A small body of emerging evidence identifies the uniqueness 
of cancer-related symptoms in the geriatric population, the interrelationship among 
symptoms, and population-specific aspects of symptom assessment and management. 
There are several valid and reliable measurement tools available for assessing cancer-
related symptoms, including the Symptom Distress Scale (Degner & Sloan, 1995; 
McCorkle & Young, 1978), Edmonton Symptom Assessment Scale (Bruera, Kuehn, 
Miller, Selmser, & Macmillan, 1991), Memorial Symptom Assessment Scale (Portenoy 
et al., 1994), Rotterdam Symptom Checklist (de Haes, van Knippenberg, & Neijt, 1990), 
and M. D. Anderson Symptom Inventory (Chang, Hwang, Feuerman, & Kasimis, 2000; 
Cleeland et al., 2000); however, there are no specific measures for the oncology, chronic 
illness, or aging population that integrate symptom presence, symptom perception, and 
symptom attribution. The coupling of symptom perception and symptom attribution 
provides clinicians with unique patient-centered perspectives for symptom assessment 
and intervention. 
Older age may be related to increased physical symptoms mediated by an 
increased number of chronic illnesses (Kolk, Hanewald, Schagen, & Gijsbers van Wijk, 
2003). A study of individuals aged 65 to 89 with advanced lung cancer receiving cancer 




reported by those with one comorbidity (1.7 symptoms) and those with five or more 
comorbidities (>3.5 symptoms; Gift, Jablonski, Stommel, & Given, 2004). An 
interviewer-administered tool to measure specific comorbidities and their associated 
symptoms was developed by Crabtree, Gray, Hildreth, O’Connell, and Brown (2000). 
The Comorbidity Symptom Scale was developed based on interview data that incorporate 
the presence of 23 comorbidities and the severity of their associated symptoms in older 
adults. This scale allows the interviewer to obtain symptom data directly from the patient, 
but only comorbidity-associated symptoms are identified. This measure provides a 
general overview of specific comorbidities and their associated symptoms, but does not 
allow for assessment of multiple symptom attributions such as aging, cancer and its 
treatment, chronic conditions, and others.  
The Symptom Bother–Revised Scale was developed by Heidrich, Egan, 
Hengudomsub, and Randolph (2006) to measure symptom distress related to 13 
symptoms commonly reported by older adults with chronic illnesses or conditions. This 
scale has a reported reliability range of .78–.89 (alpha coefficient). Heidrich et al. (2006) 
used a revised version of this scale with a population of older women, including breast 
cancer survivors (n = 18) and those without breast cancer (n = 24). Half of the breast 
cancer survivors were reported to be on hormonal therapy at the time of the study. 
Participants reported on 37 symptoms common to the breast cancer survivor population, 
including symptom presence, level of distress, and perceived cause, including breast 
cancer, other illness, aging, or “don’t know.” The most frequently reported chronic 
illnesses across both groups were arthritis, cataracts, hypertension, osteoporosis, 




frequent perceived cause of symptoms, followed by chronic illness. A critical evaluation 
of the literature on cancer and comorbidity, measurement of comorbidity, cancer-related 
symptom measurement, and symptom appraisal revealed no self-report tools that measure 
the relationship between comorbidity burden, symptom perception, and symptom 




The purpose of this methodological study was to conduct initial psychometric 
testing of the COSMOS v2 and examine the feasibility of utilizing it with older adults 
with cancer and comorbidities. Specific aims of the study included the following: (a) 
determine the construct validity of the COSMOS v2 with known groups of older adults 
on active cancer treatment and off treatment; (b) determine initial test-retest reliability of 
the COSMOS v2 subscales in a group of older adults cancer survivors who have finished 
active cancer treatment; (c) determine the feasibility of a self-administered measurement 
tool of comorbidities and symptoms in a population of older adults with cancer, including 
completion time, response patterns, scale comprehension, missing items, and patterns in 
missing data; and (d) explore the relationship between comorbidities, symptoms, and 
general functioning. This study was designed to evaluate the initial validity, reliability, 
and feasibility of using a self-report method of determining comorbidity burden and 




A convenience sample of 65 participants was recruited from several outpatient 




included age>65 years; cancer diagnosis for >2 months; >two comorbidities as confirmed 
by self-report; >one symptom as confirmed by self-report; and the ability to read, write, 
comprehend, and speak English. An initial subset of 39 participants was screened for 
intact cognition using the Mini Mental Status Exam (MMSE). A score of >23 was needed 
to qualify for the study. No potential participants in this initial group scored below 23, 
and some potential participants objected to the screening exam because they associated it 
with psychiatric and cognitive testing. This formal criterion was subsequently replaced by 
a determination of capacity to complete the instruments based on a preconsent telephone 
discussion that required following instructions to call the principal investigator. The 
discussion included appraisal of the responses of the potential participant to specific 
eligibility questions regarding age, cancer history, comorbidities, and symptoms for 
indication of cognitive dysfunction. 
Both male and female participants were stratified into two groups according to 
treatment status: those in active treatment and those off treatment. Those currently 
undergoing active cancer treatment (surgery, chemotherapy, hormonal and/or radiation 
therapy) constituted the active-treatment group, and those who had completed any cancer 
treatment by 1 or more years constituted the off-treatment group. Recruitment extended 
over several years until at least 30 complete data sets were collected in each participant 
group. The variable most likely to show the impact of the time frame for recruitment is 
the treatment type and its associated treatment-related symptoms. During the recruitment 
period, cancer treatments shifted to an increase in targeted therapies for primary 
treatment and long-term secondary treatments; however, these therapies were not 




Recruitment strategies included referrals from health care providers in cancer 
treatment clinics, community-based health care providers, community events for cancer 
survivors, cancer support groups, and distribution of flyers. Four hundred potential 
participants were initially screened based on age, cancer history, and treatment status 
between June 2010 and June 2015; 154 who met the initial screening criteria and 
expressed interest in the study were contacted by me for further screening. Ninety-six 
(62%) met full screening criteria and were invited to participate; 31 declined to 
participate due to time constraints, length of the survey packet, and decreased interest 
after further consideration. A total of 65 participants were consented. Sixty-two 
participants completed the comorbidity burden subscale (CoB) and 61 participants 
completed the symptom perception subscale (SxP). The first 17 participants in the off-
treatment group were recruited for test-retest data collection, with a yield of 15 completed 
surveys. In addition, 7 participants were interviewed regarding their experience with 





Comorbidity- and symptom-related data were collected using a newly developed 
COSMOS that uniquely combines a self-report assessment of a broad range of chronic 
illnesses and conditions commonly found in older adults with a comprehensive symptom-
perception assessment. Initial content validity for COSMOS v1 was established for each 
subscale using an expert panel (Lacasse, 2016a).  
COSMOS v2 includes a revised version of the CoB and the SxP. The CoB 




presence of comorbidities and the effect of each comorbidity on daily life. Total scores 
range from zero for no comorbidities to 152. Higher scores indicate a higher comorbidity 
burden. The SxP includes 32 symptoms and is comprised of two dimensions that assess 
the presence of symptoms and their effect on daily life. Total scores range from zero for 
no symptoms to 96, with higher scores indicating higher symptom burden. The symptom 
attribution checklist is a five-category list designed to collect descriptive data on the 
participants’ perceptions regarding the attribution of each symptom, including aging, 
cancer and cancer treatment, noncancer medications, and other explanations or a 
combination of attributions. These data inform the perception of each symptom. 
In addition, the functional interference subscale of the Functional Performance 
Index was used to evaluate the overall effect of general health (inclusive of comorbidity 
and symptoms) on general functioning (Leidy, 1999). The functional interference 
subscale is a five-item summative scale, with each item rated on the amount of 
interference posed by current health on life functioning (Appendix I). The scores range 
from 1 to 30, with high scores indicating higher levels of functional interference. The 
functional interference subscale had a Cronbach’s α of .79, indicating acceptable internal 
consistency reliability in this study sample. 
A general information questionnaire (GIQ) was used to collect descriptive data on 
each participant, including demographics, self-reported cancer history, and current 
medications list. The medication count was used as a general measure of comorbidity. In 








Interview Data  
 
A small sample of participants was interviewed about their impressions of each 
subscale, including the clarity of instructions for each section, the length of each section, 
and the clarity of the questions in each section. In addition, participants were asked to 
indicate how they felt about each section, if the sections brought up questions about their 
own health, what they thought about before talking with health care providers about 




Study approval was granted by the University of Utah Institutional Review Board. 
After granting informed consent, eligible participants were asked to complete a data-
collection packet in the following order: the COSMOS v2 subscales, functional 
interference subscale, and GIQ. All participants were assessed for their ability to 
complete the survey packet on their own. Two participants were unable to complete the 
survey packet independently; 1 was assisted by me and only completed the CoB subscale 
due to fatigue; another participant was assisted by a family member and completed the 
subscales in two separate sections for a total completion time of 59 minutes. Each 
participant who required assistance was judged to be cognitively able to respond to the 
surveys but physically frail. Fifteen participants in the off-treatment group were contacted 
by mail 2 weeks after the initial survey packet was completed and asked to complete the 
COSMOS v2 a second time to assess reliability and stability. In addition, a modified GIQ 
was used with the second administration of the COSMOS v2 to determine any individual 







Based on recommendations for initial instrument-development studies, a 
minimum of 30 participants were recruited for both the active-treatment and off-
treatment groups. The literature on sample size for pilot studies for instrument 
development recommends a minimal sample size of 25 to 40 participants per known 
group (Hertzog, 2008; Johanson & Brooks, 2010). In addition, sample size calculations 
were explored for a power of .8 to detect a moderate effect size for differences between 
groups (Cohen’s d = .5) and a small effect size (Cohen’s d = .3) for symptom perception 
scores on comorbidity burden. Calculations indicated a need for a sample size of at least 
64 participants per known group. It was recognized that while the actual sample size was 
not large enough to detect clinically meaningful differences between active-treatment and 
off-treatment groups, it was sufficient to assess feasibility and initial psychometric 
performance. 
Analyses were conducted using SPSS® (version 23). Exploratory and descriptive 
statistics were used to analyze sample characteristics and initial COSMOS v2 data, 
including frequencies and proportions of participants experiencing each comorbidity and 
symptom. Differences between treatment status groups on categorical variables were 
analyzed using Pearson’s chi square. Continuous data were analyzed using independent 
samples t-tests. Test-retest reliability for each subscale was analyzed using a two-way, 
random effects, absolute-agreement model of the intraclass correlation coefficient (ICC).  
Each symptom was analyzed for its assigned attributes using frequencies and 
proportions as related to each specific symptom. Twenty-two different combinations of 




clinically meaningful units of analysis, including age-related, cancer and treatment-
related, and other causes (chronic conditions and medications). The symptom attribution 
data were analyzed based on treatment status using Pearson’s chi square. Pearson 
correlation coefficients were used to assess the relationship between select continuous 
variables of CoB and SxP scores, the medication count, and the functional interference 
subscale score.  
Due to the exploratory nature of the study, an a priori level of significance was set 
at .05. Interpretation of statistically significant results was carefully considered to avoid 
making a Type I error. Although consideration was given to setting the significance level 
lower, correcting for multiple statistical comparisons on a limited data set increases the 
likelihood of missing a statistically significant result (Type II error; Reid, 1983).  
In addition, scale responses were analyzed for patterns of information related to 
instrument administration. Due to the nature of self-reporting, missing data were treated 
as an answer of “No” when reporting comorbidities and symptoms regarding the 
calculation of CoB and SxP scores. Each comorbidity and symptom was analyzed 
separately to minimize the effect of missing data on overall analysis.  
A small convenience sample of 7 participants who consented to be interviewed 
were provided with a copy of the COSMOS v2 subscales and interviewed several weeks 
after completion of the survey packet. Participants were asked specific questions related 
to feasibility of the administration and content of each subscale. In addition, participants 
were asked to reflect on their symptom appraisal process in the context of their cancer 
history and chronic illness experience. Interviews were audiotaped by the principal 




for descriptive information specific to each subscale and descriptive statistics were used 
to analyze these data. Responses related to symptom appraisal were analyzed for themes 
that illuminate symptom perception and appraisal in the context of their cancer and 




The 62 study participants included 32 on active treatment and 30 off treatment for 
1 or more years; ranged in age from 65 to 90 years; were predominantly female and 
White non-Hispanic; were educated beyond the high school level; and were retired, living 
with a partner or spouse (Table 6.1). The off-treatment group had a greater proportion of 
females (χ2 = 5.79, df = 1, p = .016). Cancer-related participant data can be found in Table 
6.2. There were differences between groups on several cancer-related characteristics, 
such as years of survivorship (χ2 = 19.79, df = 3, p = .0001) and type of cancer (χ2 = 
17.87, df = 2, p = .045). The years of survivorship had a broad range in each group; 
however, the majority (78.1%) of the active-treatment group had 5 or fewer survivorship 
years, whereas the majority (70%) of the off-treatment group had 5 or more survivorship 
years. The active-treatment group had an even distribution of diagnoses between breast, 
prostate, and other types of cancer, whereas the off-treatment group included mostly 
survivors of breast cancer and small numbers of various other cancers. Prostate cancer 
survivors were underrepresented in the off-treatment group. Treatment status of the 
active-treatment group was described by a single treatment grouping, including recent 
surgery (up to 2 weeks postoperative), current chemotherapy (up to 4 weeks after 
treatment), current radiation therapy (up to 2 weeks after treatment), and current 












n = 32 
Off Treatment 
n = 30 




















47% 76.7% χ2 = 5.79 (1) .016 
Ethnicity: White non-Hispanic 
 
100% 93% χ2 = 2.14 (1) .144 
Employment status: 
Retired 
Employed full time 

























χ2 = 4.44 (4) 
 
.349 
Education level: Some college, or 
more 
 






Summary of Cancer-Related Participant Data 
 
 
Participant Characteristics Active Treatment Off Treatment Statistic (df) p 
Time since diagnosis: 
Up to 1 year 
>1 year to 5 years 
>5 years to 10 years 
>10 years 
 










χ2 = 19.79 (3) .0001 













χ2 = 17.87 (2) .045 
Multiple cancers (>1) 
 


















Cancer treatment history: 








Functional interference score (n = 31) 
13.2 
(SD = 5.9) 
(n = 30) 
11.5 
(SD = 4.6) 
 
t = 1.29 (60) .221 
a Other cancers include brain, skin, melanoma, lung, bladder, esophageal, lymphoma, and leukemia. 
b Other cancers include melanoma, ovarian, sarcoma, renal, colorectal, lung, lymphoma, bladder, kidney, 




history of two or more types of therapies, which is reflective of the general treatment 
history of cancer survivors. 
Feasibility 
 
The average time for completion of the CoB was about 9 minutes (range 3–25 
minutes) and for the SxP was about 11 minutes (range 3–35 minutes). The average 
completion time for combined subscales was 19.5 minutes (range 7–50 minutes). There 
were no differences between groups with regard to completion times (Table 6.3). 
No specific patterns of missing data were found for either subscale. Three 
participants missed a random page of the CoB, but each missed a different page. Several 
participants missed a random comorbidity and symptom question; however, no item was 
consistently skipped. In addition, when participants answered symptom bother and 
attribution questions without answering the symptom presence question, symptom 




COSMOS Completion Times (Minutes)—Participant Self-Reported 
 
 
Subscale, Mean, and Range 




t (df) p 
Comorbidity burden Subscale 




8.9 min (5.2 min) 
3–20 min 
 
9.2 min (5.3 min) 
3–25 min 
-.24 (58) .814 
Symptom perception subscale 




10.5 min (5.7 min) 
3–20 min 
 
12 min (7.4 min) 
3–20 min 
-.84 (55) .405 
Total Completion Time 




8.9 min (9.7 min) 
7–45 min 
 
20 min (7.4 min) 
7–50 min 
-.43 (56) .669 





comorbidity question without answering the bother question. A maximum of 2 
participants missed items for comorbidity or symptom presence, and a maximum of  4 
participants missed a few symptom-bother items. 
Data based on participant interviews indicated that the scale instructions were 
clear and straightforward to answer. All participants commented that the combined length 
of the subscales was too long. One out of 7 interviewed participants agreed that both 
subscales were more comprehensive than the checklists that they complete in their 
doctor’s office. In response to the question of whether each subscale section brought up 
questions about their own health or symptom-appraisal process, participants generally 
agreed that reviewing the lists of comorbidities and symptoms was helpful and assisted in 
thinking about their own situation and how they thought about their symptoms. Each 
individual described his or her own symptom-appraisal process that included their 
personal history with cancer, chronic illness, and symptom experience within their unique 
survivor-centered social context. Four major sources were used for symptom appraisal, 
including (a) personal experience of symptoms from cancer and chronic illness; (b) 
personal body awareness; (c) family experience of symptoms from chronic illness, 
including cancer; and (d) health information from professional and public sources. A 
summary of interview data is presented in Table 6.4. 
 
Comorbidity and Symptoms 
 
Data were analyzed for differences in reported comorbidities and symptoms 
between the active-treatment and off-therapy groups. Table 6.5 includes data for the 
reported chronic illnesses and Table 6.6 includes data for the reported symptoms. The 






Key Findings From Participant Interviews  













Solid tumor 20 Appraisal within the context 
of multiple years of cancer 







Solid tumor 5 Appraisal framed within the 
context of MCC and past 
symptoms and their 
impact on life 
“You’ve got to just 
deal with it. You’ve 







Solid tumor 3 Appraisal based on total 
body awareness, age, 







Solid tumor 11 Appraisal based on cancer 
and chronic illness history, 
treatment history, acquired 
professional knowledge, 
public knowledge, age, 
medication, diet, and 
seeking out opinions of 








Solid tumor 14 Appraisal based on self-
awareness of body and 
knowing how to prevent 
symptom development 






Solid tumor 9 Appraisal focused on cancer 
and treatment first, then 







Solid tumor 6 Appraisal based on personal 
history with illness and 
family history with cancer 
and cardiac disease 
 
 8 











Active Treatment Off Treatment 
χ2 p 
Rank n % Rank n % 
Arthritis 
 
1 19/32 59.4 1 21/29 72/4 1.49 .284 
High blood pressure 2 18/32 56.3 5 15/30 50.0 .24 .622 
 
Urine leaking 3 18/32 56.3 1 21/19 72.4 1.72 .189 
 
Trouble remembering 4 16/32 50.0 2 19/30 63.3 1.12 .290 
 
Gastroesophageal reflux disease 5 12/32 40.6 2 19/30 63.3 3.20 .074 
 
Depression 6 11/32 34.4 9 10/30 33.3 .01 .931 
 
Osteoporosis 7 10/32 31.3 3 17/29 58.6 4.62 .032 
 
Overweight by 50 pounds or more 7 10/32 31.3 7 11/29 37.9 .30 .583 
 
Problems with vision 7 10/32 31.3 4 12/29 54.5 .68 .411 
 
Diabetes 8 9/32 28.1 16 5/30 16.7 1.16 .281 
 
Bowel problem (nonconstipation) 9 8/32 25.0 13 7/30 23.3 .02 .878 
 
Chronic lung disease 9 8/32 25.0 19 3/30 10.0 2.39 .122 
 
Balance problems 10 7/32 21.9 8 11/30 36.7 1.64 .200 
 
Prostate problems 10 7/32 21.9 22 1/30 3.3 4.74^ 0.30 
 
Thyroid problems 10 7/32 21.9 6 14/29 48.3 4.70 .030 
 
Heart attack 11 6/32 18.8 20 2/30 6.7 2.01^ .156 
 
Irregular heart beat 11 6/32 18.8 13 7/30 23.3 .20 .658 
 
Two or more different cancers 11 6/32 18.8 10 9/29 31.0 1.24 .266 
 
Problems with hearing 11 6/32 18/8 15 5/29 17.2 .02 .878 
 
Knee or hip replacement 12 5/31 16.1 12 7/29 24.1 .60 .438 
 
Other chronic illness 12 5/31 16.1 5 15/30 50.0 7.94 .005 
 
Anemia 13 5/32 15.6 14 6/30 20.0 .20 .652 
 
Asthma 13 5/32 15.6 11 8/30 26.7 1.14 .286 
 








Active Treatment Off Treatment 
χ2 p 
Rank n % Rank n % 
Anxiety 14 4/32 12.5 12 7/30 24.1 1.39 .238 
 
Heart operation 14 4/32 12.5 20 2/30 6.7 .60^ .438 
 
Kidney problems 14 4/32 12.5 16 5/30 16.7 .22^ .642 
 
Liver problems 14 4/32 12.5 20 2/30 6.7 .60^ .438 
 
Blood clots 15 3/32 9.4 17 4/30 13.3 .24^ .623 
 
Poor circulation 15 3/32 9.4 13 7/30 23.3 2.23^ .135 
 
Heart failure 16 2/32 6.3 22 1/30 3.3 .29^ .593 
 
Bleeding 16 2/32 6.3 18 3/29 10.3 .34^ .560 
 
Shuffling/trembling 16 2/32 6.3 11 8/30 26.7 4.77^ .029 
 
Broken bone 17 1/32 3.1 0 0/30 0 .95^ .329 
 
Gall bladder problems 17 1/32 3.1 19 3/30 10.0 1.21^ .271 
 
Many infections 17 1/32 3.1 21 1/29 3.4 .01^ .944 
 
Stroke 17 1/32 3.1 20 2/30 6.7 .42^ .516 
 
Ulcer 17 1/32 3.1 20 2/30 6.7 .42^ .516 
 
Pancreas problems 0 0/32 0 22 1/30 3.3 1.08^ .298 
 
Problems with ovaries or uterus 0 0/32 0 0 0/30 0 0.00^ 0 
 











Active Treatment Off Treatment 
χ2 p 
Rank n % Rank n % 
Lack of energy 1 26/32 81.3 2 22/30 73.3 .56 .456 
 
Pain 2 22/31 71.0 1 24/30 80.0 .67 .413 
 
Feeling drowsy 3 20/31 64.5 3 19/30 63.3 .01 .923 
 
Difficulty sleeping 4 17/31 54.8 6 16/30 53.3 .01 .906 
 
Urinary symptoms 5 17/31 54.8 5 17/30 56.7 .02 .886 
 
Feeling sad 6 15/31 48.4 9 11/30 36.7 .86 .355 
 
Decreased sexual interest 7 13/30 43.3 14 6/30 20.0 .3.77 .052 
 
Dry mouth 8 13/31 41.9 10 10/30 33.3 .48 .488 
 
Numbness/tingling 8 13/31 41.9 8 13/30 43.3 .01 .912 
 
Trouble remembering 8 13/31 41.9 4 18/30 60.0 1.99 .158 
 
Skin changes 9 13/32 41.6 11 9/30 30.0 .76 .382 
 
Itching 10 12/31 38.7 7 15/30 50.0 .79 .375 
 
Feeling irritable 11 11/31 35.5 10 10/30 33.3 .03 .860 
 
Nausea 11 11/31 35.5 15 4/30 13.3 4.03^ .045 
 
Worried, anxious, nervous 12 10/31 32.3 5 17/30 56.7 3.68 .055 
 
Short of breath 12 10/31 32.3 10 10/30 33.3 .01 .929 
 
Feeling bloated 13 9/31 29.0 12 8/30 26.7 .04 .837 
 
Diarrhea 14 8/31 25.8 14 6/30 20.0 .29 .590 
 
Difficulty concentrating 14 8/31 25.8 10 10/30 33.3 .42 .519 
 
Hot flashes 14 8/31 25.8 16 3/30 10.0 2.58^ .180 
 
Dizziness 15 8/31 25.8 11 9/30 30.0 .13 .715 
 
Cough 16 8/31 25.0 13 7/30 23.3 .02 .878 
 
Lack of appetite 17 7/31 22.6 16 3/30 10.0 1.78^ .185 
 








Active Treatment Off Treatment 
χ2 p 
Rank n % Rank n % 
“I don’t look like myself” 18 6/31 19.4 0 0/30 0 6.44^ .011 
 
Constipation 19 5/29 17.2 12 8/30 26.7 .76 .383 
 
Mouth sores 20 4/31 12.9 16 3/30 10.0 .13^ .722 
 
Sweating 20 4/31 12.9 14 6/30 20.0 .56^ .454 
 
Unexpected weight loss 21 3/30 10.0 0 0/30 0 3.16^ .076 
 
Difficulty swallowing 22 3/31 9.7 16 3/30 10.0 .01^ .966 
 
Hair loss 23 2/30 6.7 16 3/30 10.0 .22^ .640 
 
Vomiting 0 0/30 0 17 1/30 3.0 1.05^ .305 
 




arthritis, hypertension, incontinence (leaking urine), trouble remembering, and 
gastroesophageal reflux disease. Several significant differences were found between 
groups regarding reported chronic illnesses. The off-treatment group reported 
significantly more osteoporosis, other chronic illnesses, thyroid problems, and shuffling 
and trembling than the active treatment group (p< .05). The active treatment group 
reported significantly more prostate problems than the off-treatment group; however, this 
is most likely due to underrepresentation of males in the off-treatment group. 
The symptoms reported by 40% or more of both groups include lack of energy, pain, 
feeling drowsy, difficulty sleeping, urinary symptoms, numbness and tingling in hands 
and feet, and trouble remembering. The active-treatment group reported significantly 
more nausea, taste changes, and body image disturbance (p<.05) than the off-treatment 
group. Several group differences approached statistical significance. The active-treatment 
group also reported decreased sexual interest more than twice the rate of the off-treatment 
group (p = .052). The off-treatment group reported more worry, anxiety, and nervousness 
than the active-treatment group (p = .055). 
Several items in the COSMOS v2 CoB may be classified as both chronic 
conditions and chronic symptoms, including problems with remembering, urinary 
symptoms, anxiety, and depression. Relationships between comorbidity burden and 
symptom perception scores for similar variables on the CoB and SxP were explored: 
trouble remembering; incontinence or general urinary symptoms; worry, anxiety, or 
nervousness; and depression or feeling sad or blue. Table 6.7 presents the data describing 








Relationships Between Similar Items on the Comorbidity Burden 




Pearson r (p) 
1 2 3 4 5 6 7 8 
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2. CoB# 
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6. SxP^ 












1.0 -- -- 
7. SxP^ 


































Note. + denotes assessment time frame of over the past year; # denotes assessment time frame of lifetime; ^ 






The symptom attribution checklist included five possible options for each 
symptom with more than 30 different combinations. Most participants chose multiple 
responses that reflected their unique symptom perceptions. 
Symptom attributions were grouped into three distinct categories for analysis. 
Aging-related attribution included the following participant selections: aging, aging and  
cancer, aging and noncancer medications, aging and other causes, and any other 
combinations that included aging. The cancer and cancer treatment attribution category 
included all combinations with cancer and cancer-related treatments except those that 
included aging. The other category included noncancer medications and other 
attributions. Table 6.8 includes the attribution results for the most frequently reported 
symptoms.  
Table 6.9 includes specific attributes identified in the “other” category. The data 
listed in the other category for symptom attribution can be grouped into several broad 
categories, including acute or chronic illness or conditions, acute or chronic physical or 
psychological symptoms, behavior-related causes, or life activities. 
Significant differences between groups regarding symptom attribution were seen 
in only 6 out of 32 symptoms reported (lack of energy, feeling drowsy, feeling 
worried/anxious/nervous, taste changes, lack of appetite, and nausea). Those off 
treatment who reported lack of energy and feeling drowsy reported no cancer-related 
attribution as compared to the active-treatment group. Those on active treatment reported 
significantly more anxiety attributed to cancer-related issues as compared to off-treatment 






Attributions for Most Frequently Reported Symptoms 
by >40% of the Study Sample 
 
 
Symptom and Attribution^ 
Active Treatment (N = 32) 
n (%) 
Off Treatment (N = 30) 
n (%) 
χ 2 (p) 


































































































































Table 6.8 (Continued) 
 
 
Symptom and Attribution^ 
Active Treatment (N = 32) 
n (%) 
















































Note. The percent sign (%) denotes the number of participants reporting a specific attribution divided by 
the total number reporting the symptom; χ2 = Pearson chi square; df = 4, ^ indicates one or more cells with 







Other Attributions for Selected Frequently Reported Symptoms 
 
 
Symptom Descriptions for “Other” Attributions 
Pain Tendonitis, fibromyalgia, shingles, “overdoing,” foot problems, arthritis, spinal 
stenosis, surgery, neuropathy, “pulled muscles,” degenerative disc disease, 
migraines 
 
Lack of energy Multiple sclerosis, fibromyalgia, shingles, pain, chronic pain, lack of sleep, 
stress, depression, chemical sensitivities, overweight, “not slowing down,” 
congestive heart failure, body rashes, amyotrophic lateral sclerosis (ALS), 
travel, arthritis 
 
Feeling drowsy Noncancer medications, shingles, “too many activities,” “not sleeping well at 
night,” stress, caring for wife, chemical sensitivities, fatigue, ALS, lack of 
exercise, physical exhaustion 
 




Treatments, doctor’s appointments, family members, stress, work, “life in 
general,” a busy schedule, ill spouse, neuropathy, caregiver, “husband not 
working,” cardiac issues, relationships, depression 
 
Urinary symptoms Chronic pelvic prolapse, childbirth, prostate issues, noncancer medications, 
overactive bladder, recurrent urinary tract infections, hysterectomy 
 
Difficulty sleeping Napping in afternoon, husband snoring, shingles, anxiety, pain, lack of 
exercise, stress, caregiver, trouble falling asleep, frequent urination, sleep 
apnea, upset stomach, acid reflux, feeling overwhelmed, exhaustion, 
caffeine, depression, low estrogen 
 
Itching Noncancer medicines, shingles, Arizona weather, dry skin, allergies, leg ulcer, 





cancer and cancer treatment for nausea, lack of appetite, and taste changes than off-
treatment participants (p = .045, p = .01, and p =.036, respectively). 
 
Relationship of Comorbidity Burden, Symptom Perception, 
and General Functioning 
 
Differences between groups regarding comorbidity burden, symptom perception, 
and general functioning were explored. Table 6.10 includes specific data on comorbidity, 
comorbidity burden, symptom burden, and function as measured in this study. Active-
treatment and off-treatment groups were comparable with regard to reported medications, 
comorbidity burden, number of symptoms, symptom burden, and functional performance 
and current activity; however, off-treatment participants reported significantly more 
chronic illnesses than those on active treatment. 
The relationship between variables of CoB, SxP, and functional performance was 
explored. Table 6.11 displays the correlations between key exploratory variables. A 
moderate correlation was found between CoB and SxP (r = .460, p = .0001). In addition, 
the functional interference score had a moderate, significant correlation with the CoB 
score (r = .296, p = .021) and the SxP score (r = .423, p = .001). The number of 
medications was not found to be significantly correlated with either CoB (r = .217, 




Test-retest reliability was analyzed using an ICC to determine the repeatability 
and stability of the scale results on a minimal subset of the off-treatment study sample (n 
= 15). The CoB was excellent (ICC = .917), while the stability of the SxP stability was 
















Statistic (df) p 
Number of medications reported 
 
9 (3.94) 8 (4.25) t = .98 (58) .333 







t = -2.48 (60) .016 







t = -1.83 (60) .072 







t = .42 (60) .676 







t = .66 (60) .511 







t = 1.29 (59) .201 
Activity now score 
Normal 
Some symptoms, no extra rest 
Some additional rest (less than half day; 
















Correlations of Key Exploratory Variables (Pearson’s r Statistic) 
 
 
Key Variable CoB Score Medication # SxP Score FIS Score 
CoB score 
 
1.00 .217 (p = .096) .460 (p = .0001) .296 (p = .021) 
Medication # 
 
-- 1.00 .162 (p = .217) .240 (p = .067) 
SxP score 
 
-- -- 1.00 .423 (p = .001) 
FIS score 
 
-- -- -- 1.00 







Based on the pilot data, it is feasible to collect critical patient-centered data on 
comorbidities and symptoms through self-report. There were no identifiable patterns 
found for missing data; however, participants with missing data may have lower 
comorbidity burden and symptom perception scores. Missing data issues may be 
mitigated with a formatting revision of each subscale. Electronic versions of each 
subscale may be constructed to build in guides for scale completion with required fields; 




Two out of 62 participants required assistance in completing the COSMOS v2; 
both participants appeared to be physically frail. The feasibility of COSMOS completion 
by frail or fatigued older adults may be affected by the length of the subscales, which 
may increase survey burden. Although the average completion time for each COSMOS 
v2 subscale was reasonable, at 9 minutes for the CoB and 11.5 minutes for SxP, the range 
for completion of both subscales approached 50 minutes or longer for some participants. 
This could impair clinical utility unless it was used as part of a patient portal that was 




Cancer survivors off treatment reported a significantly higher number of 
comorbidities than the active-treatment group, including osteoporosis, thyroid problems, 
and shuffling and trembling. Although the total CoB scores were higher in the off-




degree of variability on this measure, and the smaller sample size may have limited 
power to detect significant differences. In addition, participant interviews indicate that 
personal experience with cancer and chronic illness is integral to symptom appraisal. 
However, participant interview data should be cautiously interpreted, because it 
represents cancer survivors of 3 to 20 years and mostly off treatment. 
Current cancer survivorship literature suggests that older long-term cancer 
survivors may have a greater number of comorbidities than before the diagnosis (Kenzik, 
Kent, Martin, Bhatia, & Pisu, 2016; Leach et al., 2015); however, Grov, Fossa, and Dahl 
(2011) found no differences in reported comorbidities between older cancer survivors 
(≥70 years) compared to noncancer controls. Older cancer survivors may experience 
chronic conditions due to direct or indirect long-term effects of cancer therapies in 
conjunction with existing comorbidities prior to diagnosis and treatment of new 
conditions due to the aging process. Further longitudinal study is needed regarding the 
development of posttherapy chronic conditions in the context of physiologic aging. 
Additionally, once cancer survivors have finished initial treatment, they may shift their 
focus to the diagnosis of other chronic conditions and management of previous 
conditions.  
These findings may indicate that cancer-related treatment does not have a direct 
impact on comorbidity burden or that chronic conditions are well managed and have a 
minimal impact on overall burden. Individuals have unique expectations of aging within 
their personal view of health and well-being that provides the foundation for perception 
of comorbidity burden. In addition, overall comorbidity burden scores may indicate 




perceived quality of life of older adults. It has been suggested that chronic illness 
experiences may protect individuals from the impact of a cancer diagnosis (Blank & 
Bellizzi, 2008). 
The SxP detected minor differences between participants on active treatment as 
compared to those off treatment. Three items that were reported significantly more in the 
active-treatment group were nausea, taste changes, and “I don’t look like myself”; nausea 
was reported almost three times more in the active-treatment group. Seven active-
treatment participants reported taste changes, and “I don’t look like myself” was reported 
by 6 active-treatment participants, but no off-treatment participants reported either of 
these symptoms. These symptoms are expected in cancer survivors undergoing active 
treatment and support construct validity of the SxP. Of interest, significant differences in 
symptom attribution were noted between the active-treatment and off-treatment groups in 
almost 19% of the symptoms measured.  
The “lack of energy” and “feeling drowsy” items demonstrated a clear pattern of 
attribution, with the active-treatment group attributing these symptoms to aging and 
cancer-related causes while the off-treatment group attributed the symptoms to aging and 
other causes. Anxiety was attributed more to aging and other causes in the off-treatment 
group compared to cancer-related and other causes in the active-treatment group. The 
active-treatment group attributed symptoms of nausea, taste changes, and lack of appetite 
mostly to cancer and cancer treatments compared to the off-treatment group. These 
nuances suggest that the SxP and symptom-attribution descriptors have potential to 





The analysis for the symptom attribution list revealed three clinically meaningful 
categories, including aging-related, cancer-related, and other. The other category for 
symptom attribution included a wide variety of chronic conditions, symptoms, and life 
challenges. Life challenges noted by participants included relationships, life events, and 
health- and wellness-related issues. Using these categories illuminates specific 
differences and similarities between on-treatment and off-treatment older cancer 
survivors with regard to reported symptoms. The difference between groups regarding 
symptom attribution reflects the unique perspective of cancer survivors along the 
treatment trajectory. Both groups primarily attributed trouble remembering to aging; 
however, it is well documented that cancer treatments may have a residual effect on 
functional memory (Mandleblatt, Jacobsen, & Ahles, 2014). 
It has been suggested that the traditional retirement age may be a developmental 
marker for changes in perception of discomfort, from abnormal to a normal expectation 
that comes with age (Williamson & Schulz, 1995). The distinction among the disease 
process, treatment side effects, and the normal physiological changes of aging may guide 
individual health-behavior choices. Prohaska, Keller, Leventhal, and Leventhal (1987) 
revealed that mild symptoms of short or long duration are more likely to be attributed to 
aging than severe, short-term symptoms. In addition, cancer-related symptoms may be 
perceived as a normal part of aging or as being caused by other health problems (Repetto 
et al., 1998). The COSMOS v2 pilot results suggest a possible shift in attribution of 
specific symptoms in cancer survivors from active treatment to off treatment. Cancer 
survivors may also shift their contextual focus for symptom attribution from cancer and 




Several items on the CoB and SxP can be considered as both chronic conditions 
and symptoms, including trouble remembering, anxiety, depression, and urinary 
symptoms/incontinence. Depression and anxiety were strongly associated within their 
respective subscales; however, there was not a significant relationship between these 
items across subscales. This result suggests that each subscale measured the item 
differently based on the time frame reference and the participant’s perception of anxiety 
and depression as a symptom or chronic condition. The urinary symptoms and 
incontinence items were not related across the two subscales, indicating that each item 
measured a different dimension of urinary issues. The “trouble remembering” items on 
both subscales were significantly related, indicating a potential measurement overlap of 
this item. These results suggest that assessment time frame is an important dimension of 
measurement of chronic conditions and symptoms, and may affect overall construct 
validity. 
 
Exploratory Relationships Between Key Variables 
 
The relationship between key variables of comorbidity burden, symptom 
perception, and functional interference was explored. In this study population, a moderate 
relationship was found between CoB and functional interference scores, suggesting that 
increased comorbidity burden is related to increased interference with general 
functioning. Symptom perception scores had a moderate relationship with functional 
interference scores, suggesting that increased symptom perception is related to increased 
functional interference. Finally, the strongest relationship was found between CoB and 
SxP scores. This finding implies that increased comorbidity burden is significantly 




relationship between comorbidity burden, symptom perception, and functional 
interference, and further support validity of COSMOS v2 as a sensitive measure in older 
cancer survivors. Furthermore, these relationships are supported by reported research 
focused on older adult cancer survivors with comorbidities and symptoms (Lacasse, 
2016b). A more refined measure of CoB may illuminate this relationship further. In 
addition, a deeper understanding of the role of symptom attribution, perceptions of 





The CoB scores were relatively low for those with multiple chronic illnesses, 
which may indicate that only the “active” chronic illnesses that are associated with 
symptoms are acknowledged as having an impact on daily life. Older adults may also 
tolerate and minimize “bother” as part of their perception of symptoms of aging. The 
high test-retest reliability of the CoB is an expected outcome of the measurement of self-
reported comorbidity as a stable construct over time (Katz et al., 1996). This supports 
construct validity by demonstrating the stability of the measure of comorbidity burden 
over time in the research sample. 
The SxP scores were slightly higher in the active- treatment group; however, there 
was not a significant difference between groups. The test-retest reliability of the SxP was 
acceptable based on the expected variability of symptoms over time in the context of 
multiple chronic illnesses. Furthermore, the test-retest reliability in this study is 
comparable to other symptom-assessment tools used in oncology populations (Chang, 




2015). These results support the stability of the SxP measure over time in a construct that 





Based on the descriptive item analysis and item-to-item correlations in the CoB, 
the following items should be revised to increase the parsimony of the subscale and 
decrease instrument burden: 
▪ The items addressing heart attack burden and heart operation for vessel or 
valve disease burden scores were highly correlated (r = .901, p = .0001), 
indicating significant overlap of items. These items were collapsed into one 
cardiac-related item.  
▪ The items addressing select gastrointestinal conditions related to pancreas and 
liver were collapsed into one item due to minimal reporting (less than 5%) for 
each of these conditions. Gastrointestinal reflux disease, gall bladder disease, 
and ulcers were retained as separate conditions based on age-related risk 
factors for developing these chronic conditions (Tabloski, 2014).  
▪ Asthma and COPD had a moderate relationship (r = .306, p = .016) and were 
collapsed into one item due to the similarity in symptoms and overlapping 
disease processes.  
▪ The item “broken bones” was reported by <5% of participants and was 
clustered with osteoporosis and bone loss as indicators of bone health 
(Tabloski, 2014).  
▪ The item “multiple infections” was deleted due to minimal reporting (less than 
5%), although it may be relevant in a sample of survivors of hematologic 
malignancies.  
▪ The item labeled “bleeding” was not frequently chosen (less than 10%); 
however, this item was retained and expanded to “bruising or bleeding,” since 
this may occur with older individuals on cancer treatment, which affects bone 
marrow, or those off treatment who have cardiovascular disease and are 
treated with anticoagulant therapy.  
▪ The prostate-specific item was revised and incorporated into a more global 
item addressing genitourinary problems, either male or female. This revision 




Both the CoB and SxP incorporate the overall unique patient experience with 
chronic illness and symptoms. The COSMOS v2 subscales include four chronic 
conditions (trouble remembering, incontinence or urinary symptoms, anxiety, and 
depression or feeling sad) that are commonly found in older populations and are also 
classified as symptoms. Only one of these chronic conditions, trouble remembering, was 
moderately correlated with the corresponding symptom. These items were retained in 
both subscales because trouble remembering, urinary symptoms, anxiety, and depression, 
may be chronic conditions, acute indicators of a change in health, or effects of cancer and 
cancer treatments in cancer survivors (Hewitt et al., 2006; Tabloski, 2014). The revised 
CoB includes 33 items, as listed in Table 6.12.  
The list of items in the SxP parallels the list of symptoms in the Memorial 
Symptom Assessment Scale (Chang, Hwang, Feuerman, Kasimis, et al., 2000). This list 
includes the recommended set of core symptoms for adult patient-reported outcomes 
(Reeve et al., 2014), core symptoms included in the Symptom Distress Scale (Stapleton et 
al., 2015), and select symptoms from the recommended set of core symptoms for patient-
reported outcomes—focused on prostate, ovarian, and head and neck cancers (Chen et al., 
2014; Chera et al., 2014; Donovan et al., 2014). Each of the 32 symptoms on the SxP was 
selected by at least 3 participants, with the exception of vomiting. Based on the global 
nature of the SxP, it is recommended that the list of symptoms remain intact.  
Within the past 5 years, the PROMIS (Patient-Reported Outcomes Measurement 
Information System) tools have been developed and widely tested as standard person-
centered measures for multiple dimensions of physical, mental, and emotional health for 






Revised Comorbidity Burden Subscale Items 
 
 
Items Retained Items Revised/Deleted 




• Poor circulation 
• Stroke 
• Shuffling/tremors 
• Gastrointestinal reflux disease 
• Peptic ulcer disease 
• Gall bladder disease 
• Bowel function alterations 
• Diabetes 
• Obesity 
• Kidney problems 
• Balance problems 
• Joint replacement 
• Arthritis 
• Thyroid problems 
• Anemia 
• Hearing problems 
• Vision problems 
• Urinary incontinence* 
• Confused thoughts 
• Depression* 
• Anxiety* 
• Trouble remembering* 
Revised Items  
• Heart disease (heart attack and heart operation) 
• Chronic lung condition (asthma and chronic 
obstructive pulmonary disease 
• Gastrointestinal conditions (liver disease and 
nondiabetic pancreatic disease) 
• Bruising or bleeding  
• Genitourinary problems (if male, prostate problems; if 
female, ovary and uterus problems) 
• Bone health (osteoporosis/bone loss/broken bones) 
Deleted Items 
• Multiple infections 




Each COSMOS subscale might yield more clinically useful information if the bother/ 
interference scale for each comorbidity and symptom was expanded to match the five-
point Likert scale used in the PROMIS tools. This scale ranges from “not at all” to “very 
much” (www.nihpromis.org/measures/SampleQuestions#fatigue).  
Figure 6.1 is an example of a revised item in the comorbidity subscale. Figure 6.2 
is an example of a revised item on the symptom-perception subscale that incorporates 
changes to facilitate a clearer visual format and future translation to an online version. 




A sample of 62 participants with 30 participants per group can be considered a 
minimal number for initial health-care-related instrument development focused on 
feasibility and initial psychometric testing (Hertzog, 2008; Johanson & Brooks, 2010; 
Julius, 2005). Recommendations for comprehensive instrument development beyond the 
pilot phase requires a large sample size ranging from 10–15 participants per item for 
initial instrument testing (Pett, Lackey, & Sullivan , 2003) to 300 participants or more for 
complex multidimensional constructs (Netemeyer, Bearden, & Sharma, 2003; Nunally,  
 
Have you ever been told by a health care 
provider that you have arthritis? 
 
_____No _____Yes  
If you answered yes, 
please answer the question on the right. 
 
How much does this health problem 
affect your current daily life? (Check 
one.) 
□ Not at all 
□ A little 
□ Somewhat 
□ Quite a bit 
□ Very much 
 
 




During the past 
week, have you had 





If you answered no,  





If you answered yes,  
please answer the 




4b. How much does this 
symptom bother you?  
[Please check one.] 
□ Not at all 
□ A little bit 
□ Somewhat 
□ Quite a bit 
□ Very much 
4c. If you answered yes to the 
question about the symptom, 
please answer the following 
question. 
  
Check one of the following 
statements that you think is true 
about your symptom of fatigue. 
 The cause of this symptom 
is mostly age-related. 
 The cause of this symptom 
is mostly related to my 
cancer and/or cancer 
treatments. 
 The cause of this symptom 
is mostly related to a 
noncancer condition or 
treatment. 
 This symptom has some 
other cause.  
 (Write in what you think is 








1994). Although this study sample is small, the study yielded valuable information for 
further revision and psychometric testing of COSMOS. 
The sample studied in this pilot included a diverse group of cancer diagnoses and 
does not fully represent the four most common cancers diagnosed in adults, including 
cancers of the lung and bronchus, prostate (men), breast (women), and colon and rectum 
(Miller et al., 2016). The active-therapy group does not fully represent the typical range 
of cancer-related treatments, such as chemotherapy and radiation therapy, that may affect 
the symptoms reported by this sample. In addition, the study sample does not equally 
represent gender in the active- and off-treatment groups. This imbalance of gender 
representation was likely due to specific recruitment patterns and may lead to missed 
opportunities for discovery of gender-specific symptom and symptom-attribution 
reporting patterns. This study provides general information about older cancer survivors 
living with multiple chronic illnesses and symptoms and important information for 
revisions of the COSMOS v2.  
The assessment timeframe for comorbidities and symptoms in the COSMOS v2 
ranges from history across an individual’s lifespan through the previous month. The CoB 
includes two specific time frames for participants to consider regarding their history with 
chronic conditions. Questions within the CoB are clustered by time frame, including if 
the participant has ever been diagnosed with a specific illness, or specific chronic 
conditions diagnosed or experienced within the previous year. The SxP is focused on 
symptom recall over the previous month. This variation in the time period of recall may 
potentially influence the individual’s accuracy of self-reporting chronic illnesses and 




this may influence the accuracy of self-report when asked to recall chronic conditions or 
symptoms over an extended period. The CoB demonstrated temporal stability, indicating 
general reliability of reporting comorbidity history. Based on the focused interview data, 
the SxP scale may not reflect an accurate symptom recall over a 1-month time period. 
One recommendation for measuring symptoms is to change the symptom recall interval 
to 1 week; this time frame would focus on the reporting of the most current and 
bothersome symptoms and potentially increase accuracy of symptom reporting. 
Twenty-four percent of the cancer survivor population screened for this study met 
the comorbidity eligibility criteria of having two or more chronic illnesses or conditions 
in addition to cancer, which is lower than the reported 33.2% in the general population 
over 65 years (Ward, Schiller, & Goodman, 2014). Several cancer survivors who met 
eligibility criteria declined participation due to time restriction, fatigue/weakness from 
treatment, discomfort with answering the screening questions, or cancer recurrence. 
During the study recruitment period, which extended over several years, general 
cancer treatment practices remained stable; however, the treatments themselves evolved 
to include newer approaches, including targeted therapies (Hewitt et al., 2006; IOM, 
2013). The variables most likely to show the impact of the time frame for recruitment are 
the treatment type and associated treatment-related symptoms. All study participants had 
a history of multiple types of cancer therapies, which adds to the homogeneity of the 
study population. 
Multiple statistical tests were used to analyze data collected for each subscale, 
functional interference scale, and demographic. This pilot study yielded important 




caution based on the sample size and the risk of Type 1 error. Each significant statistic 
was carefully reviewed and considered using a conservative interpretation of results. 
Decisions for scale revisions were based on study results and validation by relevant 
cancer survivorship literature.  
 
Implications for Practice and Research 
 
The COSMOS v2 shows promise as a reliable patient-centered measure for 
comorbidity burden and symptom perception in older adult cancer survivors. Further 
testing of diagnosis-specific cancer survivor groups, including breast, prostate, lung, and 
colon cancer survivors, treatment-specific groups, and specific cohorts of older adults 
(such as 60–74 years compared with those 75+ years), is needed to further expand the 
instrumentation data. In addition, differences between cancer survivors receiving 
radiation therapy, chemotherapy, and hormonal therapy may emerge in the symptom 
perception and attribution data.  
The Charlson Self-Report Comorbidity Index can be used to further validate the 
construct of comorbidity burden as measured by the CoB (Katz et al., 1996). One 
recommendation is to use established measures to validate findings, including the 
Expectations of Aging Survey, which incorporates the dimensions of physical and mental 
health and cognitive functioning (Sarkisian, Steers, Hays, & Magione, 2005). In addition, 
an established measure of general function, such as the Medical Outcomes Study Survey: 
12-item Short Form instrument, or the PROMIS measure for physical function, can be 
used to assist in establishing criteria validity of this new measure (Hamoen, DeRooij, 
Witjes, Barentsz, & Rovers, 2015; Jensen et al., 2015). The COSMOS may also be useful 




burden in older adults with multiple chronic illnesses. In addition, this scale may be used 
to measure of the effect of patient-centered and population-specific interventions aimed 
at minimizing both comorbidity and symptom burden. 
This instrument has the potential to yield clinically meaningful data to facilitate 
collaboration between cancer survivors and health care providers regarding coordination 
of care and symptom management. The COSMOS may be a useful tool to integrate into a 
geriatric assessment and assist in screening for both comorbidity and symptom burden 
that has a direct impact on individual quality of life. Clinicians may be able to use the 
CoB and SxP as a basis for initial collaboration with patients in building a dynamic 
information map in the electronic record to chart individual comorbidity and symptom 
pathways for clinical and self-management strategies. Information from the CoB and SxP 
also has the potential to be useful in measuring clinical care outcomes and planning 
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Cancer survivors age 65 years and older are a rapidly growing population that has 
unique needs with regard to the integration of the health care specialties of geriatrics and 
oncology, guidelines for cancer survivor care, chronic illness management, and 
innovative approaches to supporting quality of life. More than 60% of all cancers are 
diagnosed in individuals aged 60 years or older, and 50% or more of this population 
experiences chronic conditions and symptoms (Deckx et al., 2012; Miller et al., 2016). 
Multiple chronic illnesses and their associated symptoms often play an important role in 
the early detection and successful treatment of common cancers experienced by older 
adults (Wildiers et al., 2014). In addition, older adults with cancer and two or more 
comorbidities have an increased frequency of geriatric syndromes that adds a degree of 
complexity to the measurement of comorbidity burden and symptom perception (Vetrano, 
et al., 2016). 
The care needs of the gero-oncology survivorship group often include careful 
management of chronic and late effects of cancer and its treatment, complex 
comorbidities, health care team collaboration across the care spectrum, and care 




2011). This group of cancer survivors may benefit from a standardized approach to care 
transitions from diagnosis and treatment phase (early survivorship) through the ongoing 
survivorship phase, which incorporates important aspects of a patient-centered, gero-
centric cancer survivorship care plan.  
The cancer survivorship population is primarily comprised of older adults, with 
74% being age 60 and older and almost 47% of survivors being age 70 or older (Miller et 
al., 2016). The most prevalent cancer diagnoses in men include prostate, colon and 
rectum, melanoma, and urinary bladder cancers, and the most prevalent cancer diagnoses 
for women include breast, uterine, colon and rectum, thyroid, and melanoma (Miller et 
al., 2016). Each of these cancers has a unique diagnosis and treatment trajectory with 
associated short- and long-term health effects. Acute effects of cancer treatment are often 
related to the specific therapies being received; however, symptoms may persist long 
after treatment is finished and may blend with similar symptoms from coexisting chronic 
conditions (Miller et al., 2016; Parry et al., 2011). 
A review of the relevant literature exploring the relationship between chronic 
illness and the symptom experience in older adults with cancer revealed that on average, 
older adult cancer survivors have two to four chronic conditions in addition to cancer 
(Lacasse, 2016b). Furthermore, the number of chronic conditions varies based on age, the 
specific cancer diagnosed, and treatments received. In addition, older adult cancer 
survivors were found to have a wide range of reported symptoms, which varied based on 
whether survivors were on active treatment or off treatment and whether or not they had 
comorbidities. Only two three studies addressed symptom attribution that included the 




Hengudomsub, & Randolph, 2006; Royer, Phelan, & Heidrich, 2009; Spoelstra et al., 
2015).  
The literature review revealed several challenges in comorbidity and symptom 
measurement (Lacasse, 2016b). The basis of these challenges resides in the wide variety 
of comorbidity and symptom measurement tools. A review of the comorbidity measures 
currently used in cancer care revealed a focus on the medical, physiologic perspective of 
comorbidity as a predictor of risk of mortality and gauge for recommending appropriate 
treatment options. Although this approach to comorbidity measurement has utility in 
treatment of acute and chronic conditions, these measures do not include a quality-of-life 
perspective. Examination of the impact of each comorbidity on life functioning allows for 
a patient-centered approach to measuring general comorbidity burden. A review of the 
symptom measures used in cancer survivorship research revealed a general list of core 
symptoms with a wide variety of other symptoms. Symptom measures used in cancer 
survivorship appear to be tailored to specific study aims or study populations.  
Several studies in the review explored the relationship between comorbidity, 
symptoms, and functioning in older adults with cancer (Lacasse, 2016b). Nine out of 13 
studies reviewed reported that increased symptoms and increased comorbidities had a 
negative impact on physical functioning. This information illuminated the need to 
continue to monitor these critical variables throughout the cancer survivorship trajectory 
in conjunction with normal aging changes, newly emerging comorbidities, and 
symptoms. Close monitoring of critical aspects of aging and cancer survivorship may 
provide important information for health care providers to use when planning and 




Study Aims and Significance 
 
The broad goal of this study was to assess the validity of a self-report tool for 
measuring comorbidity burden and symptom perception that can be easily used in the 
clinical setting as an integral component of the comprehensive geriatric assessment of 
older adults with cancer. The purpose of this methodological study was to conduct initial 
psychometric testing of the Comorbidity and Symptom Measurement in Oncology Scale 
(COSMOS) and examine the feasibility of utilizing it with older adults with cancer and 
comorbidities. The following were the specific aims: 
Aim 1.0: Determine the content validity of the COSMOS by utilizing a survey 
method that includes both quantitative and qualitative data collection from a 
panel of expert clinicians/researchers in oncology, gerontology, and geriatric 
oncology and symptom assessment and management. 
Aim 2.0: Determine the construct validity of the COSMOS by utilizing a mixed-
method approach with known groups of older adults on active cancer 
treatment and off treatment. 
Aim 3.0: Determine the initial test-retest reliability of the COSMOS in a group of 
older adult cancer survivors who have finished active cancer treatment. 
Aim 4.0: Determine the feasibility of a self-administered measurement tool of 
comorbidities and symptoms in a population of older adults with cancer, 
including tool completion time, response patterns, tool comprehension, 
missing items, and patterns in missing data. 
Secondary Aim: Explore the relationship of comorbidities, symptoms, and general 
functioning.  
 
Scale Development and Content Validity 
 
The COSMOS uniquely combines a self-report assessment of a broad range of 
chronic illnesses and conditions commonly found in older adults, such as cardiovascular, 
arthritis, renal, gastrointestinal, hepatic, endocrine, and neurological disease processes 




perception assessment. The COSMOS is based on a blended conceptual model 
incorporating key elements from the Theory of Unpleasant Symptoms (Lenz, Pugh, 
Milligan, Gift, & Suppe, 1997) and the Common Sense Model of symptom perception 
and appraisal (Leventhal, Meyer, & Nerenz, 1980). This blended model describes 
physiological, psychological, and situational factors that have an integrated effect on 
symptom perception and the cognitive and emotional representation of illness. These 
factors may moderate the perception of symptoms that has an impact on the outcomes of 
the overall symptom experience and comorbidity management.  
Comorbidity burden was defined as the presence of disease and its impact on the 
daily life of the patient. Symptom perception was defined as the presence of the symptom 
and the impact of the symptom on daily life. The concept of symptom perception also 
includes elements of symptom distress as it relates to the individual survivor. Symptom 
attribution was also measured as a descriptor of a survivor’s perception of the cause of 
each symptom that was reported. The combined data from the COSMOS have the 
potential to inform health care providers across the cancer survivor care continuum about 
the survivor’s perspective in the evaluation of critical components of their survivorship 
care, such as chronic illness and symptoms.  
Content validity for COSMOS version 1 (v1) was derived from a critical 
evaluation of relevant literature and review by a panel of experts. The scale revisions 
included the addition of three items, deletion of three items, and modification of four 
items. The content validity index for the comorbidity burden subscale was .80 (p = .05), 
and .98 (p = .05) for the symptom perception subscale. Results from the initial evaluation 




The next step in the instrument development process was to field test the 
instrument in a representative population sample (Polit & Beck, 2017). In this case, an 
appropriate field test of COSMOS v2 included quantitative assessment of the measure’s 
performance in a sample of older cancer survivors with multiple chronic illnesses and 
symptoms. The ability of COSMOS v2 to detect differences in known groups of 
survivors either on active treatment of off treatment was also measured. 
 
Description of Instrument 
 
The comorbidity burden subscale (CoB) is comprised of a list of yes/no questions 
to assess the presence of comorbidity and a scale measuring the effect of each 
comorbidity on daily life. The CoB score includes 38 chronic illnesses and conditions and 
is calculated by adding the comorbidity-presence and effect-of-comorbidity scores. Total 
scores range from zero for no comorbidities, to 152, representing the highest comorbidity 
burden if all comorbidities were present and rated at the highest level of burden on daily 
life. Higher scores indicate a higher comorbidity burden.  
The symptom perception subscale (SxP) has two components, including presence 
of physical and psychological symptoms and the effect of each symptom on daily life 
(bother). Presence is determined by a yes/no item that is scored as a “1” if the symptom is 
present. The symptom bother component is a four-point Likert scale ranging from “no 
bother” to “a great deal,” and is designed to measure the impact of symptom distress. The 
symptom burden score includes 32 symptoms and is calculated by adding symptom-
presence and symptom-bother scores. Total scores range from zero for no symptoms, to 
96, with higher scores indicating higher symptom burden. The symptom attribution 




regarding the attribution of each symptom, including aging, cancer, cancer treatment, 
noncancer medications, and other explanations or a combination of attributions. 
 
Evidence of Construct Validity 
 
Pilot testing with a group of 62 older adult cancer survivors resulted in strong 
performance outcomes for COSMOS v2  in measuring both comorbidity burden and 
symptom perception. Both the CoB and SxP were administered to a group of 32 cancer 
survivors on active treatment and 30 cancer survivors who had been off treatment for 1 or 
more years. Data indicate that the CoB was able to detect differences between survivor 
groups with regard to the types of comorbidities reported by active-treatment and off-
treatment participants. Although the CoB results indicated similar scores between groups, 
the off-treatment group reported significantly more thyroid problems (p = .03) and other 
chronic illnesses (p = .005). Similarly, the SxP scores were similar between groups; 
however, participants on active therapy reported significantly more nausea (p = .045), 
taste changes (p = .006), and body image disturbance (p = .011), which is expected in 
cancer survivors on active treatment. Although only three symptoms were identified as 
demonstrating statistical significance between groups, frequency of reported symptoms 
indicated that the symptoms of decreased sexual interest is a higher concern for survivors 
on active treatment than for those off treatment, and worry/anxiety/nervousness is a 
higher concern for off-treatment survivors than for those on active treatment. These 
results are congruent with reported clinical evidence in cancer survivorship and chronic 
illness literature.  
Several items on the CoB (urinary incontinence, anxiety, depression, and trouble 




being worried or anxious, symptoms of feeling sad or blue, trouble remembering) were 
explored for potential measurement overlap. Within the CoB, depression and anxiety 
were found to be strongly associated (r = .652, p = .0001). Similarly, in the SxP, feeling 
sad and feeling anxious or nervous were also highly correlated (r = .997, p = .0001). 
However, both depression and anxiety had a minimal association between the two 
subscales (r = -.054, p = .67, and r = -.026, p = .84, respectively). The different reference 
time frames for measuring these chronic psychological conditions or symptoms 
illuminated a possible difference between subscales versus the within-subscale 
correlations. Additionally, the chronic condition of urinary incontinence and general 
urinary symptoms were found to have a minimal association (r = .115, p =.38), indicating 
that these items may be measuring different phenomena. Interestingly, the CoB item 
“trouble remembering things” and the SxP item “trouble remembering” were strongly 
associated (r = .638, p =.0001), suggesting that the same construct was being measured 
regardless of the time frame for measurement. These results support the specificity of 
each construct, comorbidity burden or symptom perception, to be uniquely measured 
while containing overlapping chronic conditions or symptoms. Further explanation of this 
overlap in variables requires cognitive interviewing to learn about participants’ thought 
processes in evaluating these items as either chronic conditions or symptoms. 
The symptom attribution descriptor scale was collapsed to three clinically relevant 
categories, including aging-related, cancer and treatment-related, and other. The 
symptom attribution scale demonstrated the ability to discriminate between groups, 
indicating a general shift in attribution from cancer and cancer-related for those on active 




symptom attribution descriptions demonstrated the ability to discriminate between active-





Test-retest reliability for a subset of off-treatment participants was acceptable for 
both the CoB, with an intracorrelation coefficient (ICC) of .917, and the SxP, with an 
ICC of .696. The CoB subset results were expected based on the general stability of 
chronic conditions that are controlled. This finding is supported by test-retest data 
reported on common comorbidity measures used in oncology (Charlson, Szatrowski, 
Peterson, & Gold, 1994; Katz, Chang, Sandha, Fossel, & Bates, 1996). The SxP also 
demonstrated stability comparable to currently used symptom measures in oncology 
(Chang, Hwang, Feuerman, Kasimis, & Thaler, 2000; Stapleton, Holden, Epstein, & 
Wilkie, 2015). 
Exploratory analysis of internal consistency of the CoB was measured by 
Cronbach’s alpha, which resulted in a moderate reliability of .557. Interitem correlations 
for the CoB ranged from -.291 to .901. The wide range of item-to-item correlations 
reflects the heterogeneity of the construct of comorbidity burden. Most items did not 
demonstrate a strong overlap, with the exception of a small cluster of cardiac-related 
comorbidities including history of myocardial infarction and heart operation, history of 
heart failure and heart operation, and myocardial infarction and heart failure. 
Interestingly, there were several comorbidity-burden dyad correlations ranging from .348 
to .701, with a significance level of .001 and higher. These dyads included anxiety and 




other comorbidities, remembering and confusion, peptic ulcer disease and kidney 
problems, stroke and heart operation, obesity and asthma, diabetes and hypertension, and 
arrhythmias and kidney problems. These associated comorbidities suggest that there may 
be comorbidity clusters that have an effect on the measurement of overall comorbidity 
burden in cancer survivors. Exploratory analysis for internal consistency for the SxP 
resulted in a Cronbach’s alpha of .731, which indicates acceptable reliability of the 
measure.  
 
Summary of Pilot Results 
 
The COSMOS v2 was piloted on 62 cancer survivors over 65 years old with two 
or more chronic illnesses or conditions and one reported symptom. Participants were 
stratified into two groups, including those on active treatment (n = 32) and those off 
treatment for 1 or more years (n = 30). Each participant completed a paper-and-pencil 
version of COSMOS in an average of 20 minutes (range 7–50 minutes). The typical study 
participant was a 72-year-old cancer survivor who was non-Hispanic, retired, living with 
a partner or spouse, and had some postsecondary education. Participants reported a 
cancer treatment history of receiving multiple modalities. Those participants in the 
active-treatment group were receiving one specific treatment type, including radiation 
therapy, chemotherapy, or long-term hormonal therapy. Data for the on-treatment group 
indicated that 78% had five or fewer survivorship years, while 70% the off-treatment 
group had more than 5 survivorship years. A broad range of cancer diagnoses were 
represented across each group. Breast and prostate cancer were highly represented, 
although not equally, within each group. More prostate cancer survivors were in the 




Functional interference scores and current activity scores were similar across both 
groups, although a wide variance was noted in scores. 
Both active- and off-treatment groups reported multiple chronic conditions. 
Active-treatment participants reported an average of 7.9 comorbidities (range 2–14) and 
an average CoB score of 17.1 (range 2–44). The off-treatment participants reported an 
average of 9.9 comorbidities (range 3–19) and an average CoB score of 21 (range 1–35). 
The most frequently reported chronic illnesses or conditions in both groups included 
arthritis, hypertension, incontinence, trouble remembering, and gastroesophageal reflux. 
Additionally, 50% or more of the off-treatment group also reported osteoporosis and 
problems with vision. Overall, off-treatment participants reported more chronic 
conditions than active-treatment participants (t = -2.48; p = .016); however, the CoB 
scores were not significantly different between groups (t = -1.83; p = .072).  
Both groups reported similar numbers of symptoms, with active-treatment 
participants reporting an average of 10.3 and off-treatment participants reporting 9.8 (t = 
.42; p = .68). Both groups reported similar symptom-burden scores (t = .66; p = .51). The 
most frequently reported symptoms by both groups included lack of energy, pain, feeling 
drowsy, difficulty sleeping, urinary symptoms, feeling sad, dry mouth, numbness and 
tingling, and trouble remembering. Additionally, symptoms of itching and 
worry/anxiety/nervousness were reported by more than 50% of off-treatment participants. 
Symptom-attribution data revealed some very interesting findings, which may 
illuminate the shift in symptom perception between older adults receiving active 
treatment and those who are beyond treatment. Symptom-attribution data were grouped 




treatment-related, and other, which includes noncancer medications; acute and chronic 
symptoms, illnesses, or conditions; psychological symptoms or conditions; behavior-
related causes; or life activities. The off-treatment group most frequently attributed 
symptoms to aging-related causes or other causes. The active-treatment group most 
frequently attributed pain and trouble remembering to aging-related causes and lack of 
energy, feeling drowsy, and urinary symptoms to both aging-related and cancer-related 
causes. Difficulty sleeping was most frequently attributed to other causes by the active-
treatment group. These results reflect an intuitive approach to symptom perception of 
cancer survivors either in active treatment or off treatment, and are similar to findings of 
a study of older adults with breast cancer (Heidrich et al., 2006). 
Relationships between key variables of comorbidity burden, symptom perception, 
and functional interference were explored. Moderate correlation was found between 
comorbidity burden and symptom perception scores (r = .46, p = .0001). In addition, a 
moderate relationship was found between the symptom perception score and functional 
interference score (r = .42, p = .001), and a weak but significant relationship was found 
between the comorbidity burden score and the functional interference score (r = .30, p = 
.05). These results indicate that there may be key relationships between chronic 
conditions, symptoms, and physical functioning. Further exploration into these 
relationships is needed to explicate the impact of comorbidity burden and symptom 
perception on various dimensions of quality of life beyond physical functioning. 
Several participants were interviewed regarding the ease of completing the scale; 
they agreed that the instructions were clear and the scale was easy to complete. In 




integrated their personal experiences with cancer, cancer treatment, chronic illness, and 
symptoms, and unique survivor-centered circumstances such as the social context of their 
experiences.  
 
COSMOS v2 Revisions 
 
Psychometric data indicate that revisions are needed for the CoB to enhance its 
validity as a patient-centered, clinically significant measure. Suggested revisions include 
consolidating or deleting several items (Lacasse, 2016a). Based on the pilot data and the 
current literature on symptom assessment in cancer survivors, the SxP will remain intact; 
however, the question related to symptom bother will be expanded to align with the 
current categories being used to assess symptoms in the Patient-Reported Outcomes 
Measurement Information System tools (Cella et al., 2010). The symptom-attribution list 
revealed three clinically meaningful categories when determining differences between 
cancer survivors on active treatment and those off treatment. The revised categories 
include aging-related, cancer-related, and other causes of symptoms. In addition, the 
question about the attribution of each reported symptom was reframed to encourage 
cancer survivors to choose the attribution, which is most likely causing each reported 
symptom. 
In summary, data from this study indicate that self-report is a feasible method for 
measuring comorbidity burden and symptom perception in older adult cancer survivors. 
Insights into symptom attributions of cancer survivors at different stages of treatment and 
survivorship may inform clinical practice and the development of tailored educational 









A sample size of 62 participants can be considered minimal for instrument 
development. Although a smaller sample size may contribute to an increased 
measurement error, a minimum representative sample of 12 to 30 participants per group 
from the population of interest is recommended for a pilot study for preliminary scale 
development in the medical field (Johanson & Brooks, 2010; Julius, 2005). It is 
suggested that a sufficient sample size of 10 participants for simple instrumentation 
issues such as clarity of instructions, item wording, and instrument administration issues 
is appropriate (Hertzog, 2008). The study sample yielded valuable data about the general 





Due to the small sample size, further testing of the revised tool should be 
conducted with a broad range of older oncology patients, including specific racial groups 
and age stratifications (65–74, 75–85, >85 years). The population studied in this pilot 
does not fully represent the four most common cancers diagnosed in adults, including 
cancers of the lung and bronchus, prostate (men), breast (women), and colorectum 
(Miller et al., 2016). The active-therapy group does not fully represent the typical range 
of cancer-related treatments, such as chemotherapy and radiation therapy, which may 
affect the symptoms reported by this population. In addition, the study sample does not 
equally represent gender in the active- and off-treatment groups. This imbalance of 




symptoms and symptom-attribution reporting patterns. Also, the tool should be tested in 
special populations, including frail elders and elderly adults with metastatic cancer. In 
addition, future testing in subpopulations of older adults with cancer may uncover 
specific issues such as varied response sets, word misinterpretation, and instrument 
fatigue. This study does provide general information about older adults living with 
multiple chronic illnesses including cancer and symptoms and important information for 
revisions of the COSMOS. The responses of participants in this study do provide a 
general perspective on comorbidity burden and the dimensions of symptom perception 
that are congruent with general cancer survivorship experiences (Hewitt, Greenfield, & 
Stovall, 2006; Institute of Medicine, 2012). 
 
Time-Frame Reference for Assessment 
 
The CoB includes two specific time frames for participants to consider regarding 
their history with chronic illness. Many questions in the subscale ask specifically if the 
participant has ever been diagnosed with a specific illness, although a cluster of questions 
is temporal in nature and asks about changes within the previous year. The SxP is focused 
on symptom recall over the previous month. This variation in the time period of recall 
may potentially affect the individual’s accuracy of self-reporting chronic illnesses and 
symptoms. In addition, trouble remembering was reported by 50% or more participants, 
and this may also influence the accuracy of self-report. The temporal context of 
assessment frames critical perceptions of comorbidity burden and symptom perception. 
In the case of symptoms, it may be clinically relevant to capture the current symptom 







The study recruitment period extended over several years, 2010 through 2015, 
which may have had an impact on the results. Twenty-four percent of the cancer survivor 
population screened met the comorbidity eligibility criteria of having two or more 
chronic illnesses or conditions in addition to cancer, which is lower than the reported 
33.2% in the general population of 65 years or older (Ward, Schiller, & Goodman, 2014); 
however, the time frame should have minimal impact on the CoB. The variable most 
likely to show the impact of the time frame for recruitment is the treatment type. Overall, 
cancer therapies for the study participants reflect the broad range of treatments currently 
available for cancer and its associated symptoms. Although results may have been 
influenced by the recruitment time frame, it is unlikely, based on the minimal differences 
found between active-therapy and off-treatment groups. In addition, results revealed that 
the general CoB and SxP scores were similar, but different specific symptoms and 
comorbidities were reported by active-treatment versus off-treatment participants, 
indicating instrument sensitivity. 
 
Patient-Specific Treatment Variability 
 
The scale was administered to a broad sample of older adult cancer survivors, 
which included multiple ages, cancer and treatment histories, and length of survivorship. 
In addition to the stratification of “active treatment versus off treatment,” there were 
many emerging subgroups. Cancer treatment has evolved beyond the basic four treatment 
modalities (surgery, chemotherapy, radiation therapy, and biotherapy) and includes 
unique, patient-specific combinations of short- and long-term therapies. For example, 




treat their initial diagnosis and then be prescribed a long-term treatment regimen (5 years 
or more) of hormonal therapy. Each treatment modality has a specific acute and chronic 
symptom trajectory, which is incorporated into the cancer survivor’s chronic illness 
experiences. Further testing with purposeful sampling in treatment categories, age 
groups, and with various cancer and chronic illness clusters may illuminate scale 
sensitivities to specific populations. In addition, using a longitudinal or cross-sectional 




Frail older adults often need assistance in completing lengthy assessment tools 
based on typical symptoms of frailty. The Balducci criteria for frailty are specific for 
gero-oncology patients and include the following elements: aged 85 years or older, 
dependence for one or more activities of daily living, three or more comorbidities, and 
one or more geriatric syndromes (Pal, Katheria, & Hurria, 2010). This study population 
had 3 participants who were over 85 years; all had cancer and two comorbidities, and two 
thirds reported at least one geriatric syndrome (incontinence). Although the study 
population may not meet all of the parameters for frailty, many participants have 
characteristics that may increase their frailty potential, including those who reported 
cognitive changes such as trouble remembering. This may have a negative impact on the 
reliability of the results in this population. Scales may need to be constructed to include 
alternative methods of delivery, with an emphasis on electronic reporting, which will 
facilitate communication with clinicians and allow for tracking of trends for comorbidity 
burden and symptom burden in frail oncology populations. The experiences with frail 




supports needed to facilitate the completion of the scale. 
 
Multiple Statistical Tests 
 
Multiple statistical tests were used to analyze data collected for each subscale, 
functional interference scale, and demographics. The use of multiple statistical tests to 
detect the difference between groups may lead to a Type I error (Reid, 1983). This error 
may lead to detection of a statistically significant difference between groups when there 
actually is none. A Bonferroni correction may be used; however, this is a very 
conservative approach and would negate any significant findings and increase the 
likelihood of a Type II error (Polit & Beck, 2017). Another suggestion to prevent an 
increasing alpha is to decrease the level of significance to .01. In addition, when multiple 
dependent variables are analyzed in a serial fashion, the actual alpha may increase from 
multiple univariate tests. When multiple tests are conducted using a single data set, there 
is a risk of nonindependence due to the data coming from the same data participants 
(Reid, 1983). The exploratory nature of this study warrants a cautious interpretation of 






The COSMOS shows promise as a valid and reliable patient-centered measure for 
comorbidity burden and symptom perception in older adult cancer survivors. This 
instrument has the potential to yield clinically meaningful data to facilitate collaboration 
between cancer survivors and health care providers regarding survivor care and symptom 




geriatric assessment and assist in screening for and monitoring of comorbidities and 
symptoms in cancer survivors. Clinicians can use the CoB and SxP as a baseline for 
collaboration with patients in building a dynamic information map in the electronic 
record to chart individual CoB and SxP pathways for clinical and self-management 
strategies. Information from the CoB and SxP also has the potential to be useful in adding 
key data to a comprehensive geriatric assessment, providing ongoing clinical outcome 
measures and planning survivorship care transitions. 
Cancer survivors are being discharged from their oncologist’s care with cancer 
survivorship care plans, which extend their ongoing care into the community as they 
transition to their primary care physicians. A valid, reliable, and consistent measure for 
comorbidity burden and symptom perception may assist in the communication of 
symptom assessment and treatment outcomes across patient care transitions. In addition, 
a standardized comorbidity and symptom measure provides valuable information for 
ongoing geriatric assessment and symptom screening of older cancer survivors and 
informs overall quality of life (Karlamangla et al., 2007).  
In older adult cancer survivors, consistent serial symptom assessment using a 
database for trending may include sentinel symptoms that either herald emerging health 
changes or trigger a symptom cluster, which may have a profound effect on quality of 
life. Assessment of symptom attribution may also have an effect on assessment and 
treatment of general and specific symptoms during acute periods of cancer therapy. 
Employing the use of current technologies such as tablets or smart phones may increase 
patient reporting and assist with decisional support for comprehensive symptom 




Because 53% of older adults use the Internet or email, one method of transitioning to 
digital reporting with older adults is to phase in the use of self-report technology, 
beginning with individuals who are technologically adept (Zickuhr & Madden, 2012).  
Figure 7.1 depicts the proposed integration of COSMOS into a comprehensive 
geriatric assessment along the cancer survivorship trajectory. Following the initial 
diagnostic workup for individuals aged 65 and older, a standardized, comprehensive, 
geriatric screening assessment should be done to provide a pretreatment baseline for each 
cancer survivor (Horgan et al., 2012). The data collected can be reviewed by the 
interprofessional cancer care team and presented to the survivor to aid in decision making 
about treatment options. Furthermore, comorbidity burden, symptom perception, and 
symptom attribution should be tracked throughout the cancer survivorship experience to 
assist providers in developing individualized symptom management plans, guide 
transitions from cancer care to primary care, and coordinate ongoing care based on 
comorbidity burden, symptom perception, and symptom attribution. This information can 
also be used by nurses involved in coaching survivors through the various phases of 
survivorship, including early survivorship and extended survivorship (Economou, Hurria, 




Further testing of diagnosis-specific cancer survivor groups, including breast, 
prostate, lung, and colon cancer survivors, treatment-specific groups, and specific age 
groups, is needed to further expand the instrument’s psychometric data. One 
recommendation is to use established measures to validate findings, including the 













































Figure 7.1 Proposed integration of comprehensive geriatric assessment, COSMOS 
subscales, and phases of cancer survivorship. COSMOS = Comorbidity and Symptom 
Measure Oncology Scale; MMSE = Mini Mental Status Exam; PROMIS = Patient 
Reported Outcome Measurement Information System; and Mini-Cog = an assessment 
instrument for dementia. 
Patient/family meeting with cancer care team to discuss data and make treatment 
decisions based on diagnostic data, geriatric assessment data, and patient preferences 
Further Diagnostic Data and Treatment Baseline 
Comprehensive Geriatric Assessment Screening  
for Patients Age 65 Years and Older 
 
Critical Domains of Geriatric Assessment 





COSMOS CoB  







COSMOS SxP  
Screening for geriatric syndromes 
not included in comorbidity 
burden measure 
Cognition (MMSE or 
Mini-Cog measure) 
Tilburg Frailty Indicator Screening with Expectations of 
Aging measure 
 
Cancer Survivorship—Posttreatment Phase 
Posttreatment Comprehensive Integrative Assessment 
 
Posttreatment Geriatric Assessment (posttreatment baseline and ongoing based on specific 
follow-up guidelines for primary cancer) 
>>Cancer survivorship care plan development  
>>Communication of cancer survivorship plan with primary care provider 
>>Transition management to posttreatment cancer survivorship phase 
>>Ongoing care coordination for high-risk older adult cancer survivors identified by geriatric 
assessment  
During the Active-Treatment Phase 
Active-Treatment Geriatric Assessment  
>>Symptom perception and attribution subscales  
>>Develop a tailored, flexible symptom-management plan  
 
 
Initial Cancer Diagnostic Workup 






and mental health, and cognitive functioning as one ages (Sarkisian, Steers, Hays, & 
Mangione, 2005). In addition, exploration of comorbidity burden clusters in cancer 
survivors has the potential to provide individualized treatment of chronic illnesses during 
and after primary cancer treatment and ongoing survivorship care. The COSMOS may 
also be useful in clinical research that focuses on the impact of comorbidity burden and 
symptoms in older adults with multiple chronic illnesses. In addition, this scale may be 
used to measure the effect of patient-centered and population-specific interventions 
aimed at minimizing both comorbidity and symptom burden. 
Further exploration of  the impact of symptom attribution on symptom-
management outcomes is warranted. Symptom attribution may be critical in determining 
patient-specific health care behaviors and decision making. In addition, the exploration of 
symptom self-treatment within the context of comorbidities would be valuable to explore 
to determine self-care activities that are associated with symptom management in older 
adults with chronic illness, including cancer. The concepts of burden of chronic illness 
coupled with perceived symptoms and their attributions are challenging to measure; 
however, a valid and reliable measure of these interrelated concepts in cancer 
survivorship contributes to the overall understanding of the impact of comorbidities and 
symptoms on cancer survivors and provides valuable information for building systems of 




Geriatric assessment principles have been folded into advanced-practice education 
for family and adult nurse practitioners, clinical nurse specialists, and clinical nurse 




impact of cancer history or active cancer treatment should be included as a major 
educational topic in entry-level and advanced-practice nursing education; there is also a 
need to integrate general principles of chronic illness and symptom assessment into 
interprofessional education programs. The critical use of population-specific assessment 
has the potential to lead to data-driven standards of care, which are patient-centered and 
enhance quality of life while living with chronic conditions and controlled symptoms. 
Integrative symptom assessment/management is an emerging field, which can be 
incorporated into interprofessional education and practice. Traditional symptom 
assessment can be expanded to include body, mind, and spirit dimensions for each 
symptom assessed, in combination with primary attribution by the patient. Providers can 
use this patient-specific information coupled with current evidence for symptom 
management to deliver evidence-informed care based on science, population-based 
wisdom, and patient preferences. 
Mentored practice opportunities for students and practicing nurses to learn 
comprehensive geriatric screening assessments and application of the results to patient-
centered care is essential in translating research-based measures to clinical practice. 
Population-based comprehensive assessment of comorbidity and symptoms and treatment 
in older adult cancer survivors should also be a focus area in entry-level and advanced-
practice education and ongoing staff development (American Association of Colleges of 
Nursing, 2006, 2008, 2011). Implementation of standardized measures of critical patient 
assessment parameters that are integrated into the electronic medical record and patient 
portal has the potential to enhance patient–provider relationships and increase precision 




The discipline of nursing is strategically poised to make a major impact on 
symptom management and restoration of health and well-being. Distinguishing between 
chronic illness symptoms and cancer-related symptoms in older cancer survivors is 
critical to providing care focused on safe, quality outcomes, and principles of health 
promotion and risk reduction within the context of chronic illness management. 
 
Health Care Policy 
 
Information generated from COSMOS data may help inform clinicians who wish 
to shape policy on quality of life for cancer survivors and cancer survivorship care. 
Patient-centered information may also provide a clearer picture of the ongoing burden of 
illness on cancer survivors that in turn has the potential to impact chronic care 
reimbursement and care-delivery models. Current health care models are beginning to 
evolve to include innovative care coordination and transition management plans for older 
individuals requiring complex care. The early successes of these models demonstrate a 
positive impact on individual and population health, overall health care costs, and quality 
of life. The use of standardized patient-reported outcome measures coupled with 
insurance incentives may provide milestones for older adult cancer survivors to adhere to 
prescribed follow-up care and interventions to promote health restoration after cancer 
therapy.  
The Oncology Care Model is an emerging care-delivery model focused on cost 
containment while maintaining high quality of oncology care (Thomas & Ward, 2016). 
This model is characterized as bundling care for medical oncology patients within a 
blended reimbursement model that integrates fee-for-service and shared-savings 




comprehensive patient care planning, broad access to appropriate clinicians who have 
access to electronic medical records, adherence of treatments to national standards, and 
data-driven quality improvement. One area in which this general model may fall short is 
in the focus on the needs of older adults who are “complex” cancer survivors with 
multiple comorbidities and symptoms. Chronic illness and symptom management based 
on self-reported data should be streamlined into a shared electronic health record. It has 
the potential to allow health care providers to identify emerging issues in chronic illness 
and symptoms and intervene before a costly solution such as hospitalization is needed. In 
addition, older adults would benefit from having a documented comprehensive geriatric 
assessment on record to facilitate the delivery of care needed at each patient encounter 
while the patient is receiving active therapy. 
Policies that support older adults with chronic illness as they age in place may 
benefit from a standardized approach to measuring the impact of comorbidity and 
symptoms. Both chronic illness and symptoms in cancer survivors may have a severe 
effect on their ability to maintain an optimal level of functioning. As the population 
continues to age, policies are needed to support optimal care, health, and well-being of 
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COSMOS VERSION 1 
 
  






This is a 2-part survey which asks questions about your personal health and symptoms that you might have.  
Please read the survey carefully and answer all of the questions to the best of your ability. If you feel  







_____Proposed Instrument: COSMOS Comorbidity Burden Subscale______ 
 
 
Questions about your overall health  
Please check yes or 
no for each 
question. 
If you checked yes, how much does 
this health problem affect your daily 
life? 
Check one box below. 
Question Yes No  Not at 
all 
A little Some A great 
deal 
1 .Have you ever had a heart attack or a heart 
operation? 
       
2. Have you ever had problems with your 
heartbeat? 
       
3. Have you ever had a blood clot in your leg?        
4. Have you ever been diagnosed or treated for 
high blood pressure?     
       
5. Have you ever had a stroke?         
6. Have you ever had trouble moving one side of 
your body or both your legs for more than 24 
hours?  
       
7. Have you ever been diagnosed or treated for a 
stomach ulcer? 
       
8. Has a doctor ever told you that you have liver 
problems? 
       
9. Have you ever had a bowel problem such as 
chronic diarrhea or a blockage (other than 
constipation)?     
       
10. Have you ever been diagnosed or treated for 
high blood sugar (diabetes)?   






Questions about your overall health  
Please check yes or 
no for each question. 
If you checked yes, how much does 
this health problem affect your daily 
life? 
Check one box below. 
Question Yes No  Not at 
all 
A little Some A great 
deal 
11. Have you ever been diagnosed or treated for a 
thyroid problem? 
       
12. Have you ever been diagnosed with kidney 
trouble? 
       
13. Have you ever needed kidney dialysis or 
received a kidney transplant?   
       
14. Have you ever been diagnosed or treated for 
brittle bones or osteoporosis?    
       
15. Have you ever been diagnosed or treated for 
arthritis? 
       
16. Have you ever been diagnosed or treated for 
lupus? 
       
17. Have you ever been diagnosed or treated for 
behavior problems? 
       
18. Have you ever been overweight by 50 pounds 
or more? 
       
19. Have you ever been diagnosed or treated for 
depression? 
       
20. Have you ever been diagnosed or treated for 
anxiety? 
       
21. Have you ever been diagnosed with another 
type of cancer? 








Questions about your overall health during the past year  
 
Please check yes or 
no for each question. 
If you checked yes, how much does 
this health problem affect your daily 
life? 
Check one box below. 
Question Yes No  Not at 
all 
A little Some A great 
deal 
22. Have you been diagnosed with heart failure?        
23. Have you had problems with poor blood flow in 
your arms, legs, or feet? 
       
24. Have you had trouble breathing while you are 
sitting quietly? 
       
25. Have you had trouble breathing while you are 
moving around? 
       
26. Have you been treated for breathing problems?        
27. Have you had severe indigestion after meals or 
at bedtime? 
       
28. Have you had a problem with your gallbladder 
or pancreas? 
       
29. Have you had long periods of forgetfulness or 
felt disoriented? 
       
30. Have you walked with a shuffle or had a 
trembling head or hands? 
       
31. Have you had broken bones or a broken hip?        
32. Have you had problems with your eyes which 
affect your vision?  









Questions about your overall health during the past year 
 
Please check yes or 
no for each question. 
If you checked yes, how much does 
this health problem affect your daily 
life? 
Check one box below. 
Question Yes No  Not at 
all 
A little Some A great 
deal 
33. Have you had problems with your hearing?        
34. Have you had problems with your balance?        
35. Have you had many (more than 5) infections?        
36. Have you had a bleeding problem?        


















____ Proposed Instrument: COSMOS Symptom Perception Subscale ___ 
 
Questions about symptoms 
Below is a list of symptoms, if you had any of the following symptoms during the past month, please check yes. 
If you checked yes, how 
much did the symptom 
distress or bother you?  
Check one box below. 











































































            
3. Pain 
 
            
4. Lack of energy 
 
            
5. Cough 
 
            
6.Changes in skin 
 
            






Questions about symptoms 
Below is a list of symptoms, if you had any of the following symptoms during the past month, please check yes. 
 
If you checked yes, how 
much did the symptom 
distress or bother you?  
Check one box below. 








































































            
9. Feeling drowsy 
 
            
10. Numbness/ 
tingling in hands 
or feet 
 




            
12. Feeling 
bloated 







Questions about symptoms 
Below is a list of symptoms, if you had any of the following symptoms during the past month, please check yes. 
 
If you checked yes, how 
much did the symptom 
distress or bother you?  
Check one box below. 




































































   
13. Problems with 
urination 
 
            
14. Vomiting 
 
            
15. Shortness of 
breath 
 
            
16. Sweats 
 
            
17. Hot Flashes 
 
            
18. Hot Flushes 
 







Questions about symptoms 
Below is a list of symptoms, if you had any of the following symptoms during the past month, please check yes. 
 
If you checked yes, how 
much did the symptom 
distress or bother you?  
Check one box below. 




































































19. Problems with 
sexual interest or 
activity 
 




            
21. Lack of 
appetite 
 















Questions about symptoms 
Below is a list of symptoms, if you had any of the following symptoms during the past month, please check yes. 
 
If you checked yes, how 
much did the symptom 
distress or bother you?  
Check one box below. 





































































24. Mouth sores 
 
            
25. Change in the 
way food tastes 
 
            
26. Weight loss 
 
            
27. Hair loss 
 
            
28. Constipation 
 






Questions about symptoms 
Below is a list of symptoms, if you had any of the following symptoms during the past month, please check yes. 
 
If you checked yes, how 
much did the symptom 
distress or bother you?  
Check one box below. 






































































            
30. “I don’t look 
like myself” 
 
            
31. Worrying 
 



















Questions about symptoms 
Below is a list of symptoms, if you had any of the following symptoms during the past month, please check yes. 
 
If you checked yes, how 
much did the symptom 
distress or bother you?  
Check one box below. 






































































































I am a doctoral student the PhD Distance Education Program with a Focus in 
Cancer Research at The University of Utah College of Nursing. I am developing an 
instrument to measure comorbidity burden and symptom perception in older adults with 
cancer. Symptom perception in older adults may be influenced by many issues such as 
expectations of the normal aging process, comorbidities, treatments for chronic 
illnesses, and functional status. Valid and reliable measures of unique dimensions of 
symptom perception in older adults will assist health care providers in assessing and 
planning comprehensive symptom management and help clinical researchers to 
evaluate clinically significant interventions for older adults with cancer. The next step in 
the instrument development process is to establish content validity through the use of an 
expert panel. 
 
 You have been identified as a content expert in oncology, gerontology, or both 
and are invited to participate on an expert panel of clinicians and researchers to assist in 
validating the content of this new instrument. Your participation in the instrument review 
process will be invaluable as a preliminary step in developing a valid and reliable 
instrument for comprehensive symptom assessment in the context of current 
comorbidities in the older adult cancer population. Participation in this panel includes the 
review of a 37-item comorbidity burden subscale and a 34-item symptom perception 
subscale. You will be asked to judge the individual item relevancy to each subscale and 
the overall item representation of the specific domain of the subscale. In addition, you 
will be asked to suggest improvements in the format, directions for completing the scale, 
additions and deletions of items, clarity of items, and overall comprehensiveness of the 
measure. It is anticipated that this instrument review will take approximately 30 – 45 
minutes to complete within a time frame of two weeks after you receive the review 
materials. 
 
 If you are interested in participating on this expert panel please contact me at 
clacasse@nursing.arizona.edu. I look forward to hearing from you by July 15, 2006. You 
will receive a follow-up email or call if I do not hear from you. Thank you for your 





Cheryl Lacasse, MS, RN, OCN® 
Doctoral Candidate 
University of Utah College of Nursing 
and  
Associate Clinical Professor 


















 Thank you for agreeing to participate on an expert panel of clinicians and 
researchers to assist in validating the content of a newly developed instrument to 
measure comorbidity burden and symptom perception in older adults with 
cancer. The Comorbidity and Symptom Measurement in Oncology Scale 
(COSMOS) includes 2 subscales: a 37-item comorbidity burden subscale and a 
34-item symptom perception subscale. Please review and comment on each 
individual item’s relevancy to each subscale and the overall item 
representativeness to the specific domain of each subscale using the Expert 
Panel Review Form. In addition, please suggest improvements in the format, 
directions for scale completion, addition and deletions of items, clarity of items, 
and overall comprehensiveness of the measure. It is anticipated that this 
instrument review will take approximately 30 – 45 minutes to complete within a 
time frame of three weeks after you receive the review materials. Each subscale 
and the Expert Panel Review Form is attached to this email and can be 
completed and returned electronically.  
 
 Thank you for being a participant on this expert panel. I look forward to 
receiving your review and comments on the COSMOS by August 22, 2006. You 
will receive a follow-up email reminder close to this date. If you have any 






Cheryl Lacasse, MS, RN, OCN® 
Doctoral Student 
University of Utah College of Nursing 
and  
Associate Clinical Professor 


















Comorbidity burden is defined as a combination of the presence of multiple chronic illnesses 
and the interference of each illness with general daily life. 
 
 
























Questions about your overall health  
 
Please check yes or no for each question. 
If you checked yes, how much does this health problem effect your daily life? 
Check one box below. 
 
Question Yes No  Not at all A little Some A great deal 
1 .Have you ever had a heart 
attack or a heart operation? 
 
       
2. Have you ever had problems 
with your heartbeat? 
 
       
3. Have you ever had a blood clot 
in your leg? 
 
       
4. Have you ever been diagnosed 
or treated for high blood pressure? 
    








**Please comment on the following:  
 









































Please rate the relevancy of each item on the Comorbidity Burden subscale by checking a rating (1–4) as described 
below. 
 
Item (Comorbidity Burden) Item is not 
relevant 
(1) 
Unable to assess 
relevance without 
item revision OR 
item is in need of 
such revision that it 
is no longer relevant 
(2) 
Item is relevant 
but needs minor 
alteration 
(3) 






item or suggestions 
for item revision. 
1. Have you ever had a heart 
attack or a heart operation? 




2. Have you ever had problems 
with your heartbeat?  




3. Have you ever had a blood 
clot in your leg? 




4. Have you ever been 
diagnosed or treated for  
high blood pressure?  
     
5. Have you ever had a stroke? 
 
     
 
 
6. Have you ever had trouble 
moving one side of your body 
or both your legs for more than 
24 hours?  




7. Have you ever been 
diagnosed or treated for a 
stomach ulcer?  









Please rate the relevancy of each item on the Comorbidity Burden subscale by checking a rating (1 – 4) as described 
below. 
 
Item (Comorbidity Burden) Item is not 
relevant 
Unable to assess 
relevance without item 
revision OR 
item is in need of such 












Comments about item or 
suggestions for item 
revision 
8. Has a doctor you ever told 
you that you have liver 
problems? 
     
 
 
9. Have you ever had a bowel 
problem such as chronic 
diarrhea or a blockage (other 
than constipation)? 




10. Have you ever been 
diagnosed or treated for high 
blood sugar (diabetes)?  
     
 
 
11. Have you ever been 
diagnosed or treated for a 
thyroid problem? 
     
12. Have you ever been 
diagnosed with kidney trouble? 
     
 
13. Have you ever needed 
kidney dialysis or received a 
kidney transplant?  
     
 
 
14. Have you ever been 
diagnosed or treated for brittle  
bones or osteoporosis?  










Please rate the relevancy of each item on the Comorbidity Burden subscale by checking a rating (1 – 4) as described 
below. 
 
Item (Comorbidity Burden) Item is not 
relevant 
(1) 
Unable to assess 
relevance without item 
revision OR 
item is in need of such 















Comments about item or 
suggestions for item 
revision. 
15.  Have you ever been 
diagnosed or treated for 
arthritis? 
     
16. Have you ever been 
diagnosed or treated for lupus? 
     
 
17. Have you ever been 
diagnosed or treated for 
behavior problems? 
     
18. Have you ever been 
overweight by 50 pounds or 
more? 
     
19. Have you ever been 
diagnosed or treated for 
depression? 
     
20. Have you ever been 
diagnosed or treated for 
anxiety? 
     
21. Have you ever been 
diagnosed with more than one 
type of cancer?  












Please rate the relevancy of each item on the Comorbidity Burden subscale by checking a rating (1 – 4) as described 
below. 
*Also, please comment on the appropriateness of the time frame “over the past year” for the items in the above section. 
 
Item (Comorbidity Burden) 
 
Over the past year 
 
Item is not 
relevant 
(1) 
Unable to assess 
relevance without 
item revision OR 
item is in need of 
such revision that it 
is no longer relevant 
(2) 
Item is relevant 
but needs minor 
alteration 
(3) 





item or suggestions 
for item revision 
22. Have you had 
problems with heart 
failure? 
     
 
23. Have you had problem 
with poor blood flow in your 
arms or legs? 
     
 
 
24. Have you had trouble 
breathing while you are 
sitting quietly? 
     
 
25. Have you had trouble 
breathing while you are 
moving around? 
     
26. Have you been treated 
for breathing problems? 
     
 
27. Have you had severe 
indigestion after meals or 
at bedtime? 
     
 
 
28. Have you had a 
problem with your 
gallbladder or pancreas? 









29. Have you had long 
periods of forgetfulness or 
felt disoriented?  
     
Item (Comorbidity Burden) 
 
Over the past year 
 
 
Item is not 
relevant 
(1) 
Unable to assess 
relevance without 
item revision OR 
item is in need of 
such revision that it 
is no longer relevant 
(2) 
Item is relevant 
but needs minor 
alteration 
(3) 





item or suggestions 
for item revision. 
30. Have you walked with 
a shuffle or had a trembling 
head or hands? 
 
     
31. Have you had broken 
bones or a broken hip? 
 
     
32. Have you had 
problems with your eyes 
which affect your vision?
  
     
 
 
33. Have you had 
problems with your 
hearing? 
     
 
 
34. Have you had 
problems with your 
balance? 
     
35. Have you had many 
(more than 5) infections? 
 
     
36. Have you had a 
bleeding problem? 
 
     
37. Have you had a low 
red blood cell count?  








Are there any critical omissions from the Comorbidity Burden subscale?  Yes   No 









































SYMPTOM PERCEPTION SUBSCALE 
 
 
Symptom Perception is defined as a combination of the level of bother of a symptom  
and the client’s perception of its cause.  
 
 
Please review each item in the scale for its relevancy to the content of the scale based on the above 
 definition of the construct.  

































Questions about symptoms 
Below is a list of symptoms, if you had any of the following symptoms during the past month, please check yes. 
 
If you checked yes, how much did the symptom distress or bother you?  
If you checked yes, then check any of the following statements that apply.  
Check one box below.   



































































            
3. Pain 
 
















*Please address the following:  
 




































Please rate the relevancy of each item on the Symptom Perception subscale by checking a rating (1 – 4) as 
described below. 
  
Item (Symptom) Item is not 
relevant 
(1) 
Unable to assess 
relevance without item 
revision OR 
item is in need of such 
revision that it is no 
longer relevant 
(2) 
Item is relevant 
but needs minor 
alteration 
(3) 




Comments about item 









     
 
 
3. Pain      
 
 
4. Lack of energy 
 
 




     
6. Changes in 
skin 
     
 
 
7. Dry mouth      
 
 











Please rate the relevancy of each item on the Symptom Perception subscale by checking a rating (1 – 4) as 
described below. 
 
Item (Symptom) Item is not 
relevant 
(1) 
Unable to assess 
relevance without item 
revision OR 
item is in need of such 
revision that it is no 
longer relevant 
(2) 
Item is relevant 
but needs minor 
alteration 
(3) 




Comments about item 
or suggestions for item 
revision. 




tingling in hands or 
feet 
 





     
 
 
12. Feeling bloated 
  
 
     
13. Problems with 
urination 






     
 
15. Shortness of 
breath 
 













Please rate the relevancy of each item on the Symptom Perception subscale by checking a rating (1 – 4) as 
described below. 
  
Item (Symptom) Item is not 
relevant 
(1) 
Unable to assess 
relevance without item 
revision OR 
item is in need of such 
revision that it is no 
longer relevant 
(2) 
Item is relevant 
but needs minor 
alteration 
(3) 




Comments about item 
or suggestions for item 
revision 
16. Sweats      
 
 
17. Hot flashes      
 
 
18. Hot flushes 
 
 
     
19. Problems with 
sexual interest or 
activity 
 
     
20. Itching      
 
 
21. Lack of appetite      
 
 















Please rate the relevancy of each item on the Symptom Perception subscale by checking a rating (1 – 4) as 
described below. 
  
Item (Symptom) Item is not 
relevant 
(1) 
Unable to assess 
relevance without item 
revision OR 
item is in need of such 
revision that it is no 
longer relevant 
(2) 
Item is relevant 
but needs minor 
alteration 
(3) 




Comments about item 
or suggestions for item 
revision. 
24. Mouth sores      
 
 
25. Change in the 
way food tastes 
     
 
 
26. Weight loss      
 
 
27. Hair loss 
 
  
     
28. Constipation      
 
 
29. Diarrhea      
 
 
30. “I don’t look 
like myself” 
 




















Item is not 
relevant 
(1) 
Unable to assess 
relevance without item 
revision OR 
item is in need of such 
revision that it is no 
longer relevant 
(2) 








Comments about item or 










     
34. Feeling 
nervous 


























Questions about symptoms 
Below is a list of symptoms, if you had any of the following symptoms during the past month, please check yes. 
 
If you checked yes, how much did the symptom distress 
or bother you? 
Check one box below. 
If you checked yes, then check any of the following 








































I think that 
this symptom 











































**Please address the following:  
 







Are there any critical omissions from the Symptom Perception subscale? _____Yes  _____No 






















Thank you for your participation in this project. Your contributions will be very valuable to the further 





















This is a two-part survey which asks questions about your 
health, illnesses, and symptoms. Please read the survey 
carefully and answer all of the questions to the best of your 
ability. If you feel uncomfortable answering a question, skip that 





1. Have you ever had a heart attack? 
 
 _____Yes ______No 
 
 
If you answered yes, 
Please answer the question on the 
right.  
How much does this affect your current daily life? 
(Check one.) 
 
□ Not at all 
□ A little 
□ Some 
□ A great deal 
2. Have you ever needed a heart 
operation (to repair heart vessels or 
heart valves)? 
 
 _____Yes ______No 
 
If you answered yes, 
Please answer the question on the 
right.  
How much does this problem affect your current daily 
life? (Check one.) 
 
□ Not at all 
□ A little 
□ Some 
□ A great deal 
3. Have you ever had an irregular 
heartbeat that needed medications or 
a pacemaker? 
 
 _____Yes ______No 
 
If you answered yes, 
Please answer the question on the 
right.  
How much does this affect your current daily life? 
(Check one.) 
 
□ Not at all 
□ A little 
□ Some 
□ A great deal 
4. Over the past year, have you been 
told by a health care provider that 




If you answered yes, 
Please answer the question on the 
right.  
How much does this affect your current daily life? 
(Check one.) 
 
□ Not at all 
□ A little 
□ Some 
□ A great deal 
5. Over the past year, have you been 
told by a health care provider that 




If you answered yes, 
Please answer the question on the 
right.  
 
How much does this health problem affect your current 
daily life? (Check one.) 
 
□ Not at all 
□ A little 
□ Some 




6. Have you ever had a problem with 





If you answered yes, 
Please answer the question on the 
right.  
How much does this affect your current daily life? 
(Check one.) 
 
□ Not at all 
□ A little 
□ Some 
□ A great deal 
 
 
7. Over the past year, have you been 
told by a health care provider that 
you have poor circulation in your 




If you answered yes, 
Please answer the question on the 
right.  
How much does this health problem affect your current 
daily life? (Check one.) 
 
□ Not at all 
□ A little 
□ Some 
□ A great deal 





If you answered yes, 
Please answer the question on the 
right.  
How much does this health problem affect your current 
daily life? (Check one.) 
 
□ Not at all 
□ A little 
□ Some 
□ A great deal 
9. Have you ever been told by a 





If you answered yes, 
Please answer the question on the 
right.  
How much does this health problem affect your current 
daily life? (Check one.) 
 
□ Not at all 
□ A little 
□ Some 
□ A great deal 
10. Have you ever been told by a 
health care provider that you have 




If you answered yes, 
Please answer the question on the 
right.  
How much does this health problem affect your current 
daily life? (Check one.) 
 
□ Not at all 
□ A little 
□ Some 
□ A great deal 
11. Have you ever been told by a 





If you answered yes, 
Please answer the question on the 
right.  
How much does this health problem affect your current 
daily life? (Check one.) 
 
□ Not at all 
□ A little 
□ Some 




12. Over the past year, have you had 
indigestion or heartburn after meals 




If you answered yes, 
Please answer the question on the 
right.  
How much does this health problem affect your current 
daily life? (Check one.) 
 
□ Not at all 
□ A little 
□ Some 
□ A great deal 
 
13. Over the past year, have you 
been told by a health care provider 





If you answered yes, 
Please answer the question on the 
right.  
How much does this health problem affect your current 
daily life? (Check one.) 
 
□ Not at all 
□ A little 
□ Some 
□ A great deal 
14. Over the past year, have you 
been told by a health care provider 
that you have a problem with your 




If you answered yes, 
Please answer the question on the 
right.  
How much does this health problem affect your current 
daily life? (Check one.) 
 
□ Not at all 
□ A little 
□ Some 
□ A great deal 
15. Have you ever been told by a 
health care provider that you have 




If you answered yes, 
Please answer the question on the 
right.  
How much does this health problem affect your current 
daily life? (Check one.) 
 
□ Not at all 
□ A little 
□ Some 
□ A great deal 
16. Have you ever been told by a 





If you answered yes, 
Please answer the question on the 
right.  
How much does this health problem affect your current 
daily life? (Check one.) 
 
□ Not at all 
□ A little 
□ Some 
□ A great deal 
17. Have you ever had a bowel 
problem (other than constipation) 
such as chronic diarrhea or a 
blockage? 
           
_Yes ______No 
 
If you answered yes, 
How much does this health problem affect your current 
daily life? (Check one.) 
□ Not at all 
□ A little 
□ Some 




Please answer the question on the 
right.  
18. Have you ever been told by a 





If you answered yes, 
Please answer the question on the 
right.  
How much does this health problem affect your current 
daily life? (Check one.) 
□ Not at all 
□ A little 
□ Some 
□ A great deal 
 
19. Over the past year, have you had 
a problem with urine leaking out 





If you answered yes, 
Please answer the question on the 
right.  
 
How much does this health problem affect your current 
daily life? (Check one.) 
 
□ Not at all 
□ A little 
□ Some 
□ A great deal 
20. Have you ever been told by a 





If you answered yes, 
Please answer the question on the 
right.  
 
How much does this health problem affect your current 
daily life? (Check one.) 
 
□ Not at all 
□ A little 
□ Some 
□ A great deal 
21. Have you ever been told by a 
health care provider that you have 
two or more different types of cancer 
(not cancer that has spread to 




If you answered yes, 
Please answer the question on the 
right.  
 
How much does this health problem affect your current 
daily life? (Check one.) 
 
□ Not at all 
□ A little 
□ Some 
□ A great deal 
22. Have you ever been told by a 





If you answered yes, 





How much does this health problem affect your current 
daily life? (Check one.) 
 
□ Not at all 
□ A little 
□ Some 




23. Have you ever been told by a 
health care provider that you have 





If you answered yes, 




How much does this health problem affect your current 
daily life? (Check one.) 
 
□ Not at all 
□ A little 
□ Some 
□ A great deal 





If you answered yes, 
Please answer the question on the 
right.  
How much does this health problem affect your current 
daily life? (Check one.) 
 
□ Not at all 
□ A little 
□ Some 
□ A great deal 
 
25. Over the past year, have you had 




If you answered yes, 




How much does this health problem affect your current 
daily life? (Check one.) 
 
□ Not at all 
□ A little 
□ Some 
□ A great deal 
26. Over the past year, have you had 
problems with your balance that has 




If you answered yes, 





How much does this health problem affect your current 
daily life? (Check one.) 
 
□ Not at all 
□ A little 
□ Some 
□ A great deal 
27. Over the past year, have you 
walked with a shuffle or had 
trembling hands or other body parts 




If you answered yes, 




How much does this health problem affect your current 
daily life? (Check one.) 
 
□ Not at all 
□ A little 
□ Some 




28. Over the past year, have you had 




If you answered yes, 
Please answer the question on the 
right.  
How much does this health problem affect your current 
daily life? (Check one.) 
 
□ Not at all 
□ A little 
□ Some 
□ A great deal 
29. Over the past year, have you had 




If you answered yes, 
Please answer the question on the 
right.  
 
How much does this health problem affect your current 
daily life? (Check one.) 
 
□ Not at all 
□ A little 
□ Some 
□ A great deal 
30. Have you ever been diagnosed 




If you answered yes, 
Please answer the question on the 
right.  
How much does this health problem affect your current 
daily life? (Check one.) 
 
□ Not at all 
□ A little 
□ Some 
□ A great deal 
 
31. Have you ever been diagnosed 





If you answered yes, 
Please answer the question on the 
right.  
How much does this health problem affect your current 
daily life? (Check one.) 
 
□ Not at all 
□ A little 
□ Some 
□ A great deal 
32. Have you ever been overweight 




If you answered yes, 
Please answer the question on the 
right.  
How much does this health problem affect your current 
daily life? (Check one.) 
 
□ Not at all 
□ A little 
□ Some 
□ A great deal 
33. Over the past year, have you had 
any problems with your eyes that 




If you answered yes, 
Please answer the question on the 
right.  
How much does this health problem affect your current 
daily life? (Check one.) 
 
□ Not at all 
□ A little 
□ Some 
























34. Over the past year, have you had 




If you answered yes, 
Please answer the question on the 
right.  
How much does this health problem affect your current 
daily life? (Check one.) 
 
□ Not at all 
□ A little 
□ Some 
□ A great deal 
35. Over the past year, have you had 
many (more than 5) infections such 
as urinary tract or kidney infections 




If you answered yes, 
Please answer the question on the 
right.  
 
How much does this health problem affect your current 
daily life? (Check one.) 
 
□ Not at all 
□ A little 
□ Some 
□ A great deal 
36. Over the past year, have you had 
a bleeding problem that needed 




If you answered yes, 
Please answer the question on the 
right.  
 
How much does this health problem affect your current 
daily life? (Check one.) 
 
□ Not at all 
□ A little 
□ Some 











Thank you for completing this section of the survey. 
 
 
The next section of the survey continues on the next page. 
37. Over the past year, have you had 




If you answered yes, 
Please answer the question on the right. 
 
How much does this health problem affect your 
current daily life? (Check one.) 
 
□ Not at all 
□ A little 
□ Some 
□ A great deal 
38. FOR WOMEN ONLY: Over the past 
year, have you had any problems with 
your uterus or ovaries that needed the 




If you answered yes, 
Please answer the question on the right. 
 
 
How much does this health problem affect your 
current daily life? (Check one.) 
 
□ Not at all 
□ A little 
□ Some 
□ A great deal 
38. FOR MEN ONLY: Over the past year, 
have you had any prostate problems such 





If you answered yes, 
Please answer the question on the right. 
 
How much does this health problem affect your 
current daily life? (Check one.) 
 
□ Not at all 
□ A little 
□ Some 
□ A great deal 
39. If you have any other chronic illness or 









How much do these health problems affect your 
current daily life? (Check one.) 
 
□ Not at all 
□ A little 
□ Some 










This is a two-part survey which asks questions about your 
health, illnesses, and symptoms. Please read the survey 
carefully and answer all of the questions to the best of your 
ability. If you feel uncomfortable answering a question, skip that 





1. During the past month, have 
you had difficulty concentrating? 
 
 _____Yes _____No 
 
 
If you answered yes,  
please answer the questions to 
the right.  
 
1b. How much does this symptom bother you? 
 ___None OR a little 
 ___Some 
 ___A great deal 
 
1c. Check any of the following statements that you think  
 are true about your symptom of difficulty concentrating. 
 ___ It is caused by aging. 
 ___It is caused by my cancer.  
 ___It is caused by my cancer treatments. 
 ___It is caused by my medicines for non-cancer 
conditions. 
 ___This symptom has some other cause.  






2. During the past month, have 
you had trouble remembering? 
 
 _____Yes _____No 
 
 
If you answered yes,  
please answer the questions to 
the right.  
 
2b. How much does this symptom bother you? 
 ___None OR a little 
 ___Some 
 ___A great deal 
 
2c. Check any of the following statements that you think  
 are true about your symptom having trouble remembering. 
 ___It is caused by aging. 
 ___It is caused by my cancer.  
 ___It is caused by my cancer treatments. 
 ___It is caused by my medicines for non-cancer 
conditions. 
 ___This symptom has some other cause.  







3. During the past month, have 
you had pain? 
 
 _____Yes _____No 
 
 
If you answered yes,  
please answer the questions to 
the right.  
 
3b. How much does this symptom bother you? 
 ___None OR a little 
 ___Some 
 ___A great deal 
 
3c. Check any of the following statements that you think  
 are true about your symptom of pain. 
 ___It is caused by aging. 
 ___It is caused by my cancer.  
 ___It is caused by my cancer treatments. 
 ___It is caused by my medicines for non-cancer 
conditions. 
 ___This symptom has some other cause.  





4. During the past month, have 
you had fatigue or lack of 
energy? 
 
 _____Yes _____No 
 
 
If you answered yes,  
please answer the questions to 
the right.  
 
4b. How much does this symptom bother you? 
 ___None OR a little 
 ___Some 
 ___A great deal 
 
4c. Check any of the following statements that you think  
 are true about your symptom of fatigue. 
 ___It is caused by aging. 
 ___It is caused by my cancer.  
 ___It is caused by my cancer treatments. 
 ___It is caused by my medicines for non-cancer 
conditions. 
 ___This symptom has some other cause.  







5. During the past month, have 
you had a cough? 
 
 _____Yes _____No 
 
 
If you answered yes,  
please answer the questions to 
the right.  
5b. How much does this symptom bother you? 
 ___None OR a little 
 ___Some 
 ___A great deal 
 
5c. Check any of the following statements that you think  
 are true about your symptom of having a cough. 
 ___It is caused by aging. 
 ___It is caused by my cancer.  
 ___It is caused by my cancer treatments. 
 ___It is caused by my medicines for non-cancer 
conditions. 
 ___This symptom has some other cause.  







6. During the past month, have 
you had skin changes (such as 
altered skin color, thin or fragile 
skin, reddened skin or rash)? 
 
 _____Yes _____No 
 
 
If you answered yes,  
please answer the questions to 
the right.  
 
6b. How much does this symptom bother you? 
 ___None OR a little 
 ___Some 
 ___A great deal 
 
6c. Check any of the following statements that you think  
 are true about your symptom of skin changes. 
 ___It is caused by aging. 
 ___It is caused by my cancer.  
 ___It is caused by my cancer treatments. 
 ___It is caused by my medicines for non-cancer 
conditions. 
 ___This symptom has some other cause.  






7. During the past month, have 
you had a dry mouth? 
 
 _____Yes _____No 
 
 
If you answered yes,  
please answer the questions to 
the right.  
 
7b. How much does this symptom bother you? 
 ___None OR a little 
 ___Some 
 ___A great deal 
 
7c. Check any of the following statements that you think  
 are true about your symptom of having a dry mouth. 
 ___It is caused by aging. 
 ___It is caused by my cancer.  
 ___It is caused by my cancer treatments. 
 ___It is caused by my medicines for non-cancer 
conditions. 
 ___This symptom has some other cause.  







8. During the past month, have 
you had nausea? 
 
 _____Yes _____No 
 
 
If you answered yes,  
please answer the questions to 
the right.  
 
8b. How much does this symptom bother you? 
 ___None OR a little 
 ___Some 
 ___A great deal 
 
8c. Check any of the following statements that you think  
 are true about your symptom of nausea. 
 ___It is caused by aging. 
 ___It is caused by my cancer.  
 ___It is caused by my cancer treatments. 
 ___It is caused by my medicines for non-cancer 
conditions. 
 ___This symptom has some other cause.  







9. During the past month, have 
you had vomiting? 
 
 _____Yes _____No 
 
 
If you answered yes,  
please answer the questions to 
the right.  
 
9b. How much does this symptom bother you? 
 ___None OR a little 
 ___Some 
 ___A great deal 
 
9c. Check any of the following statements that you think  
 are true about your symptom of vomiting. 
 ___It is caused by aging. 
 ___It is caused by my cancer.  
 ___It is caused by my cancer treatments. 
 ___It is caused by my medicines for non-cancer 
conditions. 
 ___This symptom has some other cause.  






10. During the past month, 
have you had a feeling of being 
drowsy? 
 
 _____Yes _____No 
 
 
If you answered yes,  
please answer the questions to 
the right.  
 
10b. How much does this symptom bother you? 
 ___None OR a little 
 ___Some 
 ___A great deal 
 
10c. Check any of the following statements that you think  
 are true about your symptom of being drowsy. 
 ___It is caused by aging. 
 ___It is caused by my cancer.  
 ___It is caused by my cancer treatments. 
 ___It is caused by my medicines for non-cancer 
conditions. 
 ___This symptom has some other cause.  







11. During the past month, 
have you had numbness/ tingling 
in hands or feet? 
 
 _____Yes _____No 
 
 
If you answered yes,  
please answer the questions to 
the right.  
 
11b. How much does this symptom bother you? 
 ___None OR a little 
 ___Some 
 ___A great deal 
 
11c. Check any of the following statements that you think  
 are true about your symptom of numbness and tingling. 
 ___It is caused by aging. 
 ___It is caused by my cancer.  
 ___It is caused by my cancer treatments. 
 ___It is caused by my medicines for non-cancer 
conditions. 
 ___This symptom has some other cause.  







12. During the past month, 
have you had difficulty sleeping? 
 
 _____Yes _____No 
 
 
If you answered yes,  
please answer the questions to 
the right.  
 
12b. How much does this symptom bother you? 
 ___None OR a little 
 ___Some 
 ___A great deal 
 
12c. Check any of the following statements that you think  
 are true about your symptom of having difficulty sleeping. 
 ___It is caused by aging. 
 ___It is caused by my cancer.  
 ___It is caused by my cancer treatments. 
 ___It is caused by my medicines for non-cancer 
conditions. 
 ___This symptom has some other cause.  






13. During the past month, 
have you had a feeling of being 
bloated? 
 
 _____Yes _____No 
 
 
If you answered yes,  
please answer the questions to 
the right.  
13b. How much does this symptom bother you? 
 ___None OR a little 
 ___Some 
 ___A great deal 
 
13c. Check any of the following statements that you think  
 are true about your symptom feeling bloated. 
 ___It is caused by aging. 
 ___It is caused by my cancer.  
 ___It is caused by my cancer treatments. 
 ___It is caused by my medicines for non-cancer 
conditions. 
 ___This symptom has some other cause.  







14. During the past month, 
have you had urinary problems 
(such as going often, pain, 
leaking)? 
 
 _____Yes _____No 
 
 
If you answered yes,  
please answer the questions to 
the right.  
14b. How much does this symptom bother you? 
 ___None OR a little 
 ___Some 
 ___A great deal 
 
14c. Check any of the following statements that you think  
 are true about your symptom of urinary problems. 
 ___It is caused by aging. 
 ___It is caused by my cancer.  
 ___It is caused by my cancer treatments. 
 ___It is caused by my medicines for non-cancer 
conditions. 
 ___This symptom has some other cause.  







15. During the past month, 
have you had shortness of 
breath? 
 
 _____Yes _____No 
 
 
If you answered yes,  
please answer the questions to 
the right.  
15b. How much does this symptom bother you? 
 ___None OR a little 
 ___Some 
 ___A great deal 
 
15c. Check any of the following statements that you think  
 are true about your symptom of shortness of breath. 
 ___It is caused by aging. 
 ___It is caused by my cancer.  
 ___It is caused by my cancer treatments. 
 ___It is caused by my medicines for non-cancer 
conditions. 
 ___This symptom has some other cause.  




16. During the past month, 
have you had sweating which is 
not normal for you? 
 
 _____Yes _____No 
 
 
If you answered yes,  
please answer the questions to 
the right.  
16b. How much does this symptom bother you? 
 ___None OR a little 
 ___Some 
 ___A great deal 
 
16c. Check any of the following statements that you think  
 are true about your symptom of sweating. 
 ___It is caused by aging. 
 ___It is caused by my cancer.  
 ___It is caused by my cancer treatments. 
 ___It is caused by my medicines for non-cancer 
conditions. 
 ___This symptom has some other cause.  






17. During the past month, 
have you had hot flashes or hot 
flushes? 
 
 _____Yes _____No 
 
 
If you answered yes,  
please answer the questions to 
the right.  
 
17b. How much does this symptom bother you? 
 ___None OR a little 
 ___Some 
 ___A great deal 
 
17c. Check any of the following statements that you think  
 are true about your symptom of hot flashes or hot flushes. 
 ___It is caused by aging. 
 ___It is caused by my cancer.  
 ___It is caused by my cancer treatments. 
 ___It is caused by my medicines for non-cancer 
conditions. 
 ___This symptom has some other cause.  







18. During the past month, 
have you had problems with 
sexual interest or activity? 
 
 _____Yes _____No 
 
 
If you answered yes,  
please answer the questions to 
the right.  
 
18b. How much does this symptom bother you? 
 ___None OR a little 
 ___Some 
 ___A great deal 
 
18c. Check any of the following statements that you think  
 are true about your symptom of problems with sexual  
 interest or activity. 
 ___It is caused by aging. 
 ___It is caused by my cancer.  
 ___It is caused by my cancer treatments. 
 ___It is caused by my medicines for non-cancer 
conditions. 
 ___This symptom has some other cause.  






19. During the past month, 
have you had itching? 
 
 _____Yes _____No 
 
 
If you answered yes,  
please answer the questions to 
the right.  
19b. How much does this symptom bother you? 
 ___None OR a little 
 ___Some 
 ___A great deal 
 
19c. Check any of the following statements that you think  
 are true about your symptom of itching. 
 ___It is caused by aging. 
 ___It is caused by my cancer.  
 ___It is caused by my cancer treatments. 
 ___It is caused by my medicines for non-cancer 
conditions. 
 ___ This symptom has some other cause.  






20. During the past month, 
have you had a lack of appetite? 
 
 _____Yes _____No 
 
 
If you answered yes,  
please answer the questions to 
the right.  
20b. How much does this symptom bother you? 
 ___None OR a little 
 ___Some 
 ___A great deal 
 
20c. Check any of the following statements that you think  
 are true about your symptom of lack of appetite. 
 ___It is caused by aging. 
 ___It is caused by my cancer.  
 ___It is caused by my cancer treatments. 
 ___It is caused by my medicines for non-cancer 
conditions. 
 ___This symptom has some other cause.  







21. During the past month, 
have you had dizziness? 
 
 _____Yes _____No 
 
 
If you answered yes,  
please answer the questions to 
the right.  
21b. How much does this symptom bother you? 
 ___None OR a little 
 ___Some 
 ___A great deal 
 
21c. Check any of the following statements that you think  
 are true about your symptom of dizziness. 
 ___It is caused by aging. 
 ___It is caused by my cancer.  
 ___It is caused by my cancer treatments. 
 ___It is caused by my medicines for non-cancer 
conditions 
 ___This symptom has some other cause.  







22. During the past month, 
have you had difficulty 
swallowing? 
 
 _____Yes _____No 
 
 
If you answered yes,  
please answer the questions to 
the right.  
22b. How much does this symptom bother you? 
 ___None OR a little 
 ___Some 
 ___A great deal 
 
22c. Check any of the following statements that you think  
 are true about your symptom of difficulty swallowing. 
 ___It is caused by aging. 
 ___It is caused by my cancer.  
 ___It is caused by my cancer treatments. 
 ___It is caused by my medicines for non-cancer 
conditions 
 ___This symptom has some other cause.  






23. During the past month, 
have you had mouth sores? 
 
 _____Yes _____No 
 
 
If you answered yes,  
please answer the questions to 
the right.  
23b. How much does this symptom bother you? 
 ___None OR a little 
 ___Some 
 ___A great deal 
 
23c. Check any of the following statements that you think  
 are true about your symptom of mouth sores. 
 ___It is caused by aging. 
 ___It is caused by my cancer.  
 ___It is caused by my cancer treatments. 
 ___It is caused by my medicines for non-cancer 
conditions. 
 ___This symptom has some other cause.  







24. During the past month, 
have you had changes in the 
way food tastes? 
 
 _____Yes _____No 
 
 
If you answered yes,  
please answer the questions to 
the right.  
24b. How much does this symptom bother you? 
 ___None OR a little 
 ___Some 
 ___A great deal 
 
24c. Check any of the following statements that you think  
 are true about your symptom of taste changes. 
 ___It is caused by aging. 
 ___It is caused by my cancer.  
 ___It is caused by my cancer treatments. 
 ___It is caused by my medicines for non-cancer 
conditions. 
 ___This symptom has some other cause.  







25. During the past month, 
have you had unexpected weight 
loss? 
 
 _____Yes _____No 
 
 
If you answered yes,  
please answer the questions to 
the right.  
25b. How much does this symptom bother you? 
 ___None OR a little 
 ___Some 
 ___A great deal 
 
25c. Check any of the following statements that you think  
 are true about your symptom of unexpected weight loss. 
 ___It is caused by aging. 
 ___It is caused by my cancer.  
 ___It is caused by my cancer treatments. 
 ___It is caused by my medicines for non-cancer 
conditions. 
 ___This symptom has some other cause.  






26. During the past month, 
have you had hair loss? 
 
 _____Yes _____No 
 
 
If you answered yes,  
please answer the questions to 
the right.  
26b. How much does this symptom bother you? 
 ___None OR a little 
 ___Some 
 ___A great deal 
 
26c. Check any of the following statements that you think  
 are true about your symptom of hair loss. 
 ___It is caused by aging. 
 ___It is caused by my cancer.  
 ___It is caused by my cancer treatments. 
 ___It is caused by my medicines for non-cancer 
conditions. 
 ___This symptom has some other cause.  







27. During the past month, 
have you had constipation? 
 
 _____Yes _____No 
 
 
If you answered yes,  
please answer the questions to 
the right.  
27b. How much does this symptom bother you? 
 ___None OR a little 
 ___Some 
 ___A great deal 
 
27c. Check any of the following statements that you think  
 are true about your symptom of constipation. 
 ___It is caused by aging. 
 ___It is caused by my cancer.  
 ___It is caused by my cancer treatments. 
 ___It is caused by my medicines for non-cancer 
conditions. 
 ___This symptom has some other cause.  







28. During the past month, 
have you had diarrhea? 
 
 _____Yes _____No 
 
 
If you answered yes,  
please answer the questions to 
the right.  
28b. How much does this symptom bother you? 
 ___None OR a little 
 ___Some 
 ___A great deal 
 
28c. Check any of the following statements that you think  
 are true about your symptom of diarrhea. 
 ___It is caused by aging. 
 ___It is caused by my cancer.  
 ___It is caused by my cancer treatments. 
 ___It is caused by my medicines for non-cancer 
conditions. 
 ___This symptom has some other cause.  





29. During the past month, 
have you had a feeling that “I 
don’t look like myself”? 
 
 _____Yes _____No 
 
 
If you answered yes,  
please answer the questions to 
the right.  
29b. How much does this symptom bother you? 
 ___None OR a little 
 ___Some 
 ___A great deal 
 
29c. Check any of the following statements that you think  
 are true about your symptom of feeling that you don’t look  
 like yourself. 
 ___It is caused by aging. 
 ___It is caused by my cancer.  
 ___It is caused by my cancer treatments. 
 ___It is caused by my medicines for non-cancer 
conditions. 
 ___This symptom has some other cause.  






30. During the past month, 
have you been worried, anxious, 
or nervous? 
 
 _____Yes _____No 
 
 
If you answered yes,  
please answer the questions to 
the right.  
30b. How much does this symptom bother you? 
 ___None OR a little 
 ___Some 
 ___A great deal 
 
30c. Check any of the following statements that you think  
 are true about your symptom of being worried, anxious, or  
 nervous. 
 ___It is caused by aging. 
 ___It is caused by my cancer.  
 ___It is caused by my cancer treatments. 
 ___It is caused by my medicines for non-cancer 
conditions. 
 ___This symptom has some other cause.  







31. During the past month, 
have you had a feeling of being 
irritable? 
 
 _____Yes _____No 
 
 
If you answered yes,  
please answer the questions to 
the right.  
31b. How much does this symptom bother you? 
 ___None OR a little 
 ___Some 
 ___A great deal 
 
31c. Check any of the following statements that you think  
 are true about your symptom of feeling irritable. 
 ___It is caused by aging. 
 ___It is caused by my cancer.  
 ___It is caused by my cancer treatments. 
 ___It is caused by my medicines for non-cancer 
conditions. 
 ___This symptom has some other cause.  





32. During the past month, 
have you had a feeling of being 
sad or blue? 
 
 _____Yes _____No 
 
 
If you answered yes,  
please answer the questions to 
the right.  
 
32b. How much does this symptom bother you? 
 ___None OR a little 
 ___Some 
 ___A great deal 
 
32c. Check any of the following statements that you think  
 are true about your symptom of feeling sad or blue. 
 ___It is caused by aging. 
 ___It is caused by my cancer.  
 ___It is caused by my cancer treatments. 
 ___It is caused by my medicines for non-cancer 
conditions. 
 ___This symptom has some other cause.  








33. During the past month, 
have you had other symptoms 
not listed in this survey? 
 
 _____Yes _____No 
 
If you answered yes,  
please list the symptoms below 






33b. How much do these symptoms bother you? 
 ___None OR a little 
 ___Some 
 ___A great deal 
 
33c. Check any of the following statements that you think  
 are true about your other symptoms. 
 ___It is caused by aging. 
 ___It is caused by my cancer.  
 ___It is caused by my cancer treatments. 
 ___It is caused by my medicines for non-cancer 
conditions. 
 ___This symptom has some other cause.  
 (Write in what you think is causing the symptom.) 
 
 










General Information Questionnaire 
 
Directions: Please answer all of these questions accurately. The information you 
provide will be used only for this project and will not be seen by anyone else. 
 
1. Today’s date: ___________/________/_________ 
   month day  year 
 
2. Your age: ___________ (years) 
 
3. Your gender: _______(1) Male  _______(2) Female 
 
4. Your ethnic background (select one): 
  (1) Hispanic, Latino, or of Spanish Origin 
  (2) Not Hispanic or Latino 
 
5. Your racial background (select one or more): 
  (1) Asian 
  (2) Black or African American 
  (3) Native Hawaiian or Other Pacific Islander 
  (4) American Indian or Alaska Native 
  (5) White 
 
6. Your marital status: 
  (1) Single (never married)  
  (2) Separated or divorced 
  (3) Widow or widower 
  (4) Married 
 
7. Current living situation: 
 _____ (1) I live alone. 
 _____ (2) I live with my spouse/ partner. 
 _____ (3) I live with my adult son/ daughter. 
 _____ (4) I live with an adult relative other than my son or daughter. 
 _____ (5) I live with my children under the age of 18. 
 _____ (6) Other (Please describe) 
   ________________________________________________ 
 
8. Highest grade of school you completed: 
_____ (1) Less than 6th grade 
_____ (2) 6th - 8th grade   
_____ (3) Some high school  
_____ (4) High school graduate  
_____ (5) Technical school graduate 
_____ (6) Some college 
_____ (7) College graduate 





9. What best describes your employment status? 
  (1) Full-time  
  (2) Part-time  
  (3) Unemployed 
______     (4)Retired 
       (5)Full-time homemaker 
 
10. Are you a religious person? 
 _____       (1)Yes 
 _____       (2) No  
 
11. What is your religion? 
  (1) Catholic  
  (2) Protestant  
  (3) Jewish  
______      (4) Latter Day Saint  
     (5) Greek Orthodox 
     (6) Muslim 
     (7) Other           
______      (8) None 
 
12. How spiritual of a person would you describe yourself to be? 
  (1) Not at all spiritual 
  (2) Slightly spiritual 
  (3) Moderately spiritual 
  (4) Quite spiritual 
  (5) Very spiritual 
 
13. What is your household income before taxes? 
  (1) Under $10,000 
  (2) $10,000-$19,999 
  (3) $20,000-$29,999 
  (4) $30,000-$39,999 
  (5) $40,000-$49,999 
  (6) $50,000-$59,999 
  (7) $60,000-$79,999 
  (8) $80,000-$99,999 
  (9) $100,000 or more 
 
14. What are your present sources of financial support? Check all that apply. 
  (1) Savings  
  (2) Retirement  
  (3) Stock/bonds  
  (4) Family support  
  (5) Social Security 
  (6) Welfare 
  (7) Employment 






15. How would you describe the adequacy of your current financial situation? 
  (1) I have problems making ends meet. 
  (2) My financial situation is comfortable. 
  (3) My income is more than adequate to meet my needs. 
 
16. What type of health insurance do you have?  
  (1) Medicare 
  (2) Medicaid 
  (3) Other (please specify)________________________ 
  (4) None 
 
19. Please circle only one number that best describes your current activity level. 
0 I have normal activity without symptoms. 
1 I have some symptoms, but I do not need to spend any extra time resting 
during the day. 
2 I need some time to rest (e.g., in bed), but it amounts to less than half of my 
normal daytime. 
3 I need to rest (e.g., in bed) for more than half of my normal daytime. 
4 I am unable to get out of bed. 
 
20. What (if any) medications do you take? Please list below. 
 











































The next brief set of questions is about your cancer and treatment history. Please 
answer them as accurately as possible. The information that you provide will be used 
only for this project and will not be seen by anyone else. 
 
21. What kind of cancer have you been diagnosed with? (please check any that apply) 
 _____ Breast Cancer 
 _____ Prostate Cancer 
 _____ Lung Cancer 
 _____ Colorectal Cancer 
 _____ Lymphoma 
 _____ Melanoma 
 _____ Another kind:  
 please describe____________________________________________ 
 
22. When were you diagnosed with cancer? 
 
 _____________(month) and _______________ (year) 
 
23. What type of treatment have you received for your cancer? 
 
A. Surgery 
 _______Yes _______No 
 
If you answered yes, 
Please answer the questions to the right.  
What kind of surgery did you have? 
 
 
When did you have your surgery? 
 
B. Chemotherapy 
 _______Yes _______No 
 
If you answered yes, 
Please answer the questions to the right.  
When did you start chemotherapy? 
 
 
When did this treatment end? 
 
C. Radiation Therapy 
 _______Yes _______No 
 
If you answered yes, 
Please answer the questions to the right.  




How many days or weeks did the 
treatment last? 
 
D. Hormonal Therapy 
 _______Yes _______No 
 
If you answered yes, 
Please answer the questions to the right.  
When did you start this therapy? 
 
 
How long were you on this therapy? 
 




If you answered yes, 
Please answer the questions to the right.  









General Information Questionnaire - 2 
 
Directions: Please answer all of these questions accurately. The information you 
provide will be used only for this project and will not be seen by anyone else. 
 
1. Today’s date: ___________/________/_________ 
 
  month day  year 
 
2. Current living situation: 
 
 _____ (1) I live alone. 
 _____ (2) I live with my spouse/ partner. 
 _____ (3) I live with my adult son/ daughter. 
 _____ (4) I live with an adult relative other than my son or daughter. 
 _____ (5) I live with my children under the age of 18. 
 _____ (6) Other  
(Please describe)__________________________________________________ 
 
3. What best describes your employment status? 
 
  (1) Full-time 
  (2) Part-time 
  (3) Unemployed 
_______ (4) Retired 
_______ (5) Full-time homemaker 
 
4. Please circle only one number that best describes your current activity level. 
 
0 I have normal activity without symptoms. 
1 I have some symptoms, but I do not need to spend any extra time 
resting during the day. 
2 I need some time to rest (e.g., in bed), but it amounts to less than 
half of my normal daytime. 
3 I need to rest (e.g., in bed) for more than half of my normal daytime. 











Sample Questions for Semistructured Interview 
(Questions will be asked about each subscale separately) 
Context of Comorbidities 
 
 
Sample Questions Related to Perception of Symptoms in the Older Adult 
1 *When you think about the symptoms that you have, what types of 
things do you think about? 
-What types of things do you think about or do before you tell you 
healthcare provider about your symptoms? 
 
2 *When you think about your symptoms, do you try to figure out what is 
causing them? 
-What is the usual reason that your symptoms occur? 
 
3 *Do you think that the other diseases that you have or take medicine for 
effect how you think about your symptoms? 
-If yes, what has the most effect on your symptoms and why? 
 
4 *Do you have any comments about the tool or thoughts about how you 
think about your symptoms? 
 
5 *How do your symptoms affect your ability to do daily activities? 





*Were the instructions for the section that asked about your overall 
health (symptoms) clear? 
-If not, what might help to make them clearer? 
 
2  *Please comment on the length of this section. –Was it too long, too 
short or just right? 
-How did you feel after completing this section? 




*Were there any questions in that section that were confusing, 
difficult to understand, or difficult to answer? 
-If so, which questions were they and why did they seem difficult to 
answer? 
 
4  *Did you skip any questions in that section? 



















My name is Cheryl Lacasse and I am a doctoral student at the University of Utah College of 
Nursing. I have been an oncology nurse for over 20 years. I am conducting a research study 
which will help health care providers to understand the relationship between cancer, symptoms, 
and ongoing medical conditions and how each person thinks about them. 
 
Many cancer survivors have symptoms during and after treatment which may be caused by 
cancer, its treatment or other medical conditions. These symptoms may be difficult to measure 
and may have a great impact on the quality of life of cancer survivors. This study will help to 
determine if a newly developed survey will provide valuable information about symptoms and 
ongoing medical conditions in older cancer patients to health care providers. This information 
may help health care providers to work with cancer survivors to improve their quality of life. 
 
You have been identified as a potential participant in this study either through an initial screening 
process in collaboration with your health care provider or by your personal interest. 
 
Individuals are eligible for this study if they: 
▪ Are 65 years old or older 
▪ Have ever been diagnosed with cancer  
▪ Are currently receiving treatment for cancer OR have been off of cancer treatment for 
at least one year 
▪ Have 2 or more ongoing medical conditions (such as high blood pressure, arthritis, 
heart disease, lung disease, diabetes, or others)  
▪ At least one symptom (such as pain, feeling tired, difficulty sleeping, lack of appetite or 
others) 
▪ Can read, write, and understand English. 
 
Participation in this study involves 2 steps: 1) a brief 10 minute discussion with a researcher to 
assess your eligibility for the study and 2) completing a survey and 2 brief questionnaires and a 
brief interview. 
 
Participation in this study is voluntary. Please notify me within 2 weeks of receiving this letter if 
you are interested in learning more about this study. You can call me at 1 – 520 – 429 – 1172 and 
leave a message. I will return your call as soon as possible. If I haven’t heard from you within 2 
weeks, you will receive a follow-up phone call to answer any questions you might have about the 
study and give you an opportunity to indicate if you are interested in participating in the study. If 
you are not interested in participating in the study, please call the phone number above and 
request that no further contact be made. 
 
Thank you for considering participation in this study. 
Sincerely, 
Cheryl Lacasse, MS, RN, OCN 
Doctoral Student, University of Utah College of Nursing 
 
COSMOS STUDY 





























This is a two-part survey which asks questions about your 
health, illnesses, and symptoms. Part One has questions about 
chronic illness and conditions. 
 
Please read the survey carefully and answer all of the questions 
to the best of your ability. If you feel uncomfortable answering a 





1. Have you ever been told by a health care provider 
that you have any heart conditions such as a heart 





_____Yes   If you answered yes, 
                    please answer the question on the right.  
How much does this health problem 
affect your current daily life? (Check 
one.) 
 
□ Not at all 
□ A little bit 
□ Somewhat 
□ Quite a bit 
□ Very much 
2. Have you ever been told by a health care provider 




_____Yes   If you answered yes, 
                    please answer the question on the right.  
How much does this health problem 
affect your current daily life? (Check 
one.) 
 
□ Not at all 
□ A little bit 
□ Somewhat 
□ Quite a bit 
□ Very much 
3. Have you ever been told by a health care provider 




_____Yes   If you answered yes, 
                   please answer the question on the right.  
How much does this health problem 
affect your current daily life? (Check 
one.) 
 
□ Not at all 
□ A little bit 
□ Somewhat 
□ Quite a bit 
□ Very much 
4. Have you ever been told by a health care provider 
that you have high blood pressure or are you taking 




_____Yes   If you answered yes, 
                   please answer the question on the right. 
How much does this health problem 
affect your current daily life? (Check 
one.) 
 
□ Not at all 
□ A little 
□ Somewhat 
□ Quite a bit 
□ Very much 
5. Have you ever had a problem with blood clots in 




_____Yes   If you answered yes, 
                   please answer the question on the right. 
How much does this health problem 
affect your current daily life? (Check 
one.) 
□ Not at all 
□ A little 
□ Somewhat 
□ Quite a bit 




6. Have you ever been told by a health care provider 




_____Yes   If you answered yes, 




How much does this health problem 
affect your current daily life? (Check 
one.) 
 
□ Not at all 
□ A little 
□ Somewhat 
□ Quite a bit 
□ Very much 
 





_____Yes   If you answered yes, 
                   please answer the question on the right. 
 
 
How much does this health problem 
affect your current daily life? (Check 
one.) 
 
□ Not at all 
□ A little 
□ Somewhat 
□ Quite a bit 
□ Very much 
 
8. Have you ever been told by a health care provider 
that you have a chronic lung condition such as 





_____Yes   If you answered yes, 
                   please answer the question on the right. 
 
 
How much does this health problem 
affect your current daily life? (Check 
one.) 
 
□ Not at all 
□ A little 
□ Somewhat 
□ Quite a bit 
□ Very much 
9. Have you ever had indigestion or heartburn after 




_____Yes   If you answered yes, 
                   please answer the question on the right. 
 
 
How much does this health problem 
affect your current daily life? (Check 
one.) 
□ Not at all 
□ A little 
□ Somewhat 
□ Quite a bit 
□ Very much 
 
10. Have you ever been told by a health care 




_____Yes   If you answered yes, 
                   please answer the question on the right. 
 
How much does this health problem 
affect your current daily life? (Check 
one.) 
 
□ Not at all 
□ A little 
□ Somewhat 
□ Quite a bit 








11. Have you ever been told by a health care 





_____Yes    If you answered yes, 




How much does this health problem 
affect your current daily life? (Check 
one.) 
 
□ Not at all 
□ A little 
□ Somewhat 
□ Quite a bit 
□ Very much 
12. Have you ever been told by a health care 
provider that you have any problems with your liver 




_____Yes   If you answered yes, 
                   please answer the question on the right. 
 
 
How much does this health problem 
affect your current daily life? (Check 
one.) 
 
□ Not at all 
□ A little 
□ Somewhat 
□ Quite a bit 
□ Very much 
13. Have you ever had a bowel problem (other than 





_____Yes   If you answered yes, 




How much does this health problem 
affect your current daily life? (Check 
one.) 
 
□ Not at all 
□ A little 
□ Somewhat 
□ Quite a bit 
□ Very much 
14. Have you ever been told by a health care 




_____Yes   If you answered yes, 




How much does this health problem 
affect your current daily life? (Check 
one.) 
 
□ Not at all 
□ A little 
□ Somewhat 
□ Quite a bit 
□ Very much 
15. Have you ever been told by a health care 




_____Yes   If you answered yes, 
                   please answer the question on the right. 
How much does this health problem 
affect your current daily life? (Check 
one.) 
 
□ Not at all 
□ A little 
□ Somewhat 
□ Quite a bit 






16. Over the past year, have you had a problem with 





_____Yes    If you answered yes, 
                    please answer the question on the right. 
 
 
How much does this health problem 
affect your current daily life? (Check 
one.) 
 
□ Not at all 
□ A little 
□ Somewhat 
□ Quite a bit 
□ Very much 
17. Have you ever been told by a health care 




_____Yes   If you answered yes, 




How much does this health problem 
affect your current daily life? (Check 
one.) 
 
□ Not at all 
□ A little 
□ Somewhat 
□ Quite a bit 
□ Very much 
18. Have you ever been told by a health care 
provider that you have one or more different types of 
cancer (not cancer that has spread to another place 




_____Yes   If you answered yes, 
                   please answer the question on the right. 
 
How much does this health problem 
affect your current daily life? (Check 
one.) 
 
□ Not at all 
□ A little 
□ Somewhat 
□ Quite a bit 
□ Very much 
19. Have you ever been told by a health care 





_____Yes   If you answered yes, 
                   please answer the question on the right. 
 
 
How much does this health problem 
affect your current daily life? (Check 
one.) 
 
□ Not at all 
□ A little 
□ Somewhat 
□ Quite a bit 
□ Very much 
20. Have you ever been told by a health care 
provider that you have osteoporosis, weakened 




_____Yes   If you answered yes, 
                   please answer the question on the right. 
How much does this health problem 
affect your current daily life? (Check 
one.) 
 
□ Not at all 
□ A little 
□ Somewhat 
□ Quite a bit 











_____Yes   If you answered yes, 
                   please answer the question on the right. 
How much does this health problem 
affect your current daily life? (Check 
one.) 
 
□ Not at all 
□ A little 
□ Somewhat 
□ Quite a bit 
□ Very much 
 
 






_____Yes   If you answered yes, 
                   please answer the question on the right. 
 
 
How much does this health problem 
affect your current daily life? (Check 
one.) 
 
□ Not at all 
□ A little 
□ Somewhat 
□ Quite a bit 
□ Very much 
23. Over the past year, have you had problems with 





_____Yes   If you answered yes, 
                   please answer the question on the right. 
 
 
How much does this health problem 
affect your current daily life? (Check 
one.) 
 
□ Not at all 
□ A little 
□ Somewhat 
□ Quite a bit 
□ Very much 
24. Over the past year, have you walked with a 
shuffle or had trembling hands or other body parts 





_____Yes   If you answered yes, 
                   please answer the question on the right. 
 
How much does this health problem 
affect your current daily life? (Check 
one.) 
 
□ Not at all 
□ A little 
□ Somewhat 
□ Quite a bit 
□ Very much 





_____Yes   If you answered yes, 
                   please answer the question on the right. 
 
 
How much does this health problem 
affect your current daily life? (Check 
one.) 
□ Not at all 
□ A little 
□ Somewhat 
□ Quite a bit 











_____Yes   If you answered yes, 
                   please answer the question on the right. 
How much does this health problem 
affect your current daily life? (Check 
one.) 
□ Not at all 
□ A little 
□ Somewhat 
□ Quite a bit 
□ Very much 
 
 
27. Over the past year, have you been diagnosed 




_____Yes   If you answered yes, 




How much does this health problem 
affect your current daily life? (Check 
one.) 
□ Not at all 
□ A little 
□ Somewhat 
□ Quite a bit 
□ Very much 
28. Over the past year, have you been diagnosed 




_____Yes   If you answered yes, 




How much does this health problem 
affect your current daily life? (Check 
one.) 
□ Not at all 
□ A little 
□ Somewhat 
□ Quite a bit 
□ Very much 
29. Over the past year, have you had any problems 




_____Yes   If you answered yes, 




How much does this health problem 
affect your current daily life? (Check 
one.) 
□ Not at all 
□ A little 
□ Somewhat 
□ Quite a bit 
□ Very much 
30. Over the past year, have you had any major 




_____Yes   If you answered yes, 
                   please answer the question on the right. 
How much does this health problem 
affect your current daily life? (Check 
one.) 
 
□ Not at all 
□ A little 
□ Somewhat 
□ Quite a bit 








 *Please record the amount of time that it took for you complete this section:  ____ min. 
 
Thank you for completing this section of the survey. 
 
 
The next section of the survey continues on the next page.
31. Over the past year, have you had any problems 
with bruising or bleeding problem that needed 




_____Yes   If you answered yes, 
                   please answer the question on the right. 
How much does this health problem 
affect your current daily life? (Check 
one.) 
 
□ Not at all 
□ A little 
□ Somewhat 
□ Quite a bit 
□ Very much 
 
32. Over the past year, have you had anemia (a low 




_____Yes   If you answered yes, 
                   please answer the question on the right. 
 
 
How much does this health problem 
affect your current daily life? (Check 
one.) 
 
□ Not at all 
□ A little 
□ Somewhat 
□ Quite a bit 
□ Very much 
33. Over the past year, have you had any problems 
with your reproductive organs (such as prostate 




_____Yes   If you answered yes, 
                   please answer the question on the right. 
 
How much does this health problem 
affect your current daily life? (Check 
one.) 
 
□ Not at all 
□ A little 
□ Somewhat 
□ Quite a bit 
□ Very much 
34. If you have any other chronic illness or condition 




_____Yes   If you answered yes, 
                   please list on the lines below. 








How much do these health problems 
affect your current daily life? (Check 
one.) 
 
□ Not at all 
□ A little 
□ Somewhat 
□ Quite a bit 










This is a two-part survey which asks questions about your 
health, illnesses, and symptoms. Part Two asks questions about 
your symptoms. 
 
Please read the survey carefully and answer all of the questions 
to the best of your ability. If you feel uncomfortable answering a 




1. During the past week, have 




If you answered no,  




If you answered yes,  
Please answer the questions in 
the next 2 columns  
 
 
1b. How much does this 
symptom bother you?  
[Please check one.] 
□ Not at all 
□ A little bit 
□ Somewhat 
□ Quite a bit 
□ Very much 
1c. If you answered yes 
to the question about the 
symptom, please answer 
the following question.  
 
Check one of the following 
statements that you think is 
true about your symptom 
of difficulty concentrating. 
 The cause of this 
symptom is mostly 
age-related. 
 The cause of this 
symptom is mostly 
related to my cancer 
and/ or cancer 
treatments. 
 The cause of this 
symptom is mostly 
related to a non-cancer 
condition or treatment. 
 This symptom has 
some other cause.  
 (Write in what you 




2. During the past week, have 




If you answered no,  




If you answered yes,  
Please answer the questions in 




2b. How much does this 
symptom bother you?  
[Please check one.] 
□ Not at all 
□ A little bit 
□ Somewhat 
□ Quite a bit 
□ Very much 
2c. If you answered yes 
to the question about the 
symptom, please answer 
the following question.  
 
Check one of the following 
statements that you think is 
true about your symptom 
of trouble remembering. 
 The cause of this 
symptom is mostly 
age-related. 
 The cause of this 
symptom is mostly 
related to my cancer 
and/ or cancer 
treatments. 
 The cause of this 
symptom is mostly 
related to a non-cancer 
condition or treatment. 
 This symptom has 
some other cause.  
 (Write in what you 






3. During the past week, have 




If you answered no,  





If you answered yes,  
Please answer the questions in 
the next 2 columns  
 
 
3b. How much does this 
symptom bother you?  
[Please check one.] 
□ Not at all 
□ A little bit 
□ Somewhat 
□ Quite a bit 
□ Very much 
3c. If you answered yes 
to the question about the 
symptom, please answer 
the following question.  
 
Check one of the following 
statements that you think is 
true about your symptom 
of pain. 
 The cause of this 
symptom is mostly 
age-related. 
 The cause of this 
symptom is mostly 
related to my cancer 
and/ or cancer 
treatments. 
 The cause of this 
symptom is mostly 
related to a non-cancer 
condition or treatment. 
 This symptom has 
some other cause.  
 (Write in what you 




4. During the past week, have 




If you answered no,  




If you answered yes,  
Please answer the questions in 
the next 2 columns  
 
 
4b. How much does this 
symptom bother you?  
[Please check one.] 
□ Not at all 
□ A little bit 
□ Somewhat 
□ Quite a bit 
□ Very much 
4c. If you answered yes 
to the question about the 
symptom, please answer 
the following question.  
 
Check one of the following 
statements that you think is 
true about your symptom 
of fatigue. 
 The cause of this 
symptom is mostly 
age-related. 
 The cause of this 
symptom is mostly 
related to my cancer 
and/ or cancer 
treatments. 
 The cause of this 
symptom is mostly 
related to a non-cancer 
condition or treatment. 
 This symptom has 
some other cause.  
 (Write in what you 






5. During the past week, have 




If you answered no,  





If you answered yes,  
Please answer the questions in 
the next 2 columns  
 
 
5b. How much does this 
symptom bother you?  
[Please check one.] 
□ Not at all 
□ A little bit 
□ Somewhat 
□ Quite a bit 
□ Very much 
5c. If you answered yes 
to the question about the 
symptom, please answer 
the following question.  
 
Check one of the following 
statements that you think is 
true about your symptom 
of a cough. 
 The cause of this 
symptom is mostly 
age-related. 
 The cause of this 
symptom is mostly 
related to my cancer 
and/ or cancer 
treatments. 
 The cause of this 
symptom is mostly 
related to a non-cancer 
condition or treatment. 
 This symptom has 
some other cause.  
 (Write in what you 




6. During the past week, have 
you had skin changes (such as 
altered skin color, thin or fragile 




If you answered no,  




If you answered yes,  
Please answer the questions in 
the next 2 columns  
 
 
6b. How much does this 
symptom bother you?  
[Please check one.] 
 Not at all 
 A little bit 
 Somewhat 
 Quite a bit 
 Very much 
6c. If you answered yes 
to the question about the 
symptom, please answer 
the following question.  
 
Check one of the following 
statements that you think is 
true about your symptom 
of skin changes. 
 The cause of this 
symptom is mostly 
age-related. 
 The cause of this 
symptom is mostly 
related to my cancer 
and/ or cancer 
treatments. 
 The cause of this 
symptom is mostly 
related to a non-cancer 
condition or treatment. 
 This symptom has 
some other cause.  
 (Write in what you 






7. During the past week, have 




If you answered no,  




If you answered yes,  
Please answer the questions in 




7b. How much does this 
symptom bother you?  
[Please check one.] 
 Not at all 
 A little bit 
 Somewhat 
 Quite a bit 
 Very much 
7c. If you answered yes 
to the question about the 
symptom, please answer 
the following question.  
 
Check one of the following 
statements that you think is 
true about your symptom 
of dry mouth. 
 The cause of this 
symptom is mostly 
age-related. 
 The cause of this 
symptom is mostly 
related to my cancer 
and/ or cancer 
treatments. 
 The cause of this 
symptom is mostly 
related to a non-cancer 
condition or treatment. 
 This symptom has 
some other cause.  
 (Write in what you 
think is causing the 
symptom.) 
 
8. During the past week, have 




If you answered no,  





If you answered yes,  
Please answer the questions in 
the next 2 columns  
 
 
8b. How much does this 
symptom bother you?  
[Please check one.] 
 Not at all 
 A little bit 
 Somewhat 
 Quite a bit 
 Very much 
8c. If you answered yes 
to the question about the 
symptom, please answer 
the following question.  
 
Check one of the following 
statements that you think is 
true about your symptom 
of nausea. 
 The cause of this 
symptom is mostly 
age-related. 
 The cause of this 
symptom is mostly 
related to my cancer 
and/ or cancer 
treatments. 
 The cause of this 
symptom is mostly 
related to a non-cancer 
condition or treatment. 
 This symptom has 
some other cause.  
 (Write in what you 







9. During the past week, have 





If you answered no,  





If you answered yes,  
Please answer the questions in 




9b. How much does this 
symptom bother you?  
[Please check one.] 
 Not at all 
 A little bit 
 Somewhat 
 Quite a bit 
 Very much 
9c. If you answered yes 
to the question about the 
symptom, please answer 
the following question.  
 
Check one of the following 
statements that you think is 
true about your symptom 
of vomiting. 
 The cause of this 
symptom is mostly 
age-related. 
 The cause of this 
symptom is mostly 
related to my cancer 
and/ or cancer 
treatments. 
 The cause of this 
symptom is mostly 
related to a non-cancer 
condition or treatment. 
 This symptom has 
some other cause.  
 (Write in what you 
think is causing the 
symptom.) 
 
10. During the past week, have 





If you answered no,  




If you answered yes,  
Please answer the questions in 
the next 2 columns  
 
 
10b. How much does this 
symptom bother you?  
[Please check one.] 
 Not at all 
 A little bit 
 Somewhat 
 Quite a bit 
 Very much 
10c. If you answered yes 
to the question about the 
symptom, please answer 
the following question.  
 
Check one of the following 
statements that you think is 
true about your symptom 
of being drowsy. 
 The cause of this 
symptom is mostly 
age-related. 
 The cause of this 
symptom is mostly 
related to my cancer 
and/ or cancer 
treatments. 
 The cause of this 
symptom is mostly 
related to a non-cancer 
condition or treatment. 
 This symptom has 
some other cause.  
 (Write in what you 







11. During the past week, have 
you had numbness/ tingling in 




If you answered no,  




If you answered yes,  
Please answer the questions in 
the next 2 columns  
 
 
11b. How much does this 
symptom bother you?  
[Please check one.] 
 Not at all 
 A little bit 
 Somewhat 
 Quite a bit 
 Very much 
11c. If you answered yes 
to the question about the 
symptom, please answer 
the following question.  
 
Check one of the following 
statements that you think is 
true about your symptom 
of numbness/ tingling in 
hands or feet. 
 The cause of this 
symptom is mostly 
age-related. 
 The cause of this 
symptom is mostly 
related to my cancer 
and/ or cancer 
treatments. 
 The cause of this 
symptom is mostly 
related to a non-cancer 
condition or treatment. 
 This symptom has 
some other cause.  
 (Write in what you 
think is causing the 
symptom.) 
 
12. During the past week, have 




If you answered no,  




If you answered yes,  
Please answer the questions in 




12b. How much does this 
symptom bother you?  
[Please check one.] 
 Not at all 
 A little bit 
 Somewhat 
 Quite a bit 
 Very much 
12c. If you answered yes 
to the question about the 
symptom, please answer 
the following question.  
 
Check one of the following 
statements that you think is 
true about your symptom 
of difficulty sleeping. 
 The cause of this 
symptom is mostly 
age-related. 
 The cause of this 
symptom is mostly 
related to my cancer 
and/ or cancer 
treatments. 
 The cause of this 
symptom is mostly 
related to a non-cancer 
condition or treatment. 
 This symptom has 
some other cause.  
 (Write in what you 






13. During the past week, have 





If you answered no,  




If you answered yes,  
Please answer the questions in 
the next 2 columns  
  
 
13b. How much does this 
symptom bother you?  
[Please check one.] 
 Not at all 
 A little bit 
 Somewhat 
 Quite a bit 
 Very much 
13c. If you answered yes 
to the question about the 
symptom, please answer 
the following question.  
 
Check one of the following 
statements that you think is 
true about your symptom 
of being bloated. 
 The cause of this 
symptom is mostly 
age-related. 
 The cause of this 
symptom is mostly 
related to my cancer 
and/ or cancer 
treatments. 
 The cause of this 
symptom is mostly 
related to a non-cancer 
condition or treatment. 
 This symptom has 
some other cause.  
 (Write in what you 




14. During the past week, have 
you had urinary problems (such 




If you answered no,  




If you answered yes,  
Please answer the questions in 
the next 2 columns  
 
 
14b. How much does this 
symptom bother you?  
[Please check one.] 
 Not at all 
 A little bit 
 Somewhat 
 Quite a bit 
 Very much 
 
14c. If you answered yes 
to the question about the 
symptom, please answer 
the following question.  
 
Check one of the following 
statements that you think is 
true about your symptom 
of urinary problems. 
 The cause of this 
symptom is mostly 
age-related. 
 The cause of this 
symptom is mostly 
related to my cancer 
and/ or cancer 
treatments. 
 The cause of this 
symptom is mostly 
related to a non-cancer 
condition or treatment. 
 This symptom has 
some other cause.  
 (Write in what you 






15. During the past week, have 




If you answered no,  




If you answered yes,  
Please answer the questions in 
the next 2 columns  
  
 
15b. How much does this 
symptom bother you?  
[Please check one.] 
 Not at all 
 A little bit 
 Somewhat 
 Quite a bit 
 Very much 
 
15c. If you answered yes 
to the question about the 
symptom, please answer 
the following question.  
 
Check one of the following 
statements that you think is 
true about your symptom 
of shortness of breath. 
 The cause of this 
symptom is mostly 
age-related. 
 The cause of this 
symptom is mostly 
related to my cancer 
and/ or cancer 
treatments. 
 The cause of this 
symptom is mostly 
related to a non-cancer 
condition or treatment. 
 This symptom has 
some other cause.  
 (Write in what you 
think is causing the 
symptom.) 
 
16. During the past week, have 
you had sweating which is not 




If you answered no,  




If you answered yes,  
Please answer the questions in 
the next 2 columns  
 
 
16b. How much does this 
symptom bother you?  
[Please check one.] 
 Not at all 
 A little bit 
 Somewhat 
 Quite a bit 
 Very much 
16c. If you answered yes 
to the question about the 
symptom, please answer 
the following question.  
 
Check one of the following 
statements that you think is 
true about your symptom 
of sweating. 
 The cause of this 
symptom is mostly 
age-related. 
 The cause of this 
symptom is mostly 
related to my cancer 
and/ or cancer 
treatments. 
 The cause of this 
symptom is mostly 
related to a non-cancer 
condition or treatment. 
 This symptom has 
some other cause.  
 (Write in what you 







17. During the past week, have 





If you answered no,  




If you answered yes,  
Please answer the questions in 
the next 2 columns  
  
 
17b. How much does this 
symptom bother you?  
[Please check one.] 
 Not at all 
 A little bit 
 Somewhat 
 Quite a bit 
 Very much 
17c. If you answered yes 
to the question about the 
symptom, please answer 
the following question.  
 
Check one of the following 
statements that you think is 
true about your symptom 
of hot flashes. 
 The cause of this 
symptom is mostly 
age-related. 
 The cause of this 
symptom is mostly 
related to my cancer 
and/ or cancer 
treatments. 
 The cause of this 
symptom is mostly 
related to a non-cancer 
condition or treatment. 
 This symptom has 
some other cause.  
 (Write in what you 
think is causing the 
symptom.) 
 
18. During the past week, have 
you had problems with sexual 




If you answered no,  




If you answered yes,  
Please answer the questions in 




18b. How much does this 
symptom bother you?  
[Please check one.] 
 Not at all 
 A little bit 
 Somewhat 
 Quite a bit 
 Very much 
18c. If you answered yes 
to the question about the 
symptom, please answer 
the following question.  
 
Check one of the following 
statements that you think is 
true about your symptom 
of problems with sexual 
interest. 
 The cause of this 
symptom is mostly 
age-related. 
 The cause of this 
symptom is mostly 
related to my cancer 
and/ or cancer 
treatments. 
 The cause of this 
symptom is mostly 
related to a non-cancer 
condition or treatment. 
 This symptom has 
some other cause.  
 (Write in what you 






19. During the past week, have 




If you answered no,  




If you answered yes,  
Please answer the questions in 




19b. How much does this 
symptom bother you?  
[Please check one.] 
 Not at all 
 A little bit 
 Somewhat 
 Quite a bit 
 Very much 
19c. If you answered yes 
to the question about the 
symptom, please answer 
the following question.  
 
Check one of the following 
statements that you think is 
true about your symptom 
of itching. 
 The cause of this 
symptom is mostly 
age-related. 
 The cause of this 
symptom is mostly 
related to my cancer 
and/ or cancer 
treatments. 
 The cause of this 
symptom is mostly 
related to a non-cancer 
condition or treatment. 
 This symptom has 
some other cause.  
 (Write in what you 
think is causing the 
symptom.) 
 
20. During the past week, have 




If you answered no,  




If you answered yes,  
Please answer the questions in 
the next 2 columns  
 
 
20b. How much does this 
symptom bother you?  
[Please check one.] 
 Not at all 
 A little bit 
 Somewhat 
 Quite a bit 
 Very much 
20c. If you answered yes 
to the question about the 
symptom, please answer 
the following question.  
 
Check one of the following 
statements that you think is 
true about your symptom 
of lack of appetite. 
 The cause of this 
symptom is mostly 
age-related. 
 The cause of this 
symptom is mostly 
related to my cancer 
and/ or cancer 
treatments. 
 The cause of this 
symptom is mostly 
related to a non-cancer 
condition or treatment. 
 This symptom has 
some other cause.  
 (Write in what you 







21. During the past week, have 




If you answered no,  





If you answered yes,  
Please answer the questions in 




21b. How much does this 
symptom bother you?  
[Please check one.] 
 Not at all 
 A little bit 
 Somewhat 
 Quite a bit 
 Very much 
21c. If you answered yes 
to the question about the 
symptom, please answer 
the following question.  
 
Check one of the following 
statements that you think is 
true about your symptom 
of dizziness. 
 The cause of this 
symptom is mostly 
age-related. 
 The cause of this 
symptom is mostly 
related to my cancer 
and/ or cancer 
treatments. 
 The cause of this 
symptom is mostly 
related to a non-cancer 
condition or treatment. 
 This symptom has 
some other cause.  
 (Write in what you 
think is causing the 
symptom.) 
 
22. During the past week, have 




If you answered no,  




If you answered yes,  
Please answer the questions in 
the next 2 columns  
 
 
22b. How much does this 
symptom bother you?  
[Please check one.] 
 Not at all 
 A little bit 
 Somewhat 
 Quite a bit 
 Very much 
22c. If you answered yes 
to the question about the 
symptom, please answer 
the following question.  
 
Check one of the following 
statements that you think is 
true about your symptom 
of difficulty swallowing. 
 The cause of this 
symptom is mostly 
age-related. 
 The cause of this 
symptom is mostly 
related to my cancer 
and/ or cancer 
treatments. 
 The cause of this 
symptom is mostly 
related to a non-cancer 
condition or treatment. 
 This symptom has 
some other cause.  
 (Write in what you 







23. During the past week, have 




If you answered no,  




If you answered yes,  
Please answer the questions in 




23b. How much does this 
symptom bother you?  
[Please check one.] 
 Not at all 
 A little bit 
 Somewhat 
 Quite a bit 
 Very much 
23c. If you answered yes 
to the question about the 
symptom, please answer 
the following question.  
 
Check one of the following 
statements that you think is 
true about your symptom 
of mouth sores. 
 The cause of this 
symptom is mostly 
age-related. 
 The cause of this 
symptom is mostly 
related to my cancer 
and/ or cancer 
treatments. 
 The cause of this 
symptom is mostly 
related to a non-cancer 
condition or treatment. 
 This symptom has 
some other cause.  
 (Write in what you 
think is causing the 
symptom.) 
 
24. During the past week, have 





If you answered no,  




If you answered yes,  
Please answer the questions in 




24b. How much does this 
symptom bother you?  
[Please check one.] 
 Not at all 
 A little bit 
 Somewhat 
 Quite a bit 
 Very much 
 
24c. If you answered yes 
to the question about the 
symptom, please answer 
the following question.  
 
Check one of the following 
statements that you think is 
true about your symptom 
of taste changes. 
 The cause of this 
symptom is mostly 
age-related. 
 The cause of this 
symptom is mostly 
related to my cancer 
and/ or cancer 
treatments. 
 The cause of this 
symptom is mostly 
related to a non-cancer 
condition or treatment. 
 This symptom has 
some other cause.  
 (Write in what you 







25. During the past week, have 




If you answered no,  




If you answered yes,  
Please answer the questions in 
the next 2 columns  
 
 
25b. How much does this 
symptom bother you?  
[Please check one.] 
 Not at all 
 A little bit 
 Somewhat 
 Quite a bit 
 Very much 
 
25c. If you answered yes 
to the question about the 
symptom, please answer 
the following question.  
 
Check one of the following 
statements that you think is 
true about your symptom 
of unexpected weight loss. 
 The cause of this 
symptom is mostly 
age-related. 
 The cause of this 
symptom is mostly 
related to my cancer 
and/ or cancer 
treatments. 
 The cause of this 
symptom is mostly 
related to a non-cancer 
condition or treatment. 
 This symptom has 
some other cause.  
 (Write in what you 
think is causing the 
symptom.) 
 
26. During the past week, have 




If you answered no,  




If you answered yes,  
Please answer the questions in 
the next 2 columns  
 
 
26b. How much does this 
symptom bother you?  
[Please check one.] 
 Not at all 
 A little bit 
 Somewhat 
 Quite a bit 
 Very much 
26c. If you answered yes 
to the question about the 
symptom, please answer 
the following question.  
 
Check one of the following 
statements that you think is 
true about your symptom 
of hair loss. 
 The cause of this 
symptom is mostly 
age-related. 
 The cause of this 
symptom is mostly 
related to my cancer 
and/ or cancer 
treatments. 
 The cause of this 
symptom is mostly 
related to a non-cancer 
condition or treatment. 
 This symptom has 
some other cause.  
 (Write in what you 







27. During the past week, have 





If you answered no,  




If you answered yes,  
Please answer the questions in 
the next 2 columns  
 
 
27b. How much does this 
symptom bother you?  
[Please check one.] 
 Not at all 
 A little bit 
 Somewhat 
 Quite a bit 
 Very much 
27c. If you answered yes 
to the question about the 
symptom, please answer 
the following question.  
 
Check one of the following 
statements that you think is 
true about your symptom 
of constipation. 
 The cause of this 
symptom is mostly 
age-related. 
 The cause of this 
symptom is mostly 
related to my cancer 
and/ or cancer 
treatments. 
 The cause of this 
symptom is mostly 
related to a non-cancer 
condition or treatment. 
 This symptom has 
some other cause.  
 (Write in what you 
think is causing the 
symptom.) 
 
28. During the past week, have 




If you answered no,  





If you answered yes,  
Please answer the questions in 
the next 2 columns  
 
 
28b. How much does this 
symptom bother you?  
[Please check one.] 
 Not at all 
 A little bit 
 Somewhat 
 Quite a bit 
 Very much 
28c. If you answered yes 
to the question about the 
symptom, please answer 
the following question.  
 
Check one of the following 
statements that you think is 
true about your symptom 
of diarrhea. 
 The cause of this 
symptom is mostly 
age-related. 
 The cause of this 
symptom is mostly 
related to my cancer 
and/ or cancer 
treatments. 
 The cause of this 
symptom is mostly 
related to a non-cancer 
condition or treatment. 
 This symptom has 
some other cause.  
 (Write in what you 







29. During the past week, have 





If you answered no,  




If you answered yes,  
Please answer the questions in 
the next 2 columns  
 
 
29b. How much does this 
symptom bother you?  
[Please check one.] 
 Not at all 
 A little bit 
 Somewhat 
 Quite a bit 
 Very much 
 
29c. If you answered yes 
to the question about the 
symptom, please answer 
the following question.  
 
Check one of the following 
statements that you think is 
true about your symptom 
of feeling “I don’t look like 
myself”. 
 The cause of this 
symptom is mostly 
age-related. 
 The cause of this 
symptom is mostly 
related to my cancer 
and/ or cancer 
treatments. 
 The cause of this 
symptom is mostly 
related to a non-cancer 
condition or treatment. 
 This symptom has 
some other cause.  
 (Write in what you 
think is causing the 
symptom.) 
 
30. During the past week, have 




If you answered no,  




If you answered yes,  
Please answer the questions in 




30b. How much does this 
symptom bother you?  
[Please check one.] 
 Not at all 
 A little bit 
 Somewhat 
 Quite a bit 
 Very much 
 
30c. If you answered yes 
to the question about the 
symptom, please answer 
the following question.  
 
Check one of the following 
statements that you think is 
true about your symptom 
of being nervous or 
anxious. 
 The cause of this 
symptom is mostly 
age-related. 
 The cause of this 
symptom is mostly 
related to my cancer 
and/ or cancer 
treatments. 
 The cause of this 
symptom is mostly 
related to a non-cancer 
condition or treatment. 
 This symptom has 
some other cause.  
 (Write in what you 





31. During the past week, have 





If you answered no,  




If you answered yes,  
Please answer the questions in 
the next 2 columns  
 
 
31b. How much does this 
symptom bother you?  
[Please check one.] 
 Not at all 
 A little bit 
 Somewhat 
 Quite a bit 
 Very much 
 
31c. If you answered yes 
to the question about the 
symptom, please answer 
the following question.  
 
Check one of the following 
statements that you think is 
true about your symptom 
of feeling irritable. 
 The cause of this 
symptom is mostly 
age-related. 
 The cause of this 
symptom is mostly 
related to my cancer 
and/ or cancer 
treatments. 
 The cause of this 
symptom is mostly 
related to a non-cancer 
condition or treatment. 
 This symptom has 
some other cause.  
 (Write in what you 




32. During the past week, have 





If you answered no,  




If you answered yes,  
Please answer the questions in 
the next 2 columns  
 
 
32b. How much does this 
symptom bother you?  
[Please check one.] 
 Not at all 
 A little bit 
 Somewhat 
 Quite a bit 
 Very much 
32c. If you answered yes 
to the question about the 
symptom, please answer 
the following question.  
 
Check one of the following 
statements that you think is 
true about your symptom 
of feeling sad. 
 The cause of this 
symptom is mostly 
age-related. 
 The cause of this 
symptom is mostly 
related to my cancer 
and/ or cancer 
treatments. 
 The cause of this 
symptom is mostly 
related to a non-cancer 
condition or treatment. 
 This symptom has 
some other cause.  
 (Write in what you 






33. During the past week, have 
you had other symptoms not listed 





Please list other symptoms: 
 
If you answered yes,  
Please answer the questions in 
the next 2 columns  
 
 
33b. How much does this 
symptom bother you?  
[Please check one.] 
 Not at all 
 A little bit 
 Somewhat 
 Quite a bit 
 Very much 
 
33c. If you answered yes 
to the question about the 
symptom, please answer 
the following question.  
 
Check one of the following 
statements that you think is 
true about your symptom. 
 The cause of this 
symptom is mostly 
age-related. 
 The cause of this 
symptom is mostly 
related to my cancer 
and/ or cancer 
treatments. 
 The cause of this 
symptom is mostly 
related to a non-cancer 
condition or treatment. 
 This symptom has 
some other cause.  
 (Write in what you 






Thank you for your time in completing this survey. 
